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Abstract
Complement plays an important role in the humoral response to protein 
antigens, but its role in anti-capsular antibody responses is unclear. The 
immunogenicity of a panel of twelve CPSs from S. pneumoniae was 
investigated in mice deficient in complement receptors 1 and 2 (CD35/CD21, 
respectively). With the exception of serotype 4, IgM anti-polysaccharide 
responses were not dependent on the presence of CD35/CD21. In contrast 
IgG anti-polysaccharide responses, which were infrequently and variably 
elicited in C57BL/6 mice, were critically dependent on the presence of 
CD21/CD35. Although classified as T-independent type 2 (TI-2) antigens, 
antibody responses to pneumococcal CPSs, except serotype 4, were 
different from those to dinitrophenol (DNP)-Ficoll, a model TI-2 antigen. Our 
results indicated that complement plays a critical role in IgG anti­
polysaccharide and anti-hapten responses. However IgM anti-pneumococcal 
CPS responses, with the only one exception, were surprisingly complement- 
independent. Our findings establish a differential role of complement in 
humoral responses to a model TI-2 antigen and clinically relevant 
polysaccharide antigens.
In addition to the studies of S. pneumoniae CPSs, the adjuvant properties of 
CPSs from K. pneumoniae were also invesitgated. Several K. pneumoniae 
CPS preparations, in particular K1 and K3, have been reported to possess 
potent immunomodulatory properties. However the purity of CPSs used was 
not investigated adequately. We modified previously established methods of 
CPS purification in order to obtain highly purified CPSs for our studies. Pure
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CPSs with molecular weights of 1-2 x 106 daltons failed to augment the 
antibody response to chicken gamma globulin (CGG) when used as an 
adjuvant in mice. In vitro studies also demonstrated that crude but not highly 
purified CPSs induced the proliferation of or cytokine production from 
splenocytes from normal and LPS-hyporesponsive mice. The active 
component (s) in crude CPSs has not been identified, but it is resistant to 
heat, protease, nuclease and alkaline treatments. W e have also ruled out the 
possibility that the immunomodulatory effects were due to bacterial DNA or 
LPS, two common contaminants in these preparations. Since not all the 
components in CPS extracts from K. pneumoniae have been characterised, 
further investigations may identify novel adjuvant candidate (s).
3
Publications and Abstracts
Publications
1) Zamze,S., Martinez-Pomares, L., Jones, H., Taylor, P. R., Stillion, R. 
J., Gordon, S. and Wong, S. Y. (2002) Recognition of bacterial 
capsular polysaccharides and lipopolysaccharides by the macrophage 
mannose receptor J. Biol Chem, 277, 41613-23.
2) Jones, H., Taylor P. R., Carroll, M. C., Wong, S. Y. and Zamze, S. 
Differential dependency on complement C3 and complement receptors 
CD21/CD35 in murine antibody responses toward pneumococcal 
capsular polysaccharides and a model T-independent type II antigen. 
(Manuscript in preparation)
Abstracts
1) Jones, H., Taylor P. R., Carroll, M. C., Wong, S. Y. and Zamze, S.
The role of complement in the humoral immune response to capsular 
polysaccharides from Streptococcus pneumoniae. Abstract was 
selected for oral presentation by H. Jones at the 12th International 
Congress of Immunology, Montreal, Canada, 2004.
4
Acknowledgements
I would first like to thank Dr. Simon Wong for giving me the opportunity to 
study at the Edward Jenner Institute and for his help and advice. Special 
thanks to Dr. Susanne Zamze who has always been there to help me and 
answer my questions. I have learnt a lot from her and for that I am extremely 
grateful.
I would like to thank all of the past and present members of the Carbohydrate 
Immunology Group. Many thanks to Geoffrey for his help with the HPLC and 
Terry for providing me with endless entertainment throughout my first year. I 
would also like to thank the girls, (Jo, Rona, Simona and Vanessa) whose 
friendship and help has made those hard times much easier to get through.
Many thanks also to Dr. Arun Kamath who was always willing to give me help 
and advice. I must also thank Jema and Pauline for looking after my mice 
and being there to help me with those nasty males!
I would also like to thank all my friends, especially Chris, Clare, Jo, Liz G, 
Bret, Anna, Liz L, Caroline and James, who have kept me sane through the 
hard times of my PhD. I would especially like to thank Craig who has always 
given me something to smile about. Whenever I am down he always knows 
the right thing to say. Thanks for your constant support and the ability to 
pretend you are listening to my moaning even when you are playing on your 
playstation! Thank you.
5
Last but certainly not least, I would like to thank my Mom and Dad who have 
always been there for me. They have encouraged me to better myself and 
whatever I have done they have been proud. This one is for you Mom and 
Dad!
6
Table of Contents
Abstract 2
Publi cations and Abstracts 4
Acknowledgements 5
Table of Contents 7
List of Figures and Tables 11
Abbreviations 15
Chapter One -  Introduction 17
1.1 General Introduction 18
1.2 Bacterial Polysaccharides 21
1.2.1 Capsular polysaccharides 21
1.2.2 Lipopolysaccharides 29
1.2.3 Lipoteichoic and teichoic acid 32
1.3 Innate Immunity 33
1.3.1 Macrophages and Dendritic cells 34
1.3.2 Innate immune recognition of pathogens 35
1.3.2a Soluble receptors 35
1.3.2b Cell associated receptors 42
1.3.3 Natural antibodies and B-1 cells 53
1.4 Humoral response to T independent type 2 antigens 55
1.4.1 T independent and T dependent antigens 55
1.4.2 B cell activation by TI-2 antigens 56
1.4.3 Modulation of TI-2 responses by complement 57
1.4.4 Modulation of TI-2 responses by T cells 59
1.4.5 Modulation of TI-2 responses by NK cells 62
1.4.6 Modulation of TI-2 responses by DCs and Macrophages 63
1.4.7 Lymphoid tissues and cell types involved in TI-2 responses 64
1.5 Polysaccharide and Conjugate vaccines 67
1.6 Adjuvants 70
1.7 Aims 72
Chapter Two -  Materials & Methods 74
2.1 Materials 75
2.1.1 Antibodies 75
2.1.1a Monoclonal antibodies used in flow cytometric 
analysis 75
2.1.1b Antibodies used for ELISA assays 75
2.1.2 Cytometric Bead Array (CBA) kits 76
2.1.3 Biochemical Reagents 76
2.1.4 Tissue culture reagents 79
2.1.5 Plastics 80
7
2.2 Methods 81
2.2.1 Purification of capsular polysaccharides from Klebsiella 
pneumoniae 81
2.2.1a Bacterial strains 81
2.2.1b Growth of bacteria and extraction of capsular 
polysaccharides 81
2.2.1c Purification of capsular polysaccharides 82
2.2.1 d Gel filtration chromatography 83
2.2.1 e Removal of sodium deoxycholate dissociating buffer 84 
2.2.1f Removal of lipopolysaccharide 85
2.2.2 Purification of lipopolysaccharide from Klebsiella 
pneumoniae 86
2.2.2a Growth of bacteria and extraction of 
lipopolysaccharide 86
2.2.2b Purification of lipopolysaccharide 87
2.2.3 Analysis and characterisation of capsular polysaccharides
from Klebsiella pneumoniae 88
2.2.3a Confirmation of K. pneumoniae capsular serotype 88 
2.2.3b Quantification of carbohydrate 88
2.2.3c Quantification of protein 89
2.2.3d Quantification of uronic acid 89
2.2.3e Quantification of lipopolysaccharide 90
2.2.3f Quantification of nucleic acid 90
2.2.3g Sodium Dodecyl Sulphate Polyacrylamide 
electrophoresis 90
2.2.3h Western blotting 92
2.2.3i Silver Staining 93
2.2.4 Characterisation of humoral response 94
2.2.4a Protocol of S. pneumoniae CPS immunisations 94
2.2.4b Protocol of K. pneumoniae CPS immunisations 95
2.2.4c Protocol of chicken gamma globulin immunisations 97 
2.2.4d Preparation of mouse serum 98
2.2.4e Characterisation of serum antibody response to 
S. pneumoniae capsular polysaccharides by ELISA 98
2.2.4f Characterisation of serum antibody response to 
K  pneumoniae capsular polysaccharides by ELISA 100
2.2.4g Characterisation of serum antibody response to 
chicken gamma globulin by ELISA 101
2.2.5 In vitro cell assays 101
2.2.5a Cell proliferation assay using 3H thymidine 101
2.2.5b Cytokine release assays 102
2.2.5c CFSE labelling of mouse splenocytes 102
2.2.5d Cytokine detection 103
2.2.5e Immunofluorescence staining of cell surface markers 103
2.2.6 Statistics 104
8
Chapter Three -  Purification and characterisation of 
capsular polysaccharides from Klebsiella pneumoniae 105
3.1 Introduction 106
3.2 Objectives 107
3.3 Purification of K. pneumoniae capsular polysaccharides 108
3.3.1 K. pneumoniae CPS extraction 108
3.3.2 Size fractionatuion and purification 108
3.3.3 Removal of LPS from CPS extracts 113
3.3.3a Triton X -114 113
3.3.3b Gel filtration chromatography under dissociating 
conditions 113
3.3.4 Gel filtration chromatography of K. pneumoniae CPS extracts 
and further analysis of pooled samples 115
3.3.4a Recovery and MW of polysaccharide 115
3.3.4b Effect of separating conditions on CPS
antigenicity 116
3.3.4c Analysis of CPS purified by dissociating
conditions. 117
3.4 Characterisation of K. pneumoniae capsular serotypes by SDS-PAGE 120
3.5 Characterisation of K. pneumoniae LPS 128
3.5.1 Purification of K. pneumoniae LPS 128
3.5.2 SDS-PAGE analysis of LPS from different O antigenic types
of K. pneumoniae 131
3.6 Discussion 131
Chapter four -  The immunogenicity and adjuvanticity of 
capsular polysaccharides from Klebsiella pneumoniae 137
4.1 Introduction 138
4.2 Objectives 141
4.3 The adjuvant effect of K. pneumoniae CPS and LPS extracts on the 
humoral response to CGG in mice. 141
4.3.1 Adjuvant properties of K. pneumoniae CPS and LPS in 
C57BL/6 mice 142
4.3.2 Adjuvant properties of K. pneumoniae CPS and LPS in 
C3H/HeN and C3H/HeJ mice 144
4.4 The contribution of the polysaccharide component of K. pneumoniae 
CPS extracts to adjuvanticity 150
4.5 Humoral response to capsular polysaccharides from K. pneumoniae 158
4.6 Discussion 161
Chapter Five -  Possible mechanisms of adjuvant action of 
capsular polysaccharide extracts from Klebsiella 
pneumoniae 166
5.1 Introduction 167
5.2 Objectives 170
5.3 Results 170
5.3.1 Proliferation of C3H/HeJ and C3H/HeN splenocytes in 
response to K. pneumoniae capsular polysaccharide extracts. 170
9
5.3.2 Proliferation of C3H/HeJ and C3H/HeN B and T cells in 
response to K. pneumoniae capsular polysaccharide extracts. 178
5.3.3 Cytokine production from C3H/HeJ splenocytes after 
stimulation with K. pneumoniae capsular polysaccharide extracts. 182
5.4 Discussion 184
Chapter Six -  The role of complement in the humoral 
response to Streptococcus pneumoniae capsular 
polysaccharides 193
6.1 Introduction 194
6.2 Objectives 198
6.3 Results 198
6.3.1 Expression of CD21/CD35 in Cr2-/- and C57BL/6 mice 198
6.3.2 The presence of natural serum IgM antibodies in naive
mice to S. pneumoniae CPSs 200
6.3.3 The humoral response to S. pneumoniae CPS in wild type 200 
mice
6.3.3a Dose response 200
6.3.3b Cell wall polysaccharide preabsorption 202
6.3.3c Effect of booster 204
6.3.3d Longevity of IgM response 204
6.3.4 A comparison of serum IgM response to S. pneumoniae
CPSs in C57BL/6 and Cr2-/- mice 207
6.3.5 A comparison of serum IgG responses to S. pneumoniae
CPSs in C57BL/6 and Cr2-/-mice 217
6.4 Discussion 223
Chapter Seven -  Final Discussion 232
7.1 The adjuvant properties of K. pneumoniae capsular polysaccharides 233
7.2 The role of complement in the humoral response to S. pneumoniae 
capsular polysaccharides 236
7.3 Final summary 240
References 242
10
Figures & Tables
Chapter One
Figure 1.1 Structure of the cell surface of a Gram negative and a 22
Gram positive bacterium.
Figure 1.2 Structural features of bacterial surface components
teichoic acid, lipoteichoic acid, lipopolysaccharide and 
capsular polysaccharide. 23
Figure 1.3 Structures of K. pneumoniaecapsular polysaccharides. 26
Figure 1.4 Structures of S. pneumoniae capsular polysaccharides. 27
Figure 1.5 Structures of the O-antigenic sidechains of K. pneumoniae 31
LPS.
Figure 1.6 Structure of Mannose binding lectin. 39
Chapter Two
Figure 2.1 Schedule for immunisation of mice with S. pneumoniae 
and K. pneumoniae capsular polysaccharides and serum
collection. 96
Figures 2.2 Schedule of immunisations of mice with chicken gamma
globulin and serum collection. 99
Table 2.1 Gel Filtration elution buffers 83
Table 2.2 SDS-PAGE separating gel components 90
Table 2.3 SDS-PAGE stacking gel components 91
Table 2.4 Silver staining solutions 93
Chapter Three
Figure 3.1 Gel filtration profiles of K. pneumoniae CPS serotypes
K26 and K27. 109
Figure 3.2 Gel filtration profile of dextran standards. 111
Figure 3.3 Gel filtration profiles of K. pneumoniae CPS serotype
K11 subjected to different degrees of purification. 112
Figure 3.4 Gel filtration profiles of K. pneumoniae serotype K55 LPS. 114
Figure 3.5 The binding of rabbit anti-capsular antiserum to
K. pneumoniae serotype K55 (pool 1) following gel filtration. 118 
Figure 3.6 Gel filtration profile of K. pneumoniae CPS serotype K31 119
Figure 3.7 SDS-PAGE and western blot analysis of K. pneumoniae
CPS serotypes K31 and K3. 121
Figure 3.8 10% SDS-PAGE analysis of K. pneumoniae CPS serotype
K55 after gel filtration chromatography. 123
Figure 3.9 15% SDS-PAGE analysis of K. pneumoniae CPS serotype
K55 after gel filtration chromatography. 124
l i
Figure 3.10 SDS-PAGE analysis of K. pneumoniae CPS serotype K3
pools 1 and 2. 126
Figure 3.11 SDS-PAGE analysis of K. pneumoniae CPS serotype K52. 127
Figure 3.12 Gel filtration profile of K. pneumoniae serotype K55 LPS. 129
Figure 3.13 SDS-PAGE of K55 LPS before and after gel filtration. 130
Figure 3.14 SDS-PAGE analysis of LPS from various K. pneumoniae
capsular serotypes. 132
Table 3.1 Typical contents of a CPS extract. 108
Table 3.2 Gel filtration elution buffers 115
Table 3.3 Typical contents of CPS pool 1. 120
Chapter Four
Figure 4.1 The effect of different adjuvants on the serum IgG
response to CGG in C57BL/6 mice 143
Figure 4.2 A comparison of serum IgG antibody responses in C3H/HeN
and C3H/HeJ mice after LPS removal from CGG. 145
Figure 4.3 A comparison of the adjuvanticity of CPS and LPS from
K. pneumoniae K1, K3 and K55 in C3H/HeJ mice. 146
Figure 4.4 The effect of dose of K. pneumoniae K55 CPS extract
on the IgG antibody response to CGG. 148
Figure 4.5 Relative decrease in adjuvanticity of K. pneumoniae 
CPS and LPS extracts in C3H/HeJ compared with 
C3H/HeN mice. 149
Figure 4.6 Serum IgG responses to CGG using K. pneumoniae 
K17 CPS pool 1 as an adjuvant in C3H/HeJ and 
C3H/HeN mice. 152
Figure 4.7 Serum IgG responses to CGG using K. pneumoniae
K55 CPS pools 1 and 2 as adjuvants. 153
Figure 4.8 A comparison of serum IgG response to CGG using 
K52 pool 1 and 2 as adjuvants in C3H/HeJ and 
C3H/HeN mice. 154
Figure 4.9 The effect of protease treatment on the adjuvanticity of
K55 CPS extract in C3H/HeJ mice. 156
Figure 4.10 Effect of different alkali treatments on the adjuvanticity
of the CPS extract from K. pneumoniae K55. 157
Figure 4.11 Serum IgM levels to K. pneumoniae capsular serotypes
K17 and K52 in C3H/HeN and C3H/HeJ mice. 159
Figure 4.12 Serum IgG levels to K. pneumoniae capsular serotypes
K55 and K52 and C3H/HeN and C3H/HeJ mice. 160
Chapter Five
Figure 5.1 Proliferation of splenocytes from C3H/HeN and C3H/HeJ 
mice stimulated with LPS from K. pneumoniae 
serotype K55. 172
12
Figure 5.2 Proliferation of C3H/HeJ splenocytes with K52 
and K55 CPS extracts.
Figure 5.3 Proliferation of C3H/HeN and C3H/HeJ splenocytes 
stimulated with K55 CPS.
Figure 5.4 Proliferation of C3H/HeN and C3H/HeJ splenocytes 
stimulated with K52 CPS.
Figure 5.5 CFSE analysis of T cell proliferation in response to K52 and 
K55 CPS extracts.
Figure 5.6 CFSE analysis of B cell proliferation in response to K52 
and K55 CPS extracts.
Figure 5.7 Cytokine release from C3H/HeJ mouse splenocytes 
after culture with K55 and K52 CPS extracts.
Figure 5.8 Cytokine release from C3H/HeJ mouse splenocytes after 
culture with K55 and K52 CPS extracts, Pam3Cys and 
MDP.
Table 5.1 K. pneumoniae preparations
Table 5.2 Concentration of CPS, DNA and LPS in K. pneumoniae
K55 and K52 extracts.
Chapter Six
Figure 6.1 Expression of CD21/CD35 on naive splenocytes from 
C57BL/6 and Cr2-/- mice.
Figure 6.2 A comparison of serum IgM levels in naive C57BL/6 and 
Cr2-/- to S. pneumoniae capsular polysaccharides.
Figure 6.3 Comparison of serum IgM response to S. pneumoniae 
capsular polysaccharides types 19A, 19F, 14 and 6B at 
different doses in C57BL/6 mice.
Figure 6.4 Comparison of serum IgM responses to S. pneumoniae 
capsular polysaccharides 19A and 19F before and after 
booster immunisation in C57BL/6 mice.
Figure 6.5 Long term serum IgM response to S. pneumoniae capsular 
polysaccharide types 19A and 19F in C57BL/6 mice.
Figure 6.6 Comparison of serum IgM responses to S. pneumoniae 
capsular polysaccharides types 19A, 19F, 14 and 6B at 
different doses in BALB/c mice.
Figure 6.7 The binding of serum IgM to pneumococcal CPSs after 
immunisation of C57BL/6 mice with CPS serotype 23F.
Figure 6.8 A comparison of serum IgM responses to S. pneumoniae 
capsular polysaccharides 9N, 2, 23F, 18C, 3, 6B, 9V, 14, 
19A, 1, 19F and 4 in C57BL/6 and Cr2-/- mice.
Figure 6.9 A comparison of serum IgM and IgG response to 
DNP-Ficoll in C57BL/6 and Cr2-/- mice.
Figure 6.10 A comparison of serum IgM responses to different doses of 
S. pneumoniae capsular serotype 4 in C57BL/6 and 
Cr2-/- mice.
174
175
176 
180 
181 
183
185
170
173
199
201
203
205
206
208
210
211
215
216
13
Figure 6.1
Figure 6.1 
Figure 6.1
1 A comparison of serum IgM levels in C57BL/6 and Cr2-/- 
mice immunised with a mixture of S. pneumoniae capsular 
polysaccharides 14.19A, 19F and 6B.
2 A comparison of serum IgG responses to S. pneumoniae 
capsular polysaccharides types 19A and 14 at day 21
3 Gel filtration profiles of S. pneumoniae capsular 
polysaccharide serotype 9V.
218
220
221
14
Abbreviations
ANOVA Analysis of variance
APC Antigen presenting cell
BCR B cell receptor
BSA Bovine serum albumin
CD21 Complement receptor 2
CD35 Complement receptor 1
CGG Chicken gamma globulin
CPS Capsular polysaccharide
CRD Carbohydrate recognition domain
DC Dendritic cell
FCS Foetal calf serum
FDC Follicular dendritic cell
D-Fuc Fucose
FucNAc A/-acetyl-fucosamine
D-Gal Galactose
GalA Galacturonic acid
GalNAc A/-acetyl-galactosamine
D-GIc Glucose
GIcA Gluronic acid
GlcNAc A/-acetylglucosamine
h hour
HPLC High pressure liquid chromatography
ig Immunoglobulin
i-P intraperitoneal
L litre
LAL Limulus amoebocyte lysate
LPS Lipopolysaccharide
LTA Lipoteichoic acid
D-Man Mannose
ManNAc A/-acetylmannosamine
MBL Mannose binding lectin
mins minutes
MR Mannose receptor
MHC Major histocompatibility complex
MWCO Molecular weight cut off
MZ Marginal Zone
M ZB Marginal Zone B cells
MZM Marginal Zone macrophages
MZMM Marginal Zone metallophilic macrophages
OAc O-acetyl
PBS Phosphate buffered saline
PMA Phorbol myristate acetate
L-Rha Rhamnose
L-Rib Ribose
SEM Standard error of the mean
TA Teichoic acid
TCR T cell receptor
15
TD
Tl
TLR
T-dependent 
T-independent 
Toll-like receptor
16
Chapter One
Chapter One 
Introduction
17
Chapter One
Chapter One 
Introduction
1.1 General Introduction
Polysaccharide capsules of encapsulated bacteria, such as Haemophilus 
influenzae and Streptococcus pneumoniae, can protect bacteria from innate 
immune mechanisms. Consequently, the capacity to generate opsonising 
antibody to encapsulated bacteria has been long recognised as being 
essential for host defence (Macleod et al., 1945). The clinical importance of 
antibody responses to the capsular polysaccharide (CPS) of these bacteria is 
highlighted in the high rate of mortality and morbidity from these pathogens 
during infancy. The T-independent type II nature of these antigens results in 
a lack of antibody production in the very young and those who are 
immunocompromised. Polysaccharide-only vaccines are thus ineffective in 
these populations (Mond et al., 1995b). The requirement for effective 
vaccines for infants is therefore crucial. Polysaccharide-protein conjugate 
vaccines have been shown to elicit primary and memory humoral responses 
in young children and thus have great potential as vaccines of choice against 
encapsulated bacteria. Whilst differences in the responses to polysaccharide 
and polysaccharide-protein conjugate vaccines are attributable to their ability 
in recruiting T cell help the mechanism of induction of anti-polysaccharide 
antibodies have not been well defined for either vaccine (Lindberg, 1999).
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The understanding of the immune response to encapsulated bacteria has 
increased over the last few years and the importance of specialised B cell 
populations, marginal zone B cells and peritoneal B1 cells, in the generation 
of antibodies to polysaccharides has been established (Martin et al., 2001). 
The innate immune system is also well equipped to recognise microbial 
polysaccharides and is thus critical in mounting initial defence mechanisms 
through activation of complement via the alternative and lectin pathways, 
recognition by surface and soluble receptors and the presence of natural IgM 
antibodies. The link between innate and adaptive immunity is also of 
particular interest; for example the interactions between polysaccharides and 
complement may influence subsequent humoral responses.
Further studies to characterise the link between the innate and adaptive 
immune system and to define mechanisms for enhancing antibody responses 
against polysaccharides may provide novel strategies for the production of 
vaccines against multiple serotypes of encapsulated bacteria. One of the 
main aims of this thesis was to establish the humoral responses in normal 
mice to a panel of capsular polysaccharides from S. pneumoniae, and then 
compare them to the response in mice deficient in complement receptors 1 
and 2. From these results the differences in immunogenicity of CPS and the 
role of complement receptors in the immune response to different CPSs 
could be determined. By studying possible mechanisms involved in antibody 
production to polysaccharides, it may be possible to improve vaccine 
formulations or understand better their mechanism of action.
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As well as identifying factors that determine or influence immunogenicity of 
capsular polysaccharides, another aspect of this thesis was to investigate 
polysaccharides as possible adjuvants. Certain polysaccharides of microbial 
origin have been described as having potent immunomodulating properties 
(Tzianabos., 2000). An example is (3-glucan, purified from yeast and fungi. It 
has been shown to exhibit a wide range of biological functions, including anti­
tumour activity and non specific activation of cellular and humoral 
components of the immune system (Bleicher et al., 1995). Possible 
immunostimulatory properties have also been described for certain CPS 
preparations from Klebsiella pneumoniae (Choy et al., 1996; Ho et al., 2000), 
although these studies are far fewer and less extensive than those for p- 
glucans. The other main aim of the thesis was to characterise CPS 
preparations from K. pneumoniae and determine whether CPS itself was 
responsible for any immunostimulatory or adjuvant effects observed. The 
development of new adjuvants is a major goal in vaccine development as 
currently only alum is licensed for use in humans. It is therefore important 
that studies are carried out to discover new adjuvants. Polysaccharides tend 
to be relatively non toxic and stable. If adjuvant properties can be attributed 
to these molecules they could provide a good and potentially safe adjuvant 
for use in vaccines.
This thesis was thus aimed to characterise factors that affect the humoral 
response towards CPS and to understand further the adjuvant properties of 
CPS preparations from K. pneumoniae.
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1.2 Bacterial Polysaccharides
Bacteria produce a range of complex polysaccharides which are ubiquitous 
components on the cell surface. Major groups include CPS, teichoic acid 
(TA), lipoteichoic acid (LTA), and lipopolysaccharide (LPS). CPS may be 
present on both Gram positive and Gram negative organisms whereas LPS 
is only found on Gram negative and TA and LTA on Gram positive bacteria. 
The location on the bacterial surface and the structural features of these 
polysaccharide containing molecules are shown in Figures 1.1 and 1.2, 
respectively.
1.2.1 Capsular polysaccharides
CPS are major cell surface antigens of both Gram negative and Gram 
positive bacteria (Kenne et al., 1983). The formation of the capsule around 
the surface of the bacteria may protect the bacteria from harmful effects of 
desiccation and can promote the adherence of bacteria to both surfaces and 
each other, and they thereby facilitate the formation of biofilms and the 
colonisation of ecological niches (Costerton et al., 1987; Roberts, 1996). CPS 
are high molecular weight polysaccharides, typically 106 Daltons and greater. 
With exception of homopolymers they are composed of linear or branched 
repeating units consisting of 2 -  8 monosaccharides. They are structurally 
very diverse and are nearly always polyanionic. CPS can also be lipidated, a 
modification responsible for anchoring these highly charged molecules into 
the bacterial outer membrane (Arakere et al., 1994).
K. pneumoniae and S. pneumoniae are examples of clinically relevant 
encapsulated bacteria. Both bacterial species are opportunistic pathogens,
21
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Figure 1.1 Structure of the cell surface of a Gram positive 
and a Gram negative bacterium.
This figure, taken from Salyers et al., 1994, illustrates the major 
features of a Gram negative (A) and Gram positive (B) cell 
surface. In particular the presence of lipopolysaccharide, 
lipoteichoic acid, teichoic acid and peptidoglycan. Capsular 
polysaccharide is also indicated on the diagram, this can be 
found attached to the cell surface or as ‘free’ polysaccharide.
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Bacterial Component Specific features
Teichoic Acid The cell walls of most Gram positive bacteria have teichoic acids. Teichoic acids 
are cell associated polysaccharides containing glycerol phosphate or ribitol 
phosphate residues. The teichoic acids are covalently linked to peptidoglycan, 
making them an integral part of the Gram positive cell wall.
Lipoteichoic acid Lipoteichoic acid has the same structural features as teichoic acid except that it is 
attached to the bacterial cytoplasmic membrane through di-acyl glycerol lipid 
anchor.
Lipopolysaccharide LPS is found on the surface of Gram negative bacteria. LPS is a complex molecule 
composed of distinct regions. The innermost portion, lipid A, anchors the LPS to the 
outer membrane. The polysaccharide portion of the LPS consists of a core- 
polysaccharide region and the O-polysaccharide. The structure of the 0 -  
polysaccharide is highly variable within one species, giving rise to the different 0 -  
antigenic serotypes.
Capsular polysaccharide Both Gram negative and Gram positive bacteria can have a capsule. The capsule is 
made up of repeating units consisting 2 to 8 monosaccharides. The capsule can be 
covalently linked to the outer membrane by a lipid anchor in the case of Gram 
negative bacteria, covalently linked to the peptidoglycan in the case Of Gram 
positive, or as free polysaccharide which is not tightly bound to the cell surface.
Figure 1.2 Structural features of bacterial surface components teichoic acid, lipoteichoic acid, 
lipopolysaccharide and capsular polysaccharide.
The teichoic and lipoteichoic acid repeating unit structures illustrated in this figure are those from Streptoccocus pneumoniae (Fischer 
et al., 1993). The lipopolysaccharide structure is from Salmonella enterica (Rietschel et al., 1994) and the capsular polysaccharide 
structure is from Klebsiella pneumoniae serotype K31 (Kenne et al., 1983).
Abbreviations : AATGal, 2-acetamido-4-amino-214,6-trideoxy-D-galactopyranose; acyl2Gro, di-acyl glycerol; Abe, abequose; Hep, L- 
glycero-D-mannoheptose; Kdo, 2-keto-3-deoxyoctulosonic. Other abbreviations are listed in the abbrevations section at the beginning 
of the thesis.
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and the correlate of protection is the production of antibodies to the CPSs 
(Macleod et al., 1945, Cryz et al., 1984). Vaccines against encapsulated 
bacteria consist of the CPS from the pathogen, which is discussed in Section 
1.5. CPSs of K. pneumoniae are termed the K antigen, and there are at least 
90 K antigens reported. Some of these structures are shown in Figure 1.3. 
They commonly contain glucose (D-GIc), mannose (D-Man), galactose (D- 
Gal) and rhamnose (L-Rha). Fucose (L-Fuc), a common constituent of 
mammalian glycoproteins, is found in only a few serotypes (Orskov, 1984). 
Each repeating unit contains a hexuronic acid residue, which is normally 
glucuronic acid (D-GIcA), and is frequently substituted with pyruvate acetal 
and O-acetyl groups. In the case of S. pneumoniae, 90 serotypes have been 
described (Henrichsen, 1995). Some of these are shown in Figure 1.4 to 
illustrate diversity of CPS structures. S. pneumoniae CPS tend to contain D- 
GIcA or galacturonic acid (D-GalA) acid residues and may be substituted with 
O-acetyl, pyruvate acetal, and glycerol phosphate groups (Jennings, 1996). 
Some of the pneumococcal CPSs resemble teichoic acids, as they contain 
ribitol phosphate-linked repeat units. They often contain amino sugars, such 
as amino hexoses and also A/-acetyl-D-mannuronic acid. D-Gal, D-GIc, and 
L-Rha are frequently found, but D-Man is not detected in any of the 
pneumococcal CPS structures.
The capsule is generally considered to be an important virulence factor in K. 
pneumoniae. The capsule is critical for the organism’s ability to resist 
complement-mediated killing (Kabha et al., 1995), and is involved in the 
resistance to phagocytosis by polymorphonuclear cells by acting as a
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K 1 * —<4)-[2,3-(S)-pyruvate]-P-D-GlcA-( 1 ->4)-a-L-Fuc-( 1 -+3)-p-D-Glc-( 1—
K3a* —►2)-[(4,6-(S)-pyruvate)-a-D-Man-( 1 -+4)]-a-D-GalA-( 1—3)-a-D-Man-( 1 — 2)-a-D-Man-( 1 ^ 3)-p-D-Gal-( 1 -*•
K 11 * —>3)-p-D-Glc-( 1—*-3)-[(4,6-(S)-pyruvate)-a-D-Gal-( 1 ->4)]-p-D-GlcA-( 1 —3)-<x-D-Gal-( 1—
K 11* —>3)-p-L-Rha-( 1 ^ 4)-p-D-Glc-( 1 ->2)-[a-L-Rha-( 1 -*3)]-a-L-Rha-( 1 ^ 4)-a-D-GlcA-( 1—
K22b —»4)-P-D-Glc-( 1 —3)-[(4-0-lactate)-p-D-GlcA-( 1 -»6)-a-D-Glc-( 1 ^ 4)]-p-D-Gal-( 1—
6
T
OAc
K26* —>3)-p-D-Gal-( 1 -^2)-[(4,6-(S)-pyruvate)-P-D-Gal-( 1 ^ 4)-p-D-Glc-( 1 —6)-a-D-Glc-( 1 —4)]-a-D-GlcA-( 1 -*3)-a-D-Man-( 1 —2)-a-D-Man-( 1
K27* —>3)-p-D-Glc-( 1 —»3)-?Gal-( 1 ^ 3)-[p-D-Glc-( 1 —4)]-?Gal-( 1 -+6)-p-D-Glc-( 1 -*•
6
T
l
p-D-GlcA
K31 * —+3)-p-D-Gal-( 1 —3)-p-D-Glc-( 1 -»3)-[4,6-(S)-pyruvate)-p-D-GIc-( 1 ^ 2)-a-D-Man-( 1 ^ 4)]-a-D-GlcA-( 1 - *
K36 —»2)-a-L-Rha-( 1 -^3)-p-D-Gal-( 1 — 3)-[(4,6-(S)-pyruvate)-p-D-Glc-( 1 ^ 4)-p-D-GlcA-( 1 -+2)]-a-L-Rha-( 1 ->3)-ct-L-Rha-( 1 -*■
K40c —>3)-a-L-Rha-( 1 ^ 2)-a-L-Rha-( 1 —4)-a-D-GlcA-( 1 — 2)-a-D-Man-( 1 ^ 2)-a-D-Man-( 1 —3)-tx-D-Gal-( 1 -*•
K46 —3)-a-D-Gal-( 1 -+3)-p-D-Gal-( 1 — 3)-[p-D-Glc-( 1 — 3)-(4,6-(S)-pyruvate)-?Man-( 1 — 4)]-a-D-GlcA-( 1^3)-a-D-Man-( 1 ->
K52d* —>3)-[a-D-Gal-( 1 —2)]-a-D-Gal-( 1 ->4)-a-L-Rha-(l—3)-p-D-Gal-( 1 ^ 2)-a-L-Rha-( 1 —4)-P-D-GlcA-( 1 -»
K.55* —»3)-p-D-Glc-( 1 —►4)-[a-D-GlcA-( 1 -+3)-a-D-Gal-( 1 ->3)]-<x-L-Rha-( 1—
2
T
OAc
Figure 1.3 Structures of K. pneumoniae capsular polysaccharides
The structures of some Klebsiella CPSs are shown to illustrate the diversity of these polysaccharides. K1 and 
K3 are of particular interest as they have been shown to exhibit possible adjuvant properties (Choy et al., 
1996). CPSs indicated by * have been used for experiments carried out in Chapters 3, 4, and 5 of this thesis. 
Structures are taken from Kenne et al., 1983 except for the following: (a) Dutton et al., 1986, (b) Parolis et al., 
1988, (c) Cestutti et al., 1993 and (d) Stenutz et al., 1997.
Type Structure
1 —3)-a- AATGal-( 1 -*4)-<x-D-GalA-(l-»3-a-D-GalA-( 1—
3 —>4)-P-D-Glc-( 1 —*3)-p-D-GlcA-( 1 —*
4 ^3)-P-D-ManNAc-( 1 ^ 3)-a-L-FucNAc-( 1 —3)-a-D-GalNAc-( 1 -+4)-[2,3-(S)-pynivate]-a-D-Gal-( 1
6B —2)-a-D-Gal-( 1 ^ 3)-a-D-Glc-( 1 ->3)-a-L-Rha-( 1 — 4)-D-Ribitol-(5-P—
9N —*4)-a-D-GlcA-( 1 ^ 3)-a-D-Glc-( 1 -+3)-p-D-ManNAc-( 1 —4)-p-D-Glc-( 1 ->4)-a-D-GlcNAc-( 1
9V —+4)-a-D-GlcA-( 1 --3  )-a-D-Gal-( 1 — 3)-p-D-ManNAc-( 1 — 4)-p-D-Glc-( 1 -^4)-a-D-GlcNAc-( 1—
T T
OAc OAc
14 —*4)-P-D-Glc-( 1 —»6)-[P-D-Gal( 1 ^ 4)]-p-D-GlcNAc-( 1 —3)-p-D-Gal-( 1 -►
18C —>4)-P*D-Glc-( 1 —*4)-[a-L-Glc-( 1 —2)]-P-D-Gal-( 1 —4)-a-D-Glc-( 1 —3)-a-L-Rha-( 1—
3
"J P-l -glycerol
19 A  —-4)-P-D-ManNAc-( 1 ->4)-a-D-Glc-( 1 ->3)-a-L-Rha-( 1-P -*
19F —»4)-p-D-ManNAc-( 1 —4)-a-D-Glc-( 1 -+2)-a-L-Rha-( 1-P -*
23F —>4)-P-D-Glc-( 1 —>4)-[a-L-Rha( 1 ^ 2)]-P-D-Gal-( 1 ^ 4)-p-L-Rha-( 1—
3
T
P-2-glycerol
CW-PS —>6)-P-D-Glc-( 1 —3)-a-D-AATGal-( 1 —4)-a-D-GalNAc-( 1 —3)-p-D-GalNAc-( 1 ->• 1 )-D-Ribitol-(5-P^
6 6
T T
P-choline P-choline
Figure 1.4 Structures of S. pneumoniae capsular polysaccharides
The capsular polysaccharide structures illustrated are those from serotypes associated with clinical isolates found in 
developed countries and are components of the 23-valent polysaccharide vaccine. These polysaccharides were used in 
studies carried out in Chapter 6 of this thesis. Structures are taken from Jennings et al., 1996. All sugars are in the pyranose 
conformation.
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Chapter One
physical barrier. The CPS from Klebsiella envelopes the bacterial cell surface 
and prevents cell surface components such as LPS and porins from 
activating complement (Alvarez et al., 2000). The capsule of S. pneumoniae 
is a prerequisite for virulence as non-encapsulated mutants are quickly 
cleared from the circulation (Watson and Musher, 1990; Watson et al., 1995). 
The main role of the capsule in virulence is probably to protect the 
pneumococcus from phagocytosis. Klebsiella and pneumococcal CPSs are 
therefore a major target for both the innate and adaptive immune system.
CPSs are possible targets for lectin interaction resulting in 
lectinophagocytosis (antibody-independent phagocytosis of micro organisms 
mediated by lectin interaction). It has been suggested that CPS can promote 
binding of K. pneumoniae to guinea pig alveolar macrophages in serum-free 
medium and that binding is followed by ingestion and killing of the bacteria 
(Athamna et al., 1991). It has also been suggested that macrophage 
mannose receptor is involved (Kabha et al., 1995). The binding of purified 
CPSs to the macrophage mannose receptor in vitro has recently been 
studied in our laboratory. Ten out of the twelve pneumococcal CPSs tested 
bound to the mannose receptor, despite structural variation. In contrast, 
Klebsiella CPSs failed to bind (Zamze et al., 2002). Interestingly Klebsiella 
LPS did bind to the mannose receptor which suggests that 
lectinophagocytosis is mediated through the binding of LPS, rather than CPS, 
to the mannose receptor. There are no obvious structural differences to 
explain the preferential binding of the mannose receptor to pneumococcal 
CPSs. Recogniton of structurally variable Klebsiella LPS and pneumococcal
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CPSs by the mannose receptor shows that criteria other than primary 
polysaccharide structure (e.g CPS conformation) must be taken into 
consideration for lectin receptor specificity.
There have also been several reports describing the possible adjuvant 
activity of Klebsiella CPSs independent of LPS. Yokochi and colleagues 
showed that Klebsiella CPSs augmented the antibody response to various 
antigens in mice (Yokochi et al., 1980b). Further studies in mice have shown 
that Klebsiella CPSs induced the release of TNF-a (Choy et al., 1996, Ho et 
al., 2000).
1.2.2 Lipopolysaccharide
LPS is found on the outer membrane of all Gram negative bacteria as shown 
in Figure 1.1 (Rietschel et al., 1994). Most of our understanding of LPS has 
come from studies of Enterobacteriaceae. LPS in these bacteria is composed 
of a hydrophobic domain known as lipid A, a core oligosaccharide region and 
a distal polysaccharide known as the O-specific polysaccharide. If the O- 
specific polysaccharide is absent, the LPS is known as a rough LPS. If O- 
specific polysaccharide is present the LPS is referred to as smooth LPS. The 
O-specific polysaccharide diversity is impressive; more than 60 
monosaccharides and 30 non carbohydrate components have been 
recognised (Raetz and Whitfield, 2002). Different Gram negative bacterial 
species can therefore have different O-specific polysaccharide structures. 
Lipid A, also known as endotoxin, is a diglucosamine-based phospholipid. 
Lipid A is the most conserved part of the LPS molecule and is responsible for
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some of the biological activities of LPS. The inner core oligosaccharide 
regions connect the lipid A and O-specific polysaccharide.
Some Gram negative bacteria, such as Haemophilus influenzae and 
Neisseria meningitides, express lipooligosaccharide (LOS), which is 
analogous to the LPS found on other Gram negative families (Kahler et al., 
1998; Swords et al., 2003). LOSs share similar lipid A and functional 
activities to LPSs, except LOSs lack O-specific polysaccharide units. LOS 
structures are limited to 10 saccharide units. LOS is predominantly 
expressed on mucosal bacteria whereas LPS is expressed mostly on enteric 
bacteria. The O-specific polysaccharide of LPS results in the bacterial cell 
having a hydrophilic surface. This results in the resistance of enteric bacteria 
to solubilisation by enzymes and bile in the gastrointestinal tract, whereas 
mucosal bacteria which generally lack O-specific polysaccharide tend to have 
hydrophobic surfaces which are susceptible to bile (Preston et al., 1996).
K. pneumoniae is a Gram negative bacterium which produces LPS, rather 
than LOS. There are 9 different O-specific polysaccharides identified, with 01  
being the most common among clinical isolates of K. pneumoniae. The O 
polysaccharides are composed of repeating units that contain 
monosaccharides, such as D-Man, D-Gal and L-Rha and non-carbohydrate 
substituents such as O acetyl groups. Some are termed homopolymers such 
as 0 5  which has a mannose polymer, whereas those that contain more than 
one sugar, such as 04 , are termed heteropolymers. Figure 1.5 shows
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01 Galactan I and Galactan II: —>3)-P-Ga|/-(l—►3)-a-D-Gal-(l—► and -^3)-a-D-Gal^-( 1 —>3)-P~D-Galp-( 1 — respectively.
02a Galactan I
03 Polymannose: —>3)-a-D-Man-( 1 —>3)-a-D-Man-( 1—>2)-a-D-Man-( 1 —>2)-a-D-Man-( 1 —►2)-a-D-Man-( 1 —►
04 — 2)-P-Rib/-(l-^4)-D-GaV?-(l-»
Figure 1.5 Structures of the O-antigenic sidechains of K. pneumoniae LPS
Structures are taken from Orskov et al., 1984. The majority of LPSs expressed by isolates of K. pneumoniae are of 
the 01, 02, and 03 serotypes. The K. pneumoniae strains used in studies described in Chapter 3, 4, and 5 have one 
of these O-antigen serotypes. Of particular interest is 03, which has been shown to have greater 
immunomodulatory properties than other LPS types (Ohta et al., 1 9 8 5 )./ = furanose p  = pyranose
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examples of four O-specific polysaccharide structures from K. pneumoniae 
LPS (Orskov et al., 1984).
Particular O-specific polysaccharide side chains of K. pneumoniae LPS have 
been shown to possess greater immunomodulatory properties than other 
LPS types (Ohta et al., 1985). K. pneumoniae 0 3  and 0 5  polysaccharides 
are mannose homopolymers. They have been shown to have strong adjuvant 
properties compared to other O-polysaccharide structures. The mechanism 
of action is perhaps through enhanced complement activation. Mannose 
homopolymers are 100 times more potent at activating complement 
compared to other LPS types (Kido et al., 1985).
1.2.3 Lipoteichoic and teichoic acid
The pneumococcal cell surface is composed of membrane bound LTA 
encased in a cell wall consisting of a multilayered network of peptidoglycan 
with associated TA chains (Fischer. 1997). LTA and TA are found on the 
surface of Gram positive bacteria (Figure 1.1). The term teichoic acid 
includes all cell surface associated polymers containing glycerol phosphate 
or ribitol phosphate residues. These polyalcohols are connected by 
phosphate esters and usually have other sugars and D-alanine attached. The 
TA of pneumococcus is either referred to as C polysaccharides or cell wall 
polysaccharide (CW-PS). It is evident that the repeating units of CW-PS are 
identical to that reported for LTA (Jennings et al., 1980, Behr et al., 1992). 
The LTA is hydrophobically anchored to the cytoplasmic membrane by its 
ester-linked fatty acids. LTA and TA are considered pneumococcal common 
antigens; every Gram positive bacterial species possesses its own particular
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LTA and TA. In contrast to the 90 capsular serotypes described for S. 
pneumoniae which are strain specific.
1.3 Innate immunity
The innate immune system is an ancient defence mechanism which uses a 
limited number of germ-line encoded receptors for the recognition of 
microbial pathogens. This distinguishes it from the adaptive immune system 
which is based on receptors that are generated by somatic gene 
rearrangement mechanisms. The latter mechanism generates a diverse 
repertoire of antigen receptors with random specificities which are clonally 
distributed on the surface of B and T cells. Consequently, the specificity of 
antigen receptors for T and B cells is not predetermined.
Pathogens are characterised by specific structures called pathogen- 
associated molecular patterns (PAMPs) and are recognised by pattern 
recognition receptors (PRRs) of the innate immune system (Medzhitov and 
Janeway, 1997). The PRRs are found on many cells of the innate immune 
system including dendritic cells (DCs) and macrophages. There are several 
different families of PRRs such as scavenger receptors, Toll-like receptors 
(TLRs), C-type lectins and complement receptors which will be discussed in 
more detail in the following sections. There are also several soluble factors, 
which bind PAMPs, these include complement, mannan-binding lectin (MBL), 
lipopolysaccharide binding protein (LBP) and C-reactive protein.
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1.3.1 Macrophages and Dendritic cells
Professional antigen presenting cells (APCs), DCs and macrophages, are 
specialised phagocytes that are important in the clearance of host cells and 
microbial components. They are found throughout the body and participate in 
the initial capture and processing of potential antigens (innate immunity) and 
then activation of specific T and B cell effector mechanisms (adaptive 
immunity). In addition to their efficient endocytic and phagocytic activities, 
APCs are potent secretory cells that induce and regulate local and systemic 
inflammatory and immune responses (MacMicking et al., 1997, Banchereau 
et al., 2000).
Macrophages recognise pathogens by surface receptors such as mannose 
receptor, complement receptors, and scavenger receptors. Ligation of many 
of the surface receptors that recognise pathogens leads to phagocytosis of 
the pathogen (Underhill and Ozinsky, 2002). Internalisation of the pathogen 
initiates an assortment of enzymatic and oxidative mechanisms that result in 
the killing and disposal of engulfed particles. Microbe internalisation by 
macrophages is normally accompanied by the production of proinflammatory 
signals. Recognition of microbial components by receptors such as TLRs 
generally results in increased costimulatory molecule expression and the 
production of cytokines by macrophages.
Like macrophages, DCs express cell surface receptors that recognise 
microbes and microbial components. Microbial stimulation acting through 
receptors such as TLRs on immature DCs results in their maturation. 
Maturation leads to reduced endocytic and phagocytic capability, enhanced
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expression of costimulatory molecules, increased antigen processing and 
presentation, and release of cytokines and chemokines (Rescigno, 2002). 
Mature DCs are therefore potent activators of T cell priming and 
differentiation. DCs can therefore be described as cells that link innate and 
adaptive immunity. DCs can direct the adaptive response by cytokine 
release. Cytokines are key mediators of immune responses and their release 
can tailor the induced T cell response. IL-12, IL-18, IFNy and IL-23 can 
promote Th1 responses whereas IL-4 induces a Th2 response.
1.3.2 Innate Immune Recognition of Pathogens
1.3.2a Soluble factors 
A: Complement
Complement is a complex and highly regulated biological effector system. Its 
functions include the recognition and elimination of pathogens and altered 
host cells. In this context, complement is a major constituent of the innate 
immune system, with the ability to discriminate self from non-self and to 
facilitate the removal of pathogens and any other non-self antigens, through 
multiple proinflammatory, opsonic, phagocytic, cytotoxic and cytolytic actions 
(Barrington et al., 2001).
The complement system consists of more than 30 soluble and membrane 
proteins. Activation is required for biological activity of the system. This 
initiates a highly regulated cascade of interactions between complement 
components, with each other, with the activator, and with cell membranes.
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There are three different ways to activate complement: antibody-antigen 
complexes and certain negatively charged structures initiate the classical 
pathway (Arlaud et al., 2001); the alternative pathway is initiated by 
interference with regulatory components by structures on microbial surfaces 
(Xu at al., 2001); and the mannan-binding lectin (MBL) pathway is mediated 
by binding of MBL (Gadjeva et al., 2004) or ficolins (Matsushita et al., 2001) 
to carbohydrate. Once the complement system is activated, a chain of 
reactions that involve proteolysis and assembly occurs, which results in the 
cleavage of C3. The cascade that leads to the cleavage of C3 is called the 
activation pathway. It is followed by the lytic pathway, during which the 
membrane attack complex (MAC) is formed.
Classical complement pathway
The classical pathway can be initiated by the binding of C1 directly to the 
pathogen surface or to antigen-antibody complexes. HIV-1 has been shown 
to be recognised by C1 in the absence of specific antibody (Ebenbichler et 
al., 1991). C1 binding to all activators of the classical pathway is mediated by 
its recognition subunit C1q and is believed to generate a conformational 
change that triggers activation of its catalytic subunit C1s-C1r-C1r-C1s 
comprising the two proteases C1s and C1r (Arlaud et al., 2001). After the 
autolytic activation of pro-enzyme C1r, C1r activates pro-enzyme C1s, and 
C1s cleaves complement components C4 and C2 to produce cleavage 
products C2b and C4b. C2b and C4b together form the C3 convertase of the 
classical pathway (Kerr, 1980). The C3 convertase is therefore bound to the 
surface of the pathogen and cleaves C3 molecules into C3a and C3b. C3b
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(acts as an opsonin) binds to the surface of the pathogen and facilitates its 
uptake and destruction by phagocytic cells that express CR1 (complement 
receptor 1) which has specificity for C3b. Many of the deposited C3b 
fragments are subsequently degraded to iC3b and C3dg. iC3b is a major 
opsonin that binds to CR3 and CR4, whereas C3dg and C3d (proteolytic 
fragment of C3) can only engage CR2 expressed by B cells and follicular 
dendritic cells (FDCs). C3a is an anaphylatoxin which has potent biological 
activities at very low concentrations. Activation of cells through the C3a 
receptor (Ember and Hugli, 1997) results in a variety of proinflammatory 
events including increased permeability of small blood vessels and regulation 
of vasodilation (Kohl, 2001).
C3b can also bind to the C3 convertase to form a C5 convertase (Rawal and 
Pangburn, 2003). The C5 convertase cleaves C5 into C5a and C5b. C5a is a 
chemotatic anaphylatoxin (DiScipio et al., 1988) and C5b initiates the 
formation of the membrane attack complex (MAC) which helps to destroy 
microrganisms. C5b forms a molecular complex with C6 to form C5b-6, the 
addition of this to C7 creates C5b-7. C5b-7 is capable of associating and 
intergrating into the lipid bilayer of the bacterium (DiScipio et al., 1988, 
DiScipio, 1992). After C8 adds to C5b-7, transmembrane pores are formed, 
and these grow and circularize with the accretion of C9 to produce the final 
assembly that directly lyses bacteria (Scibek et al., 2002).
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Alternative complement pathway
In the alternative pathway, assembly of the C3 convertase is initiated by the 
covalent attachment of C3b to the surface of an activator (Xu et al., 2001). 
Activators include a wide range of pathogens. CPSs of S. pneumoniae have 
been shown to bind covalently to C3b (Griffioen et al., 1991). The attachment 
of C3b is achieved through a reaction between the carbonyl of the thioester 
in C3b and, typically, hydroxyl groups on the activator surface (Law et al., 
1979). Following this, factor B, a serine protease, binds to the activator- 
linked C3b to form activator-linked C3bB. The factor B present in the 
complex is then subject to proteolysis by factor D, another serine protease, 
which results in the cleavage of factor B into Ba and Bb. Ba is released and 
Bb remains bound to C3b forming C3bBb, which is the C3 convertase of the 
alternative pathway (Xu et al., 2001). The C3bBb complex catalyzes the 
cleavage of C3 and C5 resulting in the formation of C3a, C3b, C5a, and C5b. 
The following stages are the same as those described for the classical 
pathway where C3b acts as an opsonin and C5b initiates the formation of the 
MAC.
Mannose-binding lectin pathway
MBL (Figure 1.6) is associated with serine proteases known as MBL- 
associated serine proteases (MASPS) (Gadjeva et al., 2004). These are 
structurally similar to the C1s and C1r of the classical complement pathway. 
MBL is a member of the collectin family of proteins. In addition to MBL, the 
two mucosal-associated proteins, surfactant protein A and D (SP-A and SP- 
D) also belong to this family of proteins. Collectins share common structural
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Figure 1.6 Structure of Mannose-binding lectin
This diagram was adapted from Presanis et al., 2003. The polypeptide chain of MBL is 
shown in (A). The neck region forms an a-helical coiled-coil structure which may promote 
trimerisation of three polypeptide chains as shown in (B). These trimers can assemble to 
form larger structures, the most common in humans is a six-subunit form which contains 18 
polypeptide chains as shown in (C).
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features: an amino-terminal cysteine rich region followed by a collagen-like 
region, an a-helical coiled region and a carboxy-terminal carbohydrate 
recognition domain (CRD).
MBL binds to an array of carbohydrate structures on the surface of 
microorganisms. For Gram negative organisms a major ligand for MBL is 
LPS. Lipoteichoic acids from Gram positive bacteria have also been shown to 
be ligands for MBL (Polotsky et al., 1996). Noncapsulated strains of H. 
influenzae and N. meningitidis have been shown to bind MBL better than 
their capsulated counterparts, suggesting the capsule can protect the 
bacteria from MBL (van Emmerik et al., 1994). The discrimination between 
self and non-self structures recognised by MBL resides in the specificity of 
the CRD and spatial arrangement of the CRDs. MBL preferentially 
recognises glycans with D-Man, D-Glu, L-Fuc, N-acetyl-mannosamine 
(ManNAc) and N-acetyl-glucosamine (GlcNAc) at a terminal non-reducing 
position (Turner, 1996). Thus MBL is very efficient at recognising microbial 
surfaces with high content of repetitive D-Man and/or GlcNAc such as those 
presented by S. typhimurium and N. gonorrhoeae (Devyatyarova-Johnson et 
al., 2000). Most carbohydrate structures in mammalian glycoproteins are 
terminated by sugars not recognised by MBL (e.g. galactose and sialic acid).
MBL bound to microbial surfaces is able to activate the complement system 
in an antibody independent manner. MBL-associated MASPs known as 
MASP-1, MASP-2 and MASP-3 have been shown to associate with MBL but 
evidence suggests that MASP-2 is more important in complement activation
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(Matsushita and Fujita, 1992; Thiel et al., 1997; Dahl et al., 2001). 
Complexes of MBL and MASP-2 become activated when bound to microbial 
surfaces displaying specific carbohydrate ligands. MASP-2 then exhibits 
enzymatic activity that results in the sequential cleavage of complement 
components C4 and C2. C4b fragments can bind covalently to microbial 
surfaces which then interact with C2 components generated by MASP-2 
(Turner, 1996). The C4b2a complex, is created by the cleavage of C2 and 
C4, has C3 convertase activity that is identical to the C3 convertase of the 
classical and alternative pathways. The C3 convertase can therefore 
generate opsonic C3b fragments.
B: C-reactive protein
C-reactive protein (CRP) is a pattern recognition molecule made up of five 
identical subunits; in the presence of Ca2+, each subunit binds with high 
affinity to phosphocholine (PC) (Szalai, 2002). PC is a major constituent of 
the cell wall C-polysaccharide of S. pneumoniae and has been identified on 
other Gram positive bacteria such as Clostridium spp., Lactococcus spp., and 
Bacillus spp (Gillespie et al., 1996). It has also been found on the Gram 
negative bacteria H. influenzae, N . meningitidis and N. gonorrhoeae (Kolberg 
et al., 1997). The levels of CRP in the blood rise dramatically during 
inflammatory episodes. Ligand-bound CRP can bind to C1q and thus 
activate the classical complement pathway. This leads to the deposition of 
C3b onto the ligand-bound CRP complex, and subsequent recognition of the 
complex by complement receptors on phagocytes. CRP can also bind
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directly to FcyRs (receptors for the Fc of IgG), resulting in the enhancement 
of the opsonization and phagocytosis of microbes (Stein et al., 2000).
1.3.2b Cell associated receptors 
A: Scavenger receptors
Scavenger receptors (SR) is a term used to cover groups of structurally 
related molecules expressed on macrophages, DCs and endothelia with 
broad specificity for polyanionic ligands (Platt et al., 1998, Peiser et al.,
2002). The following SRs have been implicated in bacterial uptake by 
macrophages, DCs and endothelial cells. The class A macrophage 
scavenger receptors are originally defined as receptors which bind to 
modified low-density lipoproteins (LDLs) such as oxidised LDL and 
acetylated LDL (Kraal et al., 2000). Three class A SRs that have been 
identified are SR-AI, SR-AII and MARCO (macrophage receptor with a 
collagenous domain). SR-A1 and SR-AII are alternative splice products of the 
same gene (Emi et al., 1993). The binding site for selected polyanionic 
ligands has been attributed to the collagenous domain. These receptors are 
expressed on most tissue macrophages and in vitro cultured DCs and can 
bind LTA (Dunne et al., 1994) and the lipid A part of LPS (Hampton et al., 
1991). Mice deficient in SR-AI and SR-AII have been shown to be more 
susceptible to L. monocytogenes (Suzuki et al., 1997) and S. aureus infection 
(Thomas et al., 2000). MARCO is a distinct class A SR that shares structural 
similarity to SR-AI/SR-AII. In mice it has been shown to bind both Gram 
positive and Gram negative bacteria and also bind bacterial CpG DNA (Zhu 
et al., 2001). It is constitutively expressed on the surface of splenic marginal
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zone macrophages and peritoneal macrophages (Elomaa et al., 1995) and 
upregulated on other macrophages by LPS (van der Laan et al., 1999).
B: C-type lectins
Cells of the immune system are equipped with many lectin and lectin-like 
receptors. Many of these lectins are members of the Ca2+-dependent C-type 
lectin family and recognise ligands through the structurally related Ca2+- 
dependent carbohydrate recognition domains (CRDs) (Drickamer. 1988, 
Geijtenbeek et al., 2004). Examples of these types of receptors include the 
mannose receptor and DC-SIGN. The mannose receptor is a pattern 
recognition receptor that plays an important role in the first line of host 
defence, by recognising carbohydrates that are present on the surface and 
cell walls of infectious agents. It is a 175kDa type 1 membrane molecule that 
has five domains: the amino-terminal cysteine rich region; a domain 
containing a fibronectin type II repeat; a series of 8 tandem CRDs; a 
transmembrane domain; and a cytoplasmic carboxy terminal domain (Taylor.
2001). It has been shown to mediate the endocytic uptake of soluble 
glycoconjugates and is reported to mediate lectinophagocytosis of a number 
of bacteria including K. pneumoniae (Athamna et al., 1991). The protein is 
expressed on macrophages and hepatic endothelial cells (Linehan et al., 
1999) and DCs (in vitro) (Sallusto et al., 1995). Its CRDs have specificity for 
monosaccharides L-Fuc = D-Man > GlcNAc «  D-Gal (Mullin et al., 1994). 
The CRDs of the mannose receptor have been shown to bind CPS from S. 
pneumoniae and LPS, but not CPS from K. pneumoniae (Zamze et al.,
2002). It also has a role in clearance of host serum glycoproteins, lysosomal
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enzymes and tissue plasminogen activator, and pituitary hormones such as 
lutropin and thyrotropin (Simpson et al., 1999). The mannose receptor can 
therefore function as both a pattern recognition receptor and a regulator of 
homeostasis (Allavena et al., 2004).
The mannose receptor can be found in cell bound and soluble forms. The 
soluble form of the receptor has been identified in both mouse and human 
serum. The soluble form lacks the carboxyl end of the molecule and is 
produced by the proteolytic activity of metalloproteinases (Martinez-Pomares 
and Gordon, 1999a). Recent proposals have suggested that a soluble form 
of the receptor could be involved in an antigen transport pathway (Martinez- 
Pomares and Gordon, 1999b). The discovery that there are ligands in 
specialised cell populations of secondary lymphoid organs, such as 
metallophilic macrophages from the splenic marginal zone (Martinez- 
Pomares et al., 1996), that are recognised by the cysteine rich domain of the 
mannose receptor, suggests that perhaps the soluble mannose receptor can 
target antigen to specific cell types.
DC-SIGN (human DC-specific intercellular adhesion molecule-grabbing 
nonintegrin) is a C-type lectin with a type II membrane orientation. It is a 
receptor for a number of different pathogens including Ebola virus (Alvarez et 
al., 2002), cytomegalovirus (Halary et al., 2002), hepatitis C virus (Pohlmann 
et al., 2003), human immunodeficiency virus-1 (Geijtenbeek et al., 2000) 
Dengue virus (Tassaneetrithep et al., 2003), Helicobacter pylori and certain 
strains of K. pneumoniae (Appelmelk et al., 2003). How one receptor can
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bind so many different pathogens is not clear. The recognition of these 
pathogens is probably mediated by its CRD that has specificity for 
carbohydrate residues such as Lewis-X, D-Man and L-Fuc. It was shown that 
DC-SIGN interacted with Helicobacter pylori and K. pneumoniae through LPS 
structures containing Lewis-X or mannose, respectively (Appelmelk et al.,
2003). The mannose-capped cell-wall component of Mycobacteria 
tuberculosis, lipoarabinomannan, also interacts with DC-SIGN (Maeda et al.,
2003). Recent studies have shown that mycobacteria can suppress DC 
function by binding to DC-SIGN and modulate the immune response by 
shifting the Th1 and Th2 cell balance (Geijtenbeek et al., 2003). This 
highlights the possible exploitation of DC-SIGN by pathogens to induce an 
inappropriate immune response or to gain entry into a cell to replicate. In 
contrast to these findings DC-SIGN may be important in the capture and 
internalisation of pathogens for processing and antigen presentation 
(Engering et al., 2002).
SIGN-R1 is one of five recently identified mouse genes that share amino acid 
sequence homology to human DC-SIGN. SIGN-R1 is not expressed on DCs. 
It is expressed at high levels by medullary and subcapsular sinus 
macrophages in lymph nodes and by marginal zone macrophages in the 
spleen (Kang et al., 2003). SIGN-R1 has been shown to function in vivo as a 
PRR mediating the uptake of CPS of S. pneumoniae in the marginal zone of 
the spleen (Kang et al., 2004).
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C: Toll-Like receptors.
TLRs have been identified as a major class of signalling receptors in innate 
immunity (Takeda et al., 2003). The TLR family now consists of 10 members 
(TLR1-TLR10). The cytoplasmic portion of TLRs shows a high similarity to 
that of the IL-1 receptor family, and is called the Toll/IL-1 receptors (TIR) 
domain. In spite of this similarity, the extracellular portions of both receptors 
are structurally unrelated. IL-1 receptors possess an Ig-like domain, whereas 
TLRs have leucine-rich repeats in the extracellular domain (Takeda and 
Akira, 2003). These receptor families function through the same signalling 
molecules, including MyD88, IL-1 receptor associated kinase (IRAK), TNF 
receptor associated factor (TRAF)-6, mitogen-activated protein (MAP) 
kinases and nuclear factor (NF)-kB (Akira, 2003). Activation of TLRs results 
in the activation of an inflammatory response. Individual TLRs recognise 
distinct structural components of pathogens and some studies also suggest 
recognition of endogenous ligands. These will be discussed in the following 
sections. The TLR expression varies with cell type. Human blood CD11c+ 
DCs do not express TLR9, but express all other TLRs, whereas human 
plasmacytoid DCs (PDC) do not express TLR2, 3, 4, 5 and 8 but express the 
others. Murine splenic CD4+, CD8a+, and CD4' CD8' DCs and also PDCs 
express all TLRs, with one exception. The CD8a+ subset which does not 
express TLR7 (Edwards et al., 2003). Mouse monocytes and macrophages 
express mRNA for most of the TLRs except TLR3 (Muzio et al., 2000). 
Human B cells have been shown to express TLR1, 6, 7, 9 and 10 (Hornung 
et al., 2002). Other cell types such as neutrophils (Hayashi et al., 2003) and
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mast cells (Supajatura et al., 2001) express a range of TLRs. Why the TLR 
repertoire varies amongst cell types is still not clear.
TLR1, TLR2 and TLR6
TLR2 recognises a variety of microbial components. These include 
lipoproteins from a variety of pathogens, LTA from Gram positive bacteria, 
lipoarabinomannan from mycobacteria, a phenol-soluble modulin from 
Staphylococcus epidermidis, porins from Neisseria and atypical LPS from 
Porphyromonas gingivalis (Takeda et al., 2003). The importance of TLR2 in 
the recognition of peptidoglycan has been shown in mice that are deficient in 
TLR2 (Takeuchi et al., 2000). The mechanism by which TLR2 recognises 
many structurally different microbial components may be due to its 
association with TLR1 and TLR6.
TLR2 has been shown to interact physically with TLR6 in the cell (Ozinsky et 
al., 2000). Studies in TLR6-deficient mice have shown that TLR6 cooperates 
functionally with TLR2 to recognise microbial lipopeptides and thus able to 
distinguish between pathogens (Takeuchi et al., 2001). Bacterial lipopeptides 
have an amino-terminal cysteine residue that is triacylated in contrast to 
mycoplasmal macrophage-activating lipopeptide 2 (MALP-2) which is 
diacylated. Both TLR2 and TLR6 are required to recognise MALP-2, whereas 
bacterial lipopeptides only require TLR2. TLR6 therefore associates with 
TLR2 to recognise subtle differences between triacyl and diacyl lipopeptides. 
TLR1 has also been shown to associate with TLR2. TLR1 and TLR2 have
47
Chapter One
been shown to confer responsiveness to various soluble factors of N. 
meningitidis (Wyllie et al., 2000).
TLR3
TLR3 has been shown to recognise double stranded RNA (Alexopoulou et 
al., 2001). Double stranded RNA is an intermediate produced by some 
viruses during their replication cycle. Double stranded RNA has been shown 
to induce the synthesis of type 1 interferons (IFNa/p), which have antiviral 
activities. Similar observations have been made with synthetic double 
stranded RNA, polyinosinic-polycytidylic acid (poly(l:C)). Mice deficient in 
TLR3 fail to respond to both viral double stranded RNA and poly(l:C) 
(Alexopoulou et al., 2001).
TLR4
TLR4 is an essential receptor that transduces the signals of LPS. This was 
demonstrated by the discovery that C3H/HeJ mice (hyporesponsive to LPS) 
have a single point mutation in a conserved region of the cytoplasmic domain 
of TLR4. In addition, mice deficient in TLR4 had similar manifestations to 
C3H/HeJ mice (Hoshino et al., 1999). The recognition of LPS by TLR4 
requires several additional molecules. LPS binds to LPS-binding protein 
(LBP) in serum and the LPS-LBP complex is associated with CD14 present 
on the surface of mononuclear phagocytes. Mice deficient in either LBP and 
CD14 have abrogated responses to LPS (Haziot et al., 1996, Jack et al., 
1997). Another molecule involved in the LPS response is MD-2, a protein that 
associates with the extracellular portion of TLR4. Macrophages, DCs and B
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cells from MD-2 deficient mice fail to respond to LPS (Nagai et al., 2002). An 
additional component involved in the recognition of LPS in B cells is RP105. 
RP105 contains a leucine-rich repeat domain that is structurally related to 
those found in the extracellular portion of the TLRs and is preferentially 
expressed on B cells (Miyake et al., 1995). A functional association of RP105 
and TLR4 has been shown. Thus, RP105 together with TLR4 are involved in 
the recognition of LPS in B cells.
In addition to LPS, TLR4 recognises several other ligands. Taxol, a diterpene 
purified from the bark of the Western Yew, has been shown to have LPS-like 
activities in mice (Byrd-Leifer et al., 2001). TLR4 has also been shown to 
recognise various endogenous ligands, for example heat shock protein 60 
(HSP60) (Ohashi et al., 2000), HSP70 (Asea et al., 2002), type III repeat 
extra domain A of fibronectin (Okamura et al., 2001), oligosaccharides of 
hyaluronic acid (Termeer et al., 2002) and heparan sulphate (Johnson et al., 
2002). These host products are often found during injury, infection and 
autoimmunity, thus TLR4 may be important in the recognition of endogenous 
ligands involved in the inflammatory response. However, it is also possible 
that these host products may contain LPS which could activate TLR4.
Surprisingly, there is no evidence to show direct binding of LPS to TLR4. 
Triantafilou proposed a model of LPS recognition by a cluster of receptors 
associated with lipid rafts (Triantafilou and Triantafilou, 2002). CD14,
HSP70, HSP90, are constitutively found on lipid rafts whereas chemokine 
receptor 4 (CXCR4), growth differentiation factor 5 (GDF5) and TLR4 are all
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found in lipid rafts only after LPS stimulation. LPS therefore generates an 
association of an array of receptors that could be involved with LPS 
recognition.
TLR5
TLR-5 has been shown to be activated by bacterial flagellin (Hayashi et al.,
2001). Flagellin is a monomeric constituent of bacterial flagella, which are 
polymeric rod-like appendages extending from the outer membrane of 
bacteria. Flagella serve as the propellers that move bacteria through an 
aqueous environment.
TLR7, TLR8 and TLR10
TLR7 recognises synthetic imidazoquinolines (Hemmi et al., 2002). 
Imiquimod and R-848 are examples of imidazoquinolines that possess potent 
antiviral and anti-tumour properties. They induce the production of 
inflammatory cytokines, such as IFN-y. Both TLR8 and TLR7 have been 
shown to mediate independently recognition of R-848 in humans (Jurk et al.,
2002). These compounds have structures similar to nucleic acids. Two 
recent papers have described the recognition of single stranded RNA by 
TLR7 and TLR8. Heil and colleagues have shown that mouse TLR7 and 
human TLR8 recognises guanosine and uridine rich single stranded RNA 
oligonucleotides derived from HIV-1 (Heil et al., 2004) and Diebold and 
colleagues demonstrated endosomal recognition of influenza genomic RNA 
and signalling by TLR7 (Diebold et al., 2004). This is the first time
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physiological ligands for TLR7 and TLR8 have been shown. Very little is 
known about TLR10 and no ligands have yet been published.
TLR9
An essential role for TLR9 in the recognition of bacterial CpG DNA, a potent 
activator of immune cells, has been shown. Mice deficient in TLR9 fail to 
produce a response to CpG DNA (Hemmi et al., 2000). Bacterial DNA 
contains unmethylated CpG motifs, which confer the immunostimulatory 
activity. In vertebrates, the frequency of CpG motifs is very much decreased 
and the cytosine residues of the CpG motif are highly methylated, which 
results in the abrogation of the stimulatory activity. Various synthetic 
oligodinucleotides containing CpG motifs can also activate various immune 
cells. CpG DNA has been shown to activate DCs to produce a Th1-like 
immune response (Wagner, 1999) and is a strong inducer of B cells 
activation (Krieg et al., 1995), therefore CpG DNA has promising potential as 
an adjuvant.
Although most studies have focused on bacterial DNA, it has also been 
shown that TLR9 may be important in the recognition on viral DNA. DNA 
viruses contain abundant CpG motifs (Lundberg et al., 2003). TLR9- 
dependent recognition has been shown for Murine Cytomegalovirus (Krug et 
al., 2004) and Herpes Simplex virus type 1 (Hochrein et al., 2004).
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D: Complement Receptors
Complement proteins in the serum can opsonize microbes through antibody- 
independent and antibody-dependent mechanisms as described in Section 
1.3.2a on complement. Microbes and microbial components that are 
opsonized are recognised and internalised via specific complement 
receptors. Phagocytic complement receptors include complement receptor 1 
(CR1 or CD35), complement receptor 3 (CR3, CD11b/CD18 or Mac-1), and 
complement receptor 4 (CR4 or CD11c/CD18) (Underhill and Ozinsky, 2002). 
Complement receptor 2 (CR2 or CD21) has not been shown to be a 
phagocytic receptor.
C3, when activated on a cell surface becomes covalently bound as C3b 
which is subsequently cleaved to yield iC3b. There is evidence to suggest 
that CR3 and CR4 are involved in the phagocytosis of targets opsonised with 
C3b and iC3b fragments (Cabanas et al., 1999; Ehlers, 2000). Although CR3 
is abundantly expressed by circulating monocytes, neutrophils, and NK cells, 
CR4 is the most abundant C3 receptor on tissue macrophages (Myones et 
al., 1988). Interestingly, in mouse, CR4 is highly expressed on dendritic cells 
but its role is poorly defined. The diverse functions and activites of CR3 have 
highlighted its key role in innate immunity. Some studies have suggested that 
CR3 can bind some microbial molecules directly (Cywes et al., 1997; 
Thornton et al., 1996) although this remains controversial. CR3 is not only 
important for phagocytosis but also leukocyte adherence and migration. 
Neutrophils from CR3-deficient mice have impaired adhesion and
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phagocytosis (Lu et al., 1997). These mice are also defective in bacterial 
clearance (Rosenkranz et al., 1998).
Human CD35 and CD21 are products of separate genes and are widely 
expressed, whereas murine CD35 and CD21 are alternatively spliced 
products of a single gene as designated Cr2 and are expressed almost 
exclusively on B cells and follicular dendritic cells (FDC). Human CD35 has 
been shown to bind MBL (Ghiran et al., 2000) and C1q (Klickstein et al., 
1997) as well as C3b and C4b opsonized antigens (Fearon, 1980). Human 
CD21 is a receptor for C3d. It can function as a member of a signalling 
complex CD21/CD19/CD81 which is important in B cell activation. Murine 
CD35 binds C3b, iC3b, C3d C3dg, and C4b (Pramoonjago et al., 1993), 
whereas human CD35 does not bind iC3b, C3dg or C3d (Cooper, 1969; 
Fearon, 1980). Murine CD21 binds the same ligands except for C3b and 
C4b. Like human CD21, murine CD21 is expressed as a complex with CD81 
and CD19. Both murine CD35 and CD21 are important in humoral 
responses. Binding of C3d to antigen targets antigen to B cells and FDCs. 
The role of these receptors in adaptive immunity is described in a later 
section.
1.3.3 Natural antibodies and B-1 cells.
Natural antibodies are an important part of innate immunity in the recognition 
of microbial carbohydrates. Natural antibodies are mostly of the IgM isotype 
and can bind to certain antigens or pathogens, even if the host has never 
been exposed to them previously. Natural IgM binds to invading pathogens 
as they enter the host resulting in complement activation as a first line of
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defence. Large proportions of these natural antibodies are polyreactive to 
conserved structures, such as nucleic acids, heat shock proteins, 
carbohydrates, phosphatidylcholine and phospholipids (Kantor and 
Herzenberg, 1993; Hardy and Hayakawa, 1994). These natural antibodies 
appear in the absence of apparent antigenic stimulation, and are secreted by 
the long-lived self renewing B1 subset of B cells (Boes. 2000).
B1 cells, although constituting only a minor fraction of B cells in the spleen 
and lymph nodes of mice, represent the main B cell population in the 
peritoneal and pleural cavities. B1 cells differ from B-2 cells (conventional B 
cells) by their differentiation during fetal and neonatal development. Early in 
ontogeny, TdT (terminal deoxynucleotidyl transferase) expression is minimal 
(Hayakawa and Hardy, 2000). This lack of N region insertions results in the 
predominant development of B cells expressing germ-line encoded antibody 
specificities. These germline encoded antibodies have evolved to protect 
against pathogens, recognising common motifs of bacteria. There also 
appears to be a lack of somatic mutation of V  regions of the antibody genes, 
therefore natural antibodies tend to be of low affinity. Compared to B-2 cells, 
B-1 cells have a much-restricted antibody repertoire.
B-1 cells are the source for much of the spontaneously produced natural 
antibodies, but they also participate in a variety of immune responses. It has 
been suggested that B-1 cells together with marginal zone B cells are 
important in the response against microbial carbohydrates.
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1.4 Humoral response to T-independent type 2 
antigens
1.4.1 T-independent and T-dependent antigens
With regard to their capacity for antibody induction, antigens can be classified
as either T lymphocyte-dependent (TD) or as T lymphocyte-independent (Tl) 
(Mond et al., 1995a). TD antigens, such as proteins and peptides, require T 
cell help for B cell activation and antibody production. This involves the 
binding of protein to an antigen-specific B cell receptor (BCR) followed by 
cognate interaction with T cells expressing T cell receptors (TCR) that 
recognise antigen-derived peptides presented by class II major 
histocompatibility complexes (MHC II) on the surface of the B cell. Tl 
antigens do not require T cell help for B cell activation; these antigens can 
induce antibody responses in thymectomised mice (Davies et al., 1970). Tl 
antigens are sub-divided into type 1 (TI-1) and type 2 (TI-2), based on their 
ability to induce antibody responses in CBA/N (X-linked immunodeficiency) 
and neonatal mice (Amsbaugh et al., 1972). Both CBA/N and neonatal mice 
respond normally to TD and TI-1 antigens but fail to produce an antibody 
response to TI-2 antigens. The cause of the immunodeficiency in the CBA/N 
mice has been identified as a point mutation in the gene encoding Bruton's 
tyrosine kinase (Btk) (Thomas et al., 1993). Btk participates in signalling 
pathways downstream from the B cell receptor (BCR), which appear to be 
critical for survival and differentiation of activated B cells in response to 
polysaccharide antigens (Desiderio., 1997). For TD antigens CD40 co­
stimulation occurs as well as BCR signalling. CD40 signalling converges with 
the BCR signalling pathway, which may explain why the defect in antibody
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production after BCR ligation of Btk deficient B cells can be overcome in TD 
responses (Khan et al., 1997).
TI-1 antigens are polyclonal B cell activators/mitogens that can activate B 
cells regardless of specificity. LPS is an example of this type of antigen. LPS 
is thought to induce activation of B cells through either TLR4 or RP105, this 
results in B cell proliferation and secretion of large amounts of antibody 
(Hoshino et al., 1999; Ogata et al., 2000). LPS can also activate B cells by 
cross-linking of the BCR with O-antigen sidechain, although this response is 
more likely to be classified as TI-2 (Nishiuchi et al., 2000).
TI-2 antigens are antigens that consist of repetitive biochemical structures, 
such as polymeric protein antigens, trinitrophenyl-Ficoll (TNP-Ficoll) and 
dinitrophenyl-Ficoll (DNP-Ficoll). A clinically important group among the TI-2 
antigens are the bacterial CPSs (Rijkers and Mosier, 1985). The main 
characteristics of these antigens are that they have late onset of 
responsiveness, infants under the age of 2 years being unable to make 
antibody responses to most polysaccharides, restricted antibody switching 
and a lack of affinity maturation and memory function (Mond et al., 1995b).
1.4.2 B cell activation by TI-2 antigens
The two-signal hypothesis of antibody production to TI-2 antigens was first 
proposed by Vos and colleagues (Vos et al., 2000, Mond et al., 1995b). The 
first signal involves the cross-linking of the BCR by multivalent TI-2 antigens. 
Structural analysis of TI-2 antigens showed that they have a minimal
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molecular weight of 100kDa (Dintzis et al., 1976). The cross-linking of 
membrane BCRs by TI-2 antigens is critical for B cell stimulation. It was 
estimated that B cell activation requires cross-linking of a minimum of 10-20 
BCRs (Dintzis et al., 1982). The second signal can be provided through non- 
antigen-specific stimuli and receptors. The second signal can either directly 
target B cells or have indirect effects, such as induction of cytokines or 
upregulation of costimulatory molecules by other cells of the immune system. 
These second signals can induce class switching, antibody secretion or B 
cell proliferation. The second signal is also an important requirement for 
preventing activation of B cells specific to other multivalent self antigens such 
as DNA, collagen, actin and tubulin (Mond et al., 1995a). Possible second 
signals are discussed in the following sections.
1.4.3 Modulation of TI-2 responses by complement
In addition to its importance in innate immunity complement is also involved
in adaptive responses. Complement provides an essential link between the 
adaptive and innate immune system by enhancing uptake of antigen in 
specialised microenvironments and by augmenting the BCR cross-linking 
signal (Carroll, 1998).
TI-2 antigens can activate complement by either the alternative or the 
classical pathway. If there is specific antibody present, complement will be 
activated via immune complexes. In the absence of specific antibody, 
covalent attachment of C3b (and subsequent proteolytic fragments iC3b and 
C3d) may occur by activation of the alternative or MBL pathway. Purified 
pneumococcal polysaccharides can induce direct activation of C3 via the
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alternative pathway (Griffioen et al., 1991), as was also found to be the case 
for Ficoll (van den Eertwegh et al., 1992).
In the case of both TD and Tl antigen responses, two mechanisms can 
account for actions of complement. Firstly, complement fragments bound to 
TI-2 antigens allow the engagement of complement receptor CD21 on the 
surface of B cells. CD21 is part of a B cell surface complex that includes 
CD19 and CD81. Co-ligation of the BCR and the complement complex 
(CD19/CD81/CD21) by C3 fragments bound to antigen results in a lowering 
of the threshold for B cell activation. Secondly, the presence of complement 
receptors, CD21 and CD35, on the surface of FDCs also acts to retain the 
antigen-complement complex.
Various studies have shown complement and complement receptors to be 
important in T-independent antibody responses. The conjugation of C3d to a 
pneumococcal CPS resulted in an increased antibody response and class 
switching from predominantly IgM to lgG1 in mice compared to mice 
immunised with pneumococcal CPS alone (Test et al., 2001). Marques and 
colleagues also showed a correlation between the amount of C3d deposited 
on pneumococcal polysaccharides and immunogenicity (Marques et al., 
1992). Mice deficient in either CD21 and CD35 (Cr2-/-) and complement 
component C3 had a reduced IgM and IgG response to group B 
Streptococcus type III CPS (Pozdnyakova et al., 2003). No IgG response to 
DNP-Ficoll was observed in Cr2-/- mice (Haas et al., 2002). MZ B cells, 
which are of central importance in TI-2 responses (see section 1.4.7),
58
Chapter One
express high levels of CD21 when they reach maturity at about 18 months in 
humans. Maturation of these cells correlates with responsiveness to TI-2 
antigens. These studies illustrate the importance of complement in 
modulating TI-2 responses by increasing immunogenicity or by providing 
signals to allow immunoglobulin class switching.
1.4.4 Modulation of TI-2 responses by T cells
The finding that certain antigens could stimulate antibody responses in
athymic mice, which led to their classification as T independent, suggested 
that T cells played little if any role in the immune response to these antigens. 
It is now clear that T cells can regulate responses to Tl antigens, but not via 
classical cognate, MHC class ll-restricted help. Mice deficient in MHC class 
II respond normally to TNP-ficoll but TD antibody responses are abolished 
(Markowitz et al., 1993). The possibility of other costimulatory interactions 
between T and B lymphocytes is discussed in the following paragraphs.
The production of TD antibody responses is critically dependent on the 
interaction of CD40 on B cells and CD40L on CD4+ T cells. CD40 interaction 
with CD40L plays an important role in antibody class switching (Warren and 
Berton, 1995) and is essential for germinal centre formation and memory 
function (van Kooten and Banchereau, 1997). The role of CD40L-CD40 
interaction in TI-2 responses remains unclear. Renshaw and colleagues 
showed that CD40L-deficient mice responded normally to TNP-ficoll and 
DNP-ficoll suggesting TI-2 antibody responses are CD40L-independent 
(Renshaw et al., 1994). However other studies with pneumococcal CPSs
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have shown that administration of anti-CD40 can enhance anti­
polysaccharide responses (Dullforce et al., 1998) and the immunisation of an 
antagonist to CD40L in mice resulted in the abrogation of the anti- 
polysaccharide response (Jeurissen et al., 2002). Further to this, CD4+ T 
cells were shown to be important in the enhancement of antibody responses 
to pneumococcal CPSs and this could be prevented by administration of a 
CD40L antagonist. Evidence thus suggests that T cells can contribute to the 
regulation of anti-pneumococcal CPS responses in a CD40L-dependent 
manner.
CD28, expressed constitutively on T cells, mediates a positive signal through 
binding to CD80 and CD86 on B cells. CTLA-4, a close relative of CD28, 
also binds to CD80 and CD86 but acts as a negative regulator of T cell 
activation. The role of CD28 and CTLA-4 in the regulation of TI-2 antigens 
has only been the subject of a few studies. Anti-CTI_A-4 antibody treatment 
resulted in the enhancement of isotype switching in polysaccharide-specific 
antibody responses (Jeurissen et al., 2004). This suggests that CTLA-4 can 
down regulate antibody responses to TI-2 antigens. In the case of CD28, 
CD28 knockout mice responded poorly to phosphorylcholine in comparison 
to wild type mice, suggesting that CD28 may positively regulate TI-2 antibody 
responses (Wu et al., 2000).
The B cell lymphocyte stimulator (BlyS) is expressed on macrophages, 
monocytes, DCs and T cells, and has three known receptors (TACI, BCMA, 
and BAFF-R) which are expressed on B cells. APRIL, a close relative of
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BlyS, is expressed on activated T cells and can interact with TACI and BCMA 
but not BAFF-R. TACI knockout mice were shown to have a reduced 
antibody response to NP-ficoll compared to wild type mice (von Bulow et al., 
2001). BAFF-R deficient mice responded normally to TI-2 antigens (Miller et 
al., 1992). These studies suggest that the interaction of BlyS and APRIL with 
TACI, but not BAFF-R, play a role in TI-2 immune responses.
CD 1-restricted T cells have also been implicated as a possible T cell subset 
that helps mount an antibody response to polysaccharide antigens. The CD1 
proteins are antigen-presenting molecules that present microbial nonpeptide 
antigens, such as lipids and glycolipids to T cells. While humans express 
CD1a, b, c, d, and e, mice only express CD1d (Brigl and Brenner, 2004). 
Similar in structure to MHC class I, the CD1 heavy chain associates with p2 
microglobulin to form a heterodimer that is expressed on the cell surface of 
APCs (Porcelli et al., 1998), mice that do not express p2 microglobulin have 
a reduced responses to DNP-Ficoll (Christianson et al., 1997). Interestingly, 
CD1d expression is high on splenic marginal zone B cells in mice, which is a 
cell type suggested to be important in the generation of antibodies to TI-2 
antigens (Roark et al., 1998). Some CPS from encapsulated bacteria are 
naturally lipidated (Arakere et al., 1994). Fairhurst and colleagues 
demonstrated that CD1-resticted T cells proliferated in response to a 
nonpeptide antigen from H. influenzae which they suggest may be lipidated 
CPS (Fairhurst et al., 1998a). It is hypothesised that B cells internalise the 
lipid anchored CPS through surface IgM, process the antigen, and present 
the lipid fragment in context with CD1. In this manner, B cells directly elicit T-
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cell help in their production of anti-polysaccharide antibodies (Fairhurst et al., 
1998b).
The direct interaction of B and T cells is not the only possible mechanism of 
T cell help for TI-2 antibody responses. T cells produce cytokines that could 
provide signals to B cells. Van den Eertwegh and colleagues showed that 
when murine spleen cells are stimulated with a TI-2 antigen, T cells produce 
IL-2, IL-4 and IFNy (Van den Eertwegh et al., 1993). Other cells of the 
immune system have also been implicated in cytokine production to provide 
a second signal for TI-2 responses. These are discussed later.
1.4.5 Modulation of TI-2 responses by NK cells
NK cells are a population of non-T cells that can mediate cytotoxicity and
produce a panel of cytokines (Biron et al., 1999). It is possible that NK cells 
could replace or synergise with T cells in providing ancillary help for TI-2 
antibody responses. One of the ways in which NK cells may regulate immune 
responses is through cytokine secretion. NK cells have been reported to 
secrete various cytokines such as TNF-a and IFN-y (Biron et al., 1999). IFN- 
y has been shown to be important for class switching and Ig secretion and it 
is therefore possible that NK cells could provide IFN-y for limited class 
switching events in TI-2 responses. In vitro studies have suggested NK cells 
play an important role in TI-2 antibody responses, through the induction of 
IFN-y (Vos et al., 1999; Snapper et al., 1994). A number of studies have also 
been carried out in vivo. Szomolanyi-Tsuda et al showed that antiviral TI-2 
antibody responses could be induced in NK-deficient mice, but the presence
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of NK cells was required to promote isotype switching (Szomolanyi-Tsuda et 
al., 2001). However, another study carried out by Kim et al showed that there 
was no difference in the antibody response or isotype switching to TNP-ficoll 
in NK-deficient mice compared to wild type (Kim et al., 2000). It is therefore 
not clear whether NK cells are essential for the regulation of TI-2 responses. 
If there is a major contribution through cytokine release it is possible that the 
antibody response in NK-deficient mice is normal because of the production 
of cytokines from other cell types.
1.4.6 Modulation of TI-2 responses by DCs and macrophages.
The link that TLRs provide between the innate and the adaptive immune
system suggests they have a possible role in the regulation of B cell 
responses. DCs can be stimulated via their TLRs by intact bacteria and 
bacterial wall components to secrete the B-cell stimulatory cytokines IL-1 and 
IL-6, and to induce NK cell production of IFNy via IL-12 (Reis e Sousa et al., 
1997). Bacterial DNA has also been shown to induce DC maturation and 
cytokine secretion (Sparwasser et al., 1998). Stimulation of macrophages 
with microbial stimuli can also result in their activation and the release of 
cytokines (Stacey et al., 1996; Yamamoto et al., 1997; Zhang et al., 1999). 
The TLR system can therefore provide B cells with second signals that are 
based on non-self patterns (Medzhitov and Janeway, 1997). Snapper and 
colleagues showed that the combination of bacterial lipoproteins and a 
multivalent antigen resulted in enhanced B cell proliferation and antibody 
production relative to the multivalent antigen alone (Snapper et al., 1995). A 
more recent study by Kovarik et al demonstrated an increase in antibody 
response to TNP-ficoll when mice were immunised with TNP-ficoll and CpG
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oligodeoxynucleotides compared to TNP-ficoll alone. Interestingly, CpG 
oligonucleotides failed to enhance the antibody response to pneumococcal 
CPSs (Kovarik et al., 2001). These studies show that TLR ligands can 
provide help for some TI-2 antibody responses. As mentioned in previous 
section BlyS which is expressed on DCs and macrophages is also important 
in the modulation of TI-2 responses.
1.4.7 Lymphoid tissues and cell types involved in TI-2 
responses
Lymphoid organs are organised tissues containing large numbers of 
lymphocytes in a framework of non lymphoid cells. Lymphoid organs can be 
divided broadly into primary lymphoid organs, where lymphocytes are 
generated, and secondary lymphoid organs, where adaptive responses are 
initiated and lymphocytes are maintained. Bone marrow and thymus are both 
primary lymphoid organs whereas lymph nodes and spleen are secondary 
lymphoid organs.
In contrast to TD responses, which occur in all secondary lymphoid organs, 
the spleen has a far greater capacity to respond to TI-2 antigens than lymph 
nodes. A functional spleen is therefore essential for TI-2 responses (Amlot et 
al., 1985). It has been shown that the absence or dysfunction of the spleen 
results in increased risk of infections from encapsulated bacteria. 
Splenectomised patients show an increased risk of developing severe 
bacterial infections (Krivit., 1977).
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The spleen contains both white and red pulp. The white pulp consists of three 
distinct compartments; periarteriolar lymphocyte sheath (PALS), follicles and 
the marginal zone. The PALS is preferentially a T cell area, whereas the 
follicles are B cell areas where the germinal center reaction occurs. The 
PALS and follicles are surrounded by the marginal zone which forms a 
junction between the red and white pufp. The marginal zone is where blood 
leaves the arterial system into the venous sinuses. The architectural structure 
of the marginal zone results in a strongly reduced blood-flow allowing 
intimate contact between effector cells and blood borne antigens. Marginal 
zone contains distinct cell sub-populations, which include marginal zone 
macrophages (MZM), marginal zone metallophilic macrophages (MZMM), 
marginal zone dendritic cells (MZDC) and marginal zone B cells (MZ B cells).
The non lymphoid cells of the marginal sinus are very specialised. There are 
two subpopulations of macrophages, the MZMM and the MZM. MZM are 
identified by high level expression of sialoadhesin (Crocker and Gordon, 
1989), they have close contact with MZ B cells and are situated at the red 
pulp side of the marginal sinus (Dijkstra et al., 1985). MZM have been shown 
to selectively retain and uptake ficoll (Dijkstra et al., 1985) and neutral 
polysaccharides (Kraal et al., 1989), and evidence suggests that the uptake 
of TI-2 antigens is receptor-mediated. Mouse MZM express a number of 
receptors including MARCO (Elomaa et al., 1995) and SIGN-R1 (Geijtenbeek 
et al., 2002). MARCO has been shown to bind a range of microbial antigens 
including Staphylococcus aureus and Eschericia coli whereas SIGN-RI is the 
predominant receptor for uptake of the polysaccharide dextran (Geijtenbeek
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et al., 2002; Kang et al., 2003) and S. pneumoniae and its CPS (Kang et al., 
2004). MZMM can be distinguished from MZM by antibody staining with 
MOMA-1; they are found at the inner border of the marginal sinus and they 
fail to take up Ficoll (Kraal and Janse, 1986). Although much of the evidence 
presented above suggests a role for MZM in the response to TI-2 antigens, 
depletion of these cells in mice does not alter the response to the model 
antigen, TNP-Ficoll (Kraal et al., 1989). These results suggest that MZM are 
not involved in the TI-2 response or a compensation mechanism is used. 
Similar results were observed in mice that were depleted of MZMM (Buiting 
et al., 1996).
MZ B cells have been shown to have an essential role in the immune 
responses to TI-2 antigens. Deficiency of the tyrosine kinase Pyk-2 in mice 
results in a defect in the MZ cell population. These mice displayed a marked 
suppression of TI-2 antibody responses (Guinamard et al., 2000). Infant MZ 
B cells which do not respond to TI-2 antigens have been characterised as 
CD21|0W. The appearance of adult phenotype of MZ B cells (CD21hl) also 
correlates with the ability to mount an immune response to polysaccharides, 
including those from encapsulated bacteria (Timens et al., 1989). MZ B cells 
preferentially secrete antibodies of IgM and lgG3 isotypes and the subset is 
enriched in B cell receptor specificities for bacterial pathogens such as 
phosphorylcholine (Oliver et al., 1997), reflecting the role of MZ B cells in the 
primary TI-2 response. MZ B cells represent 5% of splenic B cells in mice 
and they have a distinct surface phenotype compared to follicular B cells (MZ 
B cells are lgMhi lgDl0W/' CD21hi CD23|0W/', follicular B cells are lgMhl lgDhi
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CD21,nter CD23hl). In mice, MZ B cells also express high levels of CD1d 
(Roark et al., 1998).
After maturation, B cells either recirculate through lymphoid organs as part of 
a long-lived pool (follicular B or B2 B cells) or join more static compartments, 
in contrast, the MZ B cells are fixed and resident in the spleen, and are 
positioned for rapid activation by blood borne antigens thus helping to bridge 
the time gap between innate and adaptive immune responses. MZ B cells 
have been shown to respond faster than follicular B cells to antigens. MZ B 
cells express higher levels of CD80 and CD86 when freshly isolated and 
following in vitro stimulation than follicular B cells (Oliver et al., 1999). MZ B 
cells are also capable of generating plasma cells more efficiently and quickly 
than recirculating B cells. This is because recirculating B cells are recruited to 
germinal centres and go through affinity maturation before differentiation into 
plasma cells (Martin and Kearney, 2000). MZ B cells are present in nude and 
thymectomised rats, suggesting that they do not represent postgerminal 
center T dependent B cells (Kumararatne and MacLennan, 1981). These 
features suggest that MZ B cells are in a state of partial activation.
1.5 Polysaccharide and conjugate vaccines
H. influenzae, S. pneumoniae and N. meningitidis are examples of 
encapsulated bacteria which have a major impact on global disease burden. 
Antibodies to the CPS of these bacteria have been shown to be protective 
(Macleod et al., 1945). Many early vaccines consisted solely of purified CPS. 
The first N. meningitidis CPS polysaccharide vaccine was licensed in 1972,
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followed by 7- and 23-valent vaccines against S. pneumoniae (1977 and 
1983 respectively), and H. influenzae type b (1985). These vaccines are 
efficacious in immunocompetent adults (Shapiro et al., 1991), but due to their 
T-independent type II nature, are not generally effective in children under the 
age of 2 (Karma et al., 1985). In addition, CPSs do not elicit memory 
functions, and hence the immune response can not be boosted. It was 
therefore apparent that alternative vaccines were required for immunising 
very young children.
The discovery that the conjugation of polysaccharide to an immunogenic 
protein carrier could induce a polysaccharide response in infants, that was 
enhanced both in terms of magnitude and duration compared to 
polysaccharide alone, resulted in the development of conjugate vaccines. 
The conjugate vaccine against H. influenzae type b (Hib) has been very 
successful. Prior to introduction of the conjugate vaccine there were 30-60 
cases of invasive disease per 100,000 children under five years of age in 
Europe (Lindberg, 1999; Peltola et al., 1977). The Hib vaccine consists of the 
polysaccharide type b capsule, made of polyribosyl ribitol phosphate, 
conjugated to a protein carrier. Four different carrier proteins have been 
used, diphtheria toxoid, tetanus toxoid, CRM197 (non toxic variant of 
diphtheria toxin), and meningococcal outer membrane protein complex. All 
four conjugates were licensed in the early 1990’s. In the UK the number of 
cases of invasive disease reduced by 98% after the introduction of the 
conjugate vaccine (Moxon et al., 1999) and the same was observed in other 
developed countries. The Hib conjugate vaccine has been shown to have an
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efficacy of 90% in developing countries such as The Gambia (Mulholland et 
al., 1997). The Hib conjugate vaccine has been undoubtedly successful and 
has paved the way for the development of conjugate vaccines against the 
meningococcus and pneumococcus. H. influenzae disease has the great 
advantage of being caused predominantly by a single serotype, H. influenzae 
type b. In the case of N. meningiditis and S. pneumoniae there are many 
different serotypes which cause disease. Of the 90 identified serotypes of S. 
pneumoniae, 23 serotypes cause invasive disease. A 7-valent conjugate 
vaccine was licensed in 2000 in the US, although developments are currently 
underway to produce a vaccine that covers more serotypes. The only 
concern with this vaccine is the increased incidence of otitis media caused by 
non-vaccine serotypes (Obaro and Adegbola, 2002; Obaro, 2001). In the 
case of N. meningitidis there are 12 known serotypes. Almost 90% of cases 
of meningitis are caused by serogroups A, B and C. A conjugate vaccine 
against serogroup C was licensed in the UK in 2001, and a year later it was 
shown that carriage of serotype C meningococci was reduced by 66% in 
adolescents (Maiden and Stuart, 2002). Further studies are underway to 
produce multivalent meningococcal vaccines. Conjugate vaccines against 
other infectious pathogens, such as Staphylococcus aureus (McKenney et 
al., 1999), Streptococcus Group B (Baker et al., 2001), and Salmonella typhi 
(Szu et al., 1994) are also in development.
Polysaccharide-protein conjugate vaccines convert the immune response 
from T-independent type II to a T-dependent response (see section 1.4). 
Polysaccharide vaccines fail to activate helper T cells. They activate B cells
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in a T cell independent manner resulting in little or no affinity maturation, 
class switching, memory, or antibody response in infants. One way to involve 
helper T cells is to conjugate polysaccharide to a protein carrier. The 
polysaccharide-protein conjugate can be internalised by B cells and peptides 
from the protein can be presented by MHC class II to antigen-specific helper 
T cells. The involvement of T helper cells is expected to result in class 
switching, generation of memory B cells and thus a T-dependent response to 
the polysaccharide.
The development of polysaccharide-protein conjugate has been very 
successful, as shown by the H. influenzae type b conjugate vaccine. The 
conversion of a T independent response to a T dependent response allows 
the development of memory and responsiveness in infants, a group most at 
risk from disease due to encapsulated bacteria. Alternative methods of 
producing a vaccine that can stimulate T-dependent responses are also 
under study, such as the development of peptides that mimic the 
immunological properties of polysaccharides.
1.6 Adjuvants
Vaccines come in several forms: live-attenuated, replicating and non­
replicating pathogens, inactivated pathogens or their subunits. The last 
category is the safest, but can lack immunogenicity and often requires 
adjuvants to elicit an adequate immune response. Adjuvants are defined as a 
group of heterogeneous compounds, used to evoke or increase an immune 
response to an antigen (Gupta et al., 1993). Adjuvants have the capability to 
influence or control many parameters of the immune response such as
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antibody production (specificity, titre, memory, duration, class, isotype and 
avidity) and cell mediated immunity (CD4 or CD8). Adjuvants are thought to 
act through various mechanisms including induction of increased antigen 
transportation and presentation by APCs, sustained presence of antigen at 
injection site to increase antigen exposure time, and induction of cytokine 
release and upregulation of costimulatory molecules on APCs.
The adjuvants used in human vaccines must fulfil stringent requirements. 
The adjuvant must be non-toxic, stimulate a strong humoral or cell-mediated 
immune response, provide long term immunological memory, non-mutagenic, 
non-pyrogenic, and must be stable at a range of temperatures and pH. 
Aluminium-based adjuvants are the only ones approved for human use. They 
are emulsion-based and insoluble, the antigen and adjuvant are sequestered 
at the injection site and are released over a period of time to stimulate APCs. 
Aluminium-based adjuvants typically are effective in enhancing antibody 
responses to protein antigens such as tetanus and diphtheria toxoids. They 
induce Th2 type responses. They are not effective for cell-mediated immunity 
therefore aluminium adjuvants are not efficacious for all vaccines. There is 
therefore a major interest in finding adjuvants that are capable of inducing 
strong cellular immune responses of a Th1 type.
The activation of the innate immune system results in the initiation of a 
proinflammatory response, and the eventual activation of the adaptive 
immune response. Therefore activators of innate immunity can be used as 
adjuvants. These adjuvants include ligands of TLRs. TLRs induce signaling
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pathways, leading to activation of NF-kB in APCs, which results in the 
expression of cytokine genes, production of costimulatory ligands CD80 and 
CD86, and activation of adaptive immunity. Unmethylated CpG >2 
nucleotides, TLR9 ligand, stimulate immune cells (T cells, B cells, NK cells 
and macrophages) to produce proinflammatory cytokines, including IL-1, IL- 
6, IL-12, IL-18, TNF-a and IFN-y that promote Th1 immunity (Wagner, 1999). 
LPS also stimulates the production of proinflammatory molecules, although 
the lipid A part of the molecule is responsible for these properties. Lipid A is 
extremely toxic so lipid A mimetics have been studied for adjuvant properties. 
These microbial structures amongst others have an important future in the 
development of adjuvants for new vaccines.
1.7 Aims
The aim of this thesis is to understand further the interactions of CPS with the 
immune system and how this can determine or influence immunogenicity and 
adjuvanticity. The insights provided by this project into the induction of anti- 
CPS immune responses and possible adjuvant properties may contribute to 
the improvement of current CPS-based vaccines and adjuvants for vaccine 
formulations. The specific aims of this study are described below.
Immunomodulatory properties of K. pneumoniae CPSs
A number of studies have described possible immunomodulatory properties 
of K. pneumoniae CPS although it is not clear whether these properties can 
be attributed to the CPS itself or possible contaminants such as LPS or
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bacterial DNA. This study is to determine whether CPSs from K. pneumoniae 
have immunostimulatory properties.
♦ Establish a method of purification of CPS from K. pneumoniae.
♦ Investigate the possible adjuvant properties of purified CPS from K. 
pneumoniae.
♦ Examine possible mechanisms of adjuvant activity of CPS from K. 
pneumoniae
Role of complement in the humoral response to S. pneumoniae CPSs
The role of complement in the humoral response to physiological T- 
independent type 2 antigens, such as CPS, remains unclear. Many studies 
have focused on model TI-2 antigens, such as DNP-Ficoll. CPSs from S. 
pneumoniae are commercially available as a 23-valent vaccine and are 
structurally diverse. This provided an opportunity to study structure- 
immunogenicity relationship using a relatively large set of CPS with differing 
structures and establish the role of complement in anti-CPS antibody 
responses.
♦ Establish the humoral response to CPSs from S. pneumoniae in wild type 
and complement receptor (CD21 and CD35) deficient mice.
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Chapter Two 
Materials and Methods
2.1 Materials
2.1.1 Antibodies
2.1.1a Monoclonal antibodies used in flow cytometric analysis
Target
Molecule
Isotype Conjugate Supplier Catalogue
number
dilution
Mouse CD3 Hamster
lgG1
PE PharMingen 553063 1/200
Mouse
CD35/CD21
Rat
lgG2b
FITC PharMingen 553818 1/200
Mouse
CD45R/B220
Rat
lgG2a
APC PharMingen 553092 1/200
2.1.1b Antibodies used in ELISA assays
Product Conjugate Supplier dilution Catalogue
number
Goat anti-mouse 
(Y chain specific) 
igG
Horseradish
peroxidase
Jackson
Immunoresearch
1/1000 115-035-
164
Goat anti-mouse 
(Y chain specific) 
IgG
Alkaline
phosphatase
Southern Biotec 
Associates
1/2000 1030-04
Goat anti-mouse 
(p chain specific) 
IgM
Horseradish
peroxidase
Jackson
Immunoresearch
1/1000 115-035-
0200
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Mouse anti-rabbit Horseradish Sigma 1/1000 A 2074
immunoglobulins peroxidase
2.1.2 Cytometric Bead Array (CBA) kits.
Reagent: Supplier: Catalogue number:
Mouse Inflammation CBA 
(Lot 0000061334)
BD Biosciences 
Pharmingen
552564
Mouse TH1/TH2 cytokine 
CBA (Lot 0000049973)
BD Biosciences 
Pharmingen
551287
2.1.3 Biochemical Reagents
Reagent: Supplier Catalogue number:
ABTS (2,2 Azino -bis(3- 
ethylbenzthiazoline-6- 
sulfonic acid))
Sigma A9941
Acetic Acid BDH 153103D
Acrylamide/ bisacrylamide 
30% (v/v) solution
Bio-Rad 161-0156
Alcian Blue Sigma A9186
Ammonium hydroxide Sigma A6899
Ammonium persulphate Bio-Rad 161-0700
Betaplate scintillant Wallac SC/9200/21
Biuret Reagent Sigma 690-1
Bovine Serum Albumin Sigma A4503
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Bromophenol Blue Sigma B8026
Carbazole Sigma C5132
Carboxyfluorescein diacetate 
succinimidyl ester (CFSE)
Molecular Probes V 12883
Chicken gamma globulin 
(CGG) Lot 53423
Jackson
Immunoresearch
003-000-002
Citric acid Sigma C0759
Deoxyribonuclease 1 Sigma D5025
Dextran from Leuconostoc 
ssp. (Mr -  40,000)
Fluka 31389
Dextran from Leuconostoc 
ssp. (Mr ~ 70,000)
Fluka 31390
Dextran from Leuconostoc 
ssp. (Mr -  200,000)
Fluka 31398
Dextran from Leuconostoc 
ssp. (Mr ~ 500,000)
Fluka 31392
Dextran from Leuconostoc 
ssp. (Mr -  1,800,000)
Fluka 31427
Ethanol BDH 15338
DNP-Ficoll Biosearch
Technologies
F-1200-10
Ethylenediaminetetraacetic 
acid (EDTA)
Sigma E5134
Folin and Ciocalteu’s phenol 
reagent
Sigma F9252
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Formaldehyde (37% solution) Sigma F1635
Galacturonic acid Sigma 48280
Glycerol Sigma G6279
Glucuronic acid Sigma G5269
Glycine Sigma G8898
Hydrogen Peroxide Sigma H1009
lonomycin Sigma I0634
Lauryl sulphate Sigma L3771
Lipopolysaccharide from 
Esherichia coli 05 5 :B5
Sigma L2880
Methanol BDH 10158BG
2-Mercaptoethanol 50mM Gibco Invitrogen 31350-010
Milk Powder Marvel Off shelf
N, N, N \ N’ -tetra-methyl- 
ethylenediamine (TEMED)
Bio-Rad 161-0800
(OPD) o-Phenylenediamine 
Dihydrochloride tablet sets
Sigma P9187
Periodic Acid Sigma P5463
Phenol Sigma P5566
Phorbol myristate acetate 
(PMA)
Sigma P1585
Phosphate Buffered Saline 
(PBS), 10x, (0.01 M KH2P 0 4> 
1.5M NaCI, 0.03M Na2H P 04 
at pH 7.2), without Ca or Mg.
Gibco Invitrogen 14200-067
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p-Nitro-phenyl-phosphate
(pNpp)
Sigma N1891
Polymyxin B sulphate Sigma P4932
Potassium hydroxide Sigma P5958
Ribonuclease A Sigma R4875
Ribonuclease Type XII B Sigma R7884
Silver nitrate Sigma S6506
Sodium Azide Sigma S8032
Sodium Chloride Sigma S7653
Sodium Deoxycholate Sigma D6750
Sodium Hydroxide Sigma S8045
Subtilisin Type VIII Sigma P5380
Sucrose Sigma S7903
Sulphuric acid BDH 102761C
Thiomersal Sigma T2299
Titermax gold adjuvant liquid Sigma T2684
Triton X-114 Sigma T-114
Trizma base Sigma T1503
Tween 20 Sigma P7949
2.1.4 Tissue Culture Reagents
Reagent: Supplier Catalogue number
Dimethyl sulphoxide (DMSO) Sigma D-8418
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Foetal bovine serum 
Lot 40G2027K
Gibco Invitrogen 10270-169
HEPES buffer 1M Gibco Invitrogen 15630-056
Penicillin/Streptomycin Gibco Invitrogen 15140-122
RBC lysing buffer Sigma R7757
RPM11640 with Glutamax 1 Gibco Invitrogen, 61870-010
Trypan Blue Sigma T8154
2.1.5 Plastics
Type of Plastic: Supplier: Catalogue number:
15ml round conical tube Falcon 2096
24-well plates Falcon 3043
50ml round conical tube Falcon 2070
96-well immunoplates NUNC DIS-971-010P
96-well U bottomed plate Nunclon 163320
Cell strainer 0.4pm Falcon 2340
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2.2 Methods
2.2.1 Purification of capsular polysaccharides from Klebsiella 
pneumoniae.
2.2.1a Bacterial strains
The following O-antigen and capsular serotype (K) strains of K. pneumoniae 
were obtained from the Statens Serum Institute, Copenhagen, Denmark.
01 :K1, 02:K3, 03:K11, 01:K22, 01:K26, 02:K27, 03:K31, 04:K36, R:K40, 
01:K46, R:K52 03:K55, O5:K60.
Bacteria were grown either on nutrient agar or lactose agar plates. For long 
term storage bacterial strains were aliquoted and stored in Greaves freezing 
medium (5% BSA, 5% L-glutamic acid sodium salt, 10% glycerol and 80% 
water) at -80°C . Bacteria were recovered by streaking a partially thawed 
suspension onto a nutrient agar plate. After incubation overnight at 37°C, 
colonies were re-streaked and checked for purity.
2.2.1b Growth of bacteria and extraction of capsular polysaccharides
In order to maximise CPS production bacteria were grown on lactose plates.
Twenty to fifty plates (9cm diameter) were heavily streaked with bacteria and 
incubated at 37°C overnight. Bacterial growth was harvested by gently 
scraping the surface of the agar plates with a spatula. The bacteria were then 
suspended in 20ml of water and boiled for 10 mins at 100°C to release the 
CPS. After cooling on ice, cold acetone was added to the preparation so that
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the acetone was 80% of the total volume. When a precipitate had formed, the 
suspension was recovered by centrifugation (Sorvall RT7 plus) for 10 mins at 
400 x g at 4°C. The CPS was left to dry at room temperature (RT) overnight 
then redissolved in PBS. This was followed by centrifugation (Beckman 
Avanti J.30I) 3 times at 20,000 x g for 30 mins at 4°C. Each time the pellet 
(consisting of insoluble cell debris and denatured proteins) was discarded. 
The resulting supernatant containing the CPS was freeze dried (Savant, 
Freeze drier modulyo), and then redissolved in 5-20ml of water for 
purification as follows (Cryz et al., 1985).
2.2.1c Purification of capsular polysaccharides
The preparation was subjected to ultra-centrifugation (Beckman Avanti J.30I 
centrifuge) for 18h at 100,000 x g at 4°C. This was to further remove 
contaminating protein and LPS from the preparation. The preparation was 
then digested with Deoxyribonuclease I (70pg/ml) and Ribonuclease A 
(30pg/ml) or Ribonuclease Type XII B (30pg/ml) in 0.1M Tris/HCI, 4mM  
MgCI2 in PBS and 0.02% thiomersal for 24h at 37°C in a rocking incubator at 
an approximate CPS concentration of 500pg/ml as determined by uronic acid 
assay (Section 2.2.3d). The preparation was further digested with protease 
[Subtilisin type VIII (70pg/ml)] for 24h at 37°C in a rocking incubator. The 
preparations were then dialysed [Spectra/por 12-14 kDa MWCO (Spectrum)] 
extensively against 3L of water for 16h with 3 changes at 4°C. The 
preparation was then freeze dried (Savant, Freeze drier modulyo).
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2.2.1d Gel filtration chromatography -  size fractionation and 
purification
The HPLC system used consisted of a Waters 2690XE separations module, 
a Waters 2487 dual wavelength UV detector, and a Waters 2410 refractive 
index detector. System control and data acquisition was performed by 
Waters Millenium-32 software.
Gel filtration was carried out on a TSK G5000 HPLC column [(7.5mm ID x 
30cm) Anachem, Bedfordshire]. The void volume (V0) was determined by the 
elution position of blue dextran (2KDa) and the total volume (Vt) was 
determined by monitoring the elution position of a concentrated salt solution 
by refractive index. The eluant from samples separated on the column was 
monitored by refractive index and UV absorbance at 205nm, 260nm and 
280nm. The different buffers used are shown in Table 2.1. The flow rate was 
0.25ml/min and fractions were collected every 2 mins.
Table 2.1 Gel filtration elution buffers
Buffer CONDITIONS: Components / temperature / pH
A PBS 30°C
B* (Sodium deoxycholate buffer)10mM Tris-HCI pH8.7 containing 0.2M NaCI, 1mM 
EDTA and 0.25% (w/v) sodium deoxycholate at 60°C
C* (Sodium deoxycholate buffer) 10mM Tris-HCI pH8.7 containing 0.2M NaCI, 1mM 
EDTA and 0.25% (w/v) sodium deoxycholate at 30°C
D* (Sodium deoxycholate buffer) 10mM Tris-HCI pH7.5 containing 0.2M NaCI, 1mM 
EDTA and 0.25% (w/v) sodium deoxycholate at 30°C
E* (Sodium deoxycholate buffer) 10mM PBS pH 7.0 containing 0.25%(w/v) sodium 
deoxycholate at 60°C.
*B-E are dissociating buffers designed to separate LPS from CPS.
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Samples typically contained from 100-200pg of CPS in 100-300pl of buffer. 
For larger scale sample purifications, repeat fractionations of the same CPS 
were carried out using an automatic injector. Fractions were assayed for 
carbohydrate using the phenol sulphuric acid assay (Dubois and Giles, 
1956). Samples that were eluted with dissociating buffers required the 
removal of deoxycholate using the method described in Section 2.2.1e before 
being assayed for carbohydrate. Those containing carbohydrate were pooled 
and subjected to further analysis.
2.2.1e Removal of sodium deoxycholate dissociating buffer post gel 
filtration.
The pooled samples that were eluted from the column with dissociating 
buffers require the removal of deoxycholate before further analysis, as this 
detergent could interfere with a number of the assays. The pools were placed 
into dialysis tubing [Spectra/por 12-14 kDa MWCO (spectrum)] and then 
extensively dialysed against water at RT (deoxycholate precipitates out at 
4°C). This removed some of the buffer salts and some but not all of the 
detergent. The sample was then freeze dried, and then suspended 0.2M  
NaCI (1-2ml). To remove the remaining detergent cold ethanol was added to 
80% of the total volume. The sample was then centrifuged (Sorvall RT7 
plus) at 2200 x g for 10 mins. The supernatant was poured off and the pellet 
was allowed to air dry. The pellet was then dissolved in a minimal amount of 
water.
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2.2.1 f Removal of lipopolysaccharide 
Extraction with Triton X-114
Extraction of CPS with Triton X-114 has previously been reported to remove 
LPS from CPS (Adam et al., 1995). The CPS was dissolved in water 
(0.5mg/ml), Triton X-114 stock solution (11% w/v in water) was added to a 
final concentration of 2% (w/v) Triton. After cooling on ice, the solution was 
stirred at 4°C for 30 mins and then incubated at 37°C to induce phase 
separation. Phases were separated by centrifugation (Sorvall RT7 plus) for 
30 mins at 45 x g at 30°C. The lower phase was discarded and Triton X-114 
stock solution was added to the upper aqueous phase to a final concentration 
of 2% (w/v). The procedure was repeated as described above. The aqueous 
phase was made 0.2M in NaCI and CPS was recovered from the aqueous 
phase by precipitation with cold 80% (v/v) ethanol. The precipitate was 
recovered by centrifugation (Beckman Avanti J.301) for 30 mins at 4°C at
20,000 x g and then re-suspended in 0.2M NaCI and the ethanol precipitation 
was repeated. The sample was dialysed against water. The recovery of the 
CPS was determined by measuring total carbohydrate by the phenol 
sulphuric acid assay.
Alkaline de-O-acylation
Alkaline treatment was carried out in order to remove O-acyl fatty acids. This 
treatment results in the cleavage of the O-acyl fatty acids from the lipid A 
moiety. Since lipid A is responsible for most of the biological activity of LPS, 
this treatment detoxifies LPS (Seid et al., 1981). CPS (150pg) was dissolved
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in 750|jl of 0.1 M NaOH. This was incubated overnight at 37°C, and then 
neutralised with 0.2M acetic acid. CPS was then subjected to dialysis against 
water.
Gel filtration under dissociating conditions
Using the method already described for gel filtration wherein PBS as an 
elution buffer, LPS forms high molecular weight micelles and co-elutes with 
the CPS. However using dissociating conditions it was possible to disrupt 
micelle formation. Published dissociating conditions using sodium 
deoxycholate buffer at pH 8.7 and at 60°C (Adam et al., 1995) were used 
along with modified versions. These are shown in Table 2.1
2.2.2 Purification of lipopolysaccharide from Klebsiella pneumoniae
2.2.2a Growth of bacteria and extraction of lipopolysaccharide
Nutrient broth [0.01% bacto-tryptone, 0.005% bacto-yeast extract and 0.01%
NaCI (20ml)] was inoculated with one colony to make a starter culture. This 
was grown overnight at 37°C in a rocking incubator. A large flask containing 
2L of nutrient broth was then inoculated with 1ml of the starter culture and 
grown overnight at 37°C in a shaker incubator at 150 rpm. The culture was 
centrifuged (Beckman Avanti J301) at 10,000 x g for 30 mins at 4°C. The 
pellet was re-suspended in 50 -  100ml of PBS and the LPS was extracted 
with 45% hot aqueous phenol (Westphal and Jann, 1965) as follows. The 
suspension was heated to 68°C, to this an equal amount of pre-heated 90%  
(w/v) phenol (saturated aqueous solution) was added. The solution was then
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stirred for 15 mins at 68°C. Phase separation was obtained by cooling the 
solution on ice, followed by centrifugation (Sorvall RT7 plus) at 200 x g for 15 
mins at 4°C. The aqueous layer was removed with a pipette, leaving the 
interface material behind. An equal volume of water to that removed was 
added, and the phenol extraction was repeated. The two aqueous phases of 
each extraction were combined and dialysed [Spectra/por 12-14kDa MWCO 
(Spectrum)] against water at 4°C, with changes of water every 4-6 hours. 
After dialysis, the preparations were centrifuged (Beckman Avanti J.30I) at
100,000 x g at 4°C overnight. The supernatant was removed and the LPS 
pellet was re-suspended in water.
2.2.2b Purification of lipopolysaccharide
LPS obtained by aqueous 45% (w/v) phenol extraction was further purified by 
gel filtration using a HiPrep 26/60 Sephacryl S-300HR column (26 x 600mm), 
(Amersham Pharmacia Biotech). The buffer used was 20mM Tris-HCL, 
pH8.5, 2mM EDTA and 1% (w/v) sodium deoxycholate. The flow rate was 
0.6ml/min and 5-min fractions were collected. The HPLC system was as 
described previously. The refractive index of the eluant was monitored 
together with absorbance at 280nm and 260nm. By this method the LPS, as 
detected by refractive index, was separated from remaining protein and DNA. 
LPS-containing fractions were pooled, dialysed [Spectra/por 12-14 kDa 
MWCO (Spectrum)] at RT against 5L of water with 3 changes, and freeze 
dried. The LPS was then dissolved in 1-2ml of 0.4M NaCI and precipitated 
from 80% (v/v) cold ethanol. The precipitate was recovered by centrifugation, 
left to dry, and dissolved in a small amount of water. The recovery of LPS 
was determined by the phenol sulphuric acid assay for total carbohydrate.
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2.2.3 Analysis and characterisation of capsular polysaccharides from 
Klebsiella pneumoniae
2.2.3a Confirmation of Klebsiella pneumoniae capsular polysaccharide 
serotype
Using rabbit anti-capsular antiserum (Statens Serum Institute, Copenhagen, 
Denmark) the serotype of the CPS was confirmed by ELISA. The ideal 
coating concentration could also be confirmed at this time. Immunoplates 
were coated with 50pl/well of the CPS in a range of different concentrations 
(10pg/ml -  50pg/ml) diluted in saline. These were incubated overnight in a 
moist box. They were then washed 3 times with wash buffer [PBS and 0.05%  
Tween 20]. The antisera were serially diluted 2 fold with PBS and 0.1%  
Tween 20 and 50pl was added to each well and left for 3h at RT. The plates 
were then washed with wash buffer. To each well, 50pl of anti-rabbit IgG 
HRP diluted 1 in 1,000 in PBS and 0.05% Tween 20 was added, followed by 
incubation at RT for 2h. The plates were then washed and 50pl/well of the 
substrate 2,2-azino-di-[3-ethylbenthiazoline sulphate] (ABTS) in 50mM 
citrate-phosphate buffer, pH5.1, was added and allowed to develop. The 
plates were then read at 405nm on a plate reader [SpectraMAX 340 
(Molecular Devices)].
2.2.3b Quantification of carbohydrate
Total carbohydrate content was determined by the phenol sulphuric acid 
method (Dubois and Giles, 1956). Briefly, 100pl of 5% (w/v) phenol was 
added to 200ul sample, followed by addition of 1.2ml concentrated sulphuric 
acid and gentle mixing. Absorbance was measured at 490nm using a 
spectrophotometer (Beckman DU 640B). Each assay was carried out in 
duplicate.
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2.2.3c Quantification of protein
Protein content was measured by the Folin method (Folin et al., 1927). BSA 
(10mg/ml) solution was used to make a standard curve for protein content 
from 10pg to 100pg. The standard sample volume used was 200pl and each 
standard was done in duplicate. To the sample 2.2ml of Biuret reagent was 
added. This was mixed and then left at RT for 10 mins. Folin reagent (100pl) 
was added, sample was mixed and incubated for 30 mins at RT. An 
absorbance reading was taken at 720nm using a spectrophotometer 
(Beckman DU 640B).
2.2.3d Quantification of uronic acid
Uronic acid was measured by the carbozole method (Knutson and Jeanes, 
1968). All of the K. pneumoniae CPS contain one uronic acid residue, either 
galacturonic acid or glucuronic acid, in each repeating unit of the 
polysaccharide. By quantifying the amount of uronic acid present in the 
preparation it is possible to determine the amount of CPS present either on a 
weight basis or according to the molarity of repeating units. A standard curve 
was produced using known concentrations of glucuronic acid and 
galacturonic acid, ranging from 20 to 200nmol. A volume of 350pl of sample 
(in duplicate) was placed on ice. To this 3ml of cold acid-borate solution 
[prepared by diluting 2.5ml of stock solution of 4M potassium borate in 1.8M 
potassium hydroxide to 100ml with concentrated sulphuric acid (final 
concentration 0.1 M borate)] was added. This was mixed and allowed to cool. 
After cooling 200pl of 0.1% carbazole in absolute ethanol was added, the 
solution was mixed and then incubated in a water bath at 55°C for 30 mins. 
Absorbance was measured at 530nm using a spectrophotometer (Beckman 
DU 640B).
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2.2.3e Quantification of lipopolysaccharide
The LPS content of samples was determined by a kinetic turbidometric 
Limulus amoebocyte lysate (LAL) assay. Reagents for the LAL assay were 
purchased from Charles River Endosafe, UK and the assay was performed 
according to manufacturer’s instructions with E.coli 055 LPS as a standard.
2.2.3f Quantification of nucleic acid
Nucleic acids concentrations were measured spectrophotometrically at 
260nm wavelength.
2.2.3g Sodium Dodecyl Sulphate Polyacrylamide Electrophoresis
SDS-PAGE was carried out according to the method of Laemmli (Laemmli,
1970) using BioRad mini protean cell equipment. Samples were prepared by 
diluting the respective LPS and CPS with 0.25 volumes of sample buffer 
(0.1M Tris/HCI, pH 8.0, 4mM EDTA, 1M sucrose, 0.1% Bromophenol blue, 
and 0.2% SDS). Typically 5pg of CPS was loaded into each well, and 0.4pg 
of LPS was loaded. Samples were mixed thoroughly and then stored at 4°C  
until required.
A 15% polyacrylamide separating gel was used for the LPS samples and a 
10% separating gel was used for CPS samples. Table 2.2 shows the 
compositions of the 10% and 15% separating gels. Volumes shown are for 
10cm x 7.5cm sized gels using 1mm spacers.
Table 2.2 SDS-PAGE separating gel components
COMPONENT 10% separating gel 15% separating gel
Water 5.4ml 3.2ml
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1.5M Tris/HCLpH 8.8 3.3ml 3.3ml
30%
acrylamide/bisacrylamide
(Bio-Rad)
4.4ml 6.6ml
10% SDS 133fjl 133pl
Degas under vacuum
10% ammonium 
persulphate (Bio-Rad)
67pl 46pl
TEMED (Bio-Rad) 7pl 5pl
Mix gel solution thoroughly
The separating gel solution was then poured between two glass plates of a 
mini-protean cell overlaid with butan-1-ol saturated water and left to 
polymerise for 1h. The composition of the stacking gel is shown in Table 2.3.
Table 2.3 SDS-PAGE stacking gel components
COMPONENT STACKING GEL (4.05%)
Water 4.13ml
0.5M Tris/HCI pH 6.8 1.75ml
30% acrylamide/bisacrylamide 
(Bio-Rad)
0.95ml
10% SDS 67pl
Degas under vacuum
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10% ammonium persulphate 3 2 pi
TEMED 7 mI
Mix gel solution thoroughly
The butan-1-ol saturated water was poured off the gel. The top of the gel was 
washed thoroughly with distilled water. The stacking gel solution was then 
poured on to the separating gel. Combs were carefully inserted into the 
stacking gel and the gel was left for a further hour to allow for polymerisation.
The samples (5-30pl/well) were then loaded onto the gel. Electrophoresis 
was carried out using a Power-Pac model 3000 (BioRad). The gels were run 
at 25mA constant current until the samples had entered the separating gel. 
At this point the current was increased to 45mA until the tracking dye had 
reached the bottom of the gel. The gels were ran for approximately 1h. 
Following electrophoresis the gels were either stained using the silver 
staining method described in Section 2.2.3i (Tsai and Frasch, 1982) or used 
for western blotting as described in Section 2.2.3h.
2.2.3h Western blotting
Immediately after electrophoresis, the polyacrylamide gel and a positively 
charged Nytran membrane (Schleicher & Schuell) and filter paper was 
soaked for 30 mins in transfer buffer (48mM Tris, 39mM glycine, 20%  
methanol, and 0.375% SDS). Transfer was achieved by use of a semi-dry 
transfer cell (Bio-Rad, UK) which was run at 10V for 30 mins. After blotting, 
the gel was silver stained as described in Section 2.2.3i, and the Nytran
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membrane was then blocked with PBS + 3% milk powder for 1-2h. After 
blocking, blots were incubated overnight at 4°C with a variety of rabbit anti- 
capsular antisera (Statens Serum Institute), at a dilution of 1/100. This was 
followed by brief washing with PBS, and four 10-min washes with PBS. The 
blot was then incubated for 2h with anti-rabbit IgG horseradish peroxidase 
conjugate at a dilution of 1/800. The membrane was washed as before and 
immunoblots were developed using 3,3-diaminobenzidine tetrahydrochlorde 
(DAB) as a substrate. The reaction was stopped with extensive washing with 
water.
2.2.3i Silver staining
Table 2.4 Silver staining solutions
Solutions Components
1 40% ethanol / 5% acetic acid 
made up to 100% with water
2 0.7% periodic acid w/v dissolved in solution 1
3 Alkaline silver nitrate
Cone, ammonium hydroxide 2ml 
0.1M NaOH 28ml 
20% silver nitrate 5ml 
Distilled water 115ml
4 citric acid -  formaldehyde solution
citric acid 50mg
37% formaldehyde 0.5ml
made up to 1 litre with water.
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Table 2.4 shows components for each solution required for silver staining 
(Tsai and Frasch, 1982). Immediately after electrophoresis the gel was 
placed into solution 1 and left overnight to allow for fixation of the gel. It was 
then placed into solution 2 for 10 mins on a rocking platform. The gel was 
washed 3 times for 15 mins with distilled water. The gel was then placed into 
solution 3 for 10 mins. Again the gel was washed 3 times for 15 mins with 
distilled water before the next solution was added. The gel was added to 
solution 4, which allows development of the stain. The bands develop over 
time. To stop development the gel was transferred to water. It is important 
that all stages are performed on a rocking platform to allow maximum and 
even coverage of gel with solutions.
The method described above is for staining LPS. For staining CPS 0.01%  
(w/v) Alcian blue was added to solution 1 prior to silver staining which is 
necessary to visualise CPS (Min and Cowman, 1986).
2.2.4 Characterisation of humoral response
2.2.4a Protocol of Streptococcus pneumoniae CPS immunisations.
Mice
Female or male C57BL/6 (H-2b), BALB/c (H-2d) and Cr2 [complement 
receptors 1 and 2 deficient mice (H-2b)] mice were obtained from Charles 
River, UK (Margate, Kent, UK). Cr2 were obtained originally from Dr. M. C. 
Carroll, Center for Blood Research, Harvard Medical School, Boston, USA.
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The animals were kept under specific pathogen free conditions and the mice 
were used between 8 - 12  weeks of age.
Immunisations
Groups of 3 mice were immunised by the intra peritoneal route with a range 
of pneumococcal CPSs (capsular serotypes 1, 2, 3, 4, 6B, 9N, 9V, 14, 18C, 
19A, 19F, 23F) obtained from either the National Institute for Biological 
Standards and Control (NIBSC, Hertfordshire, UK) or the Statens Serum 
Institute, Copenhagen, Denmark. These CPSs are constituents of human 
polysaccharide vaccines for pneumococcal diseases. A range of doses were 
used (0.1 -  20pg per mouse) in a 500pl volume of sterile PBS. Control mice 
were given PBS only. The schedule for immunisations and blood sampling is 
shown in Figure 2.1.
2.2.4b Protocol of Klebsiella pneumoniae CPS immunisations.
Mice
Female or male C3H/HeN (H-2k) and C3H/HeJ [LPS hyporesponsive (H-2k)] 
mice were obtained from Harlan UK Limited (Blackthorn,UK). The animals 
were kept under specific pathogen free conditions and the mice were used 
between 8-12 weeks.
Immunisations
C3H/HeN and C3H/HeJ mice were immunised by the intra peritoneal route 
with 5pg of K. pneumoniae capsular polysaccharides in 500pl PBS. Control 
mice received PBS only. The immunisation schedule is shown in Figure 2.1.
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Figure 2.1 Schedule for immunisation of mice with Streptococcus 
pneumoniae and Klebsiella pneumoniae capsular polysaccharides and 
serum collection.
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2.2.4c Protocol of chicken gamma globulin (CGG) immunisations 
Mice
Female or male C3H/HeN and C3H/HeN mice aged 8-12 weeks were 
obtained from Harlan UK limited (Blackthorn, UK). Animals were kept under 
specific pathogen free conditions.
Removal of lipopolysaccharide from CGG
Before immunisation, contaminating LPS was removed from the CGG 
preparation using a Vivapure Mini (Q) spin column [quaternary ammonium 
strong basic anion exchanger (Vivascience Ltd, UK)]. CGG [500ul (5mg/ml in 
PBS)] was loaded onto the column and then centrifuged at 2000 x g for 10 
mins in a Beckman microfuge (model:microfuge 18). The negatively charged 
LPS bound to the column whereas the positively charged CGG was eluted in 
PBS. The eluted sample was collected and LPS removal was confirmed by 
the LAL assay as described in Section 2.2.3e.
Immunisations
Mice were immunised by the intra peritoneal route with 100pg of CGG in 
500pl PBS with or without adjuvant. When injected with Titermax, an equal 
volume of CGG in PBS was emulsified with the adjuvant before injection. 
Titermax contains three ingredients: a block polymer, CRL-8941, squalene 
and a metabolizable oil. The identities of the polymer and the oil in Titermax 
have not been disclosed. The potency of Titermax lies in its 
immunostimulatory activity of its components and in the fact that it forms a
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stable water-in-oil emulsion. For other adjuvants tested, such as the LPS and 
CPS from K. pneumoniae, a set amount of adjuvant (5-25[jg) was mixed with 
100|jg of CGG prior to injection. The immunisation schedule is shown in 
Figure 2.2.
2.2.4d Preparation of mouse serum
Mice were bled from the tail and bfood was collected. Blood was left for 1h at 
RT and then left overnight at 4°C. In order to clarify serum from coagulated 
blood, samples were centrifuged at 2500 x g for 10 mins in a Beckman 
microfuge (model:microfuge 18). Serum was removed and placed into new 
tubes and then stored at -18°C until required.
2.2.4e Characterisation of serum antibody to Streptococcus 
pneumoniae capsular polysaccharides by ELISA.
The purified pneumococcal CPSs may contain a certain amount of 
pneumococcal C polysaccharide or cell wall polysaccharide (CW-PS) which 
is a constituent of the pneumococcal cell wall. It is recommended to absorb 
sera with C polysaccharide to remove antibodies to this polysaccharide when 
testing for antibodies to pneumococcal CPS antigens (Aaberge et al., 1993). 
Mouse antisera were absorbed with 100pg/ml of CW-PS (Statens Serum 
Institute, Copenhagen, Denmark). Absorption was carried out for 1h at RT at 
a 1 in 50 serum dilution in PBS + 0.05% Tween 20, prior to further dilution in 
buffer without CW-PS.
Immunoplates were coated with 50pl/well of CPS 10pg/ml in 0.9% (w/v) NaCI 
and sealed with parafilm prior to incubation in a damp box overnight at 37°C. 
The plates were then washed 3 times with wash buffer [PBS + 0.05% Tween 
20]. Coated plates were blocked for 1h at RT with 100pl of PBS + 4% milk
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Immunisation with 
100|jg chicken 
gamma globulin 
(CGG) +/- adjuvant.
Day -1
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Day 14
Tail bleed
Tail Bleed
Day 21
Tail Bleed
Figure 2.2 Schedule of immunisations of mice with chicken gamma 
globulin (CGG) and serum collection.
Chapter Two
powder. Plates were then washed 3 times. The CW-PS absorbed mouse 
sera (as described previously) were serially diluted starting at 1 in 50. 
Diluted antiserum (50pl) was added to duplicate wells and incubated at RT 
for 2h in a moist box. Plates were washed again, followed by incubation with 
50pl/well of the secondary antibody (see Section 2.1.1b) diluted 1 in 500 in 
PBS + 0.05% Tween 20 for 2h at RT. The plates were washed then 50ul/well 
of substrate solution o-phenylenediamine dihydrochloride [OPD (horseradish 
peroxidase substrate)] or p-nitro-phenyl-phosphate [pNpp (alkaline 
phosphatase substrate)] was added. Reactions were stopped with 15pl/well 
of either 3M H2SO4 (OPD) or 3M NaOH (pNpp). Optical densities were read at 
490nm (OPD) or 405nm (pNpp) on a plate reader [spectraMAX 340 
(Molecular Devices)]
2.2.4f Characterisation of serum antibody to Klebsiella pneumoniae 
capsular polysaccharides by ELISA.
Immunoplates were coated with 10pg/ml of CPS (extracted and purified as 
described in Section 2.2.1) in 0.9% (w/v) NaCI in a damp box overnight at 
37°C. Plates were washed with wash buffer, and then blocked with 100pl/well 
of PBS + 4% milk powder for 1h at RT. Plates were washed and then mouse 
sera were serially diluted, starting at a 1 in 50 dilution and then added to wells 
(50pl/well) and incubated at RT for 2h. After washing, 50pl of secondary 
antibody was added to each well (see Section 2.1.1b) and incubated for 2 
hours at RT. The secondary antibody was diluted 1 in 500 in PBS + 0.05%  
Tween 20. Plates were washed and then 50pl/well of OPD peroxidase 
substrate was added. After 5 minutes the reaction was stopped with 15pl/well 
of 3M H2SO4 and plates were read at 490nm on a plate reader.
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2.2.4g Characterisation of serum antibody response to chicken gamma 
globulin (CGG) by ELISA.
Immunoplates were coated with 50pl/well CGG [5pg/ml in 0.1M sodium 
carbonate buffer (pH9.6)] obtained from Jackson Immunoresearch, 
Cambridge, UK. Plates were placed in a moist box and incubated overnight 
at RT. Plates were then washed 3 times with wash buffer [PBS + 0.05%  
Tween 20] and then blocked with 100pl/well of PBS + 4% milk powder for 1 
hour at RT. After washing, mouse antisera were diluted with PBS + 0.1%  
Tween 20 in serial 2-fold dilutions. Diluted antisera (50pl) was added to wells 
in duplicate and incubated at RT for 2h in a moist box. The plates were then 
washed with wash buffer. The secondary antibody (50pl/well) (see Section 
2.1.1b in Materials and Methods) was diluted in PBS + 0.05% Tween 20 was 
added to wells, and incubated at RT for 2h. After washing, 50pl/well of OPD  
peroxidase substrate was added. The reaction was stopped after 5 mins with 
15pl/well of 3M H2S04. Plates were read at 490nm on a plate reader 
[SpectraMAX 340 (Molecular Devices)]
2.2.5 In vitro cell assays
2.2.5a Cell proliferation assay using 3H thymidine
Spleens from naive mice were removed aseptically. A single cell suspension
was produced by gently pushing the spleen through a cell strainer (40pm) 
using a barrel of a 5ml syringe. The cell suspension was then centrifuged 
(Sorvall RT7 plus) at 100 x g for 5 mins at 4°C. The cells were washed twice 
with complete RPMI [c.RPMI (RPMI 1640 with 1% penicillin/streptomycin and 
10% FCS)], and trypan blue was used to confirm viability. Cells were re­
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suspended in c.RPMI to a density of 2 x 106 cells/ml. The cell suspension 
(100pl) was dispensed to each well of a 96 well U-bottomed plate. For 
stimulation 100pl of test sample in c.RPMI was added in triplicate. Phorbol 
myristate acetate (PMA) at 5ng/ml and lonomycin (200ng/ml) were used as a 
positive control, whereas medium only was used as a negative control for cell 
proliferation. The cells were then incubated at 37°C, 5% C 0 2 for 72h. 
Tritiated thymidine (Amersham Pharmacia Biotech) at 1pCi in 20pl c.RPMI 
was then added to each well, followed by a 12h incubation as above. Plates 
were harvested using a TOMTEC 96-well harvester. The filters were dried 
and sealed in a plastic bag with Betaplate scintillant. Incorporated [3H] 
thymidine was measured using a MicroBeta TRILUX counter (Wallac, Turku, 
Finland).
2.2.5b Cytokine release assay
Mouse splenocytes were prepared and stimulated following the same method 
as described in Section 2.2.5a for thymidine proliferation assays. Samples 
were tested in duplicate and supernatant was harvested after 18h, 24h, 48h 
and 72h. Supernatants were stored at -18°C until used for cytokine analysis.
2.2.5c CFSE labelling of mouse splenocytes
Cells to be labelled were resuspended at 1 x 107 cells/ml in PBS + 0.01%  
BSA. A 5mM stock solution of carboxyfluorescein diacetate succinimidyl 
ester (CFSE) in DMSO was added to a final concentration of 5pM and 
incubated at 37°C for 10 mins. At the end of the incubation period, the cells
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were immediately washed with cold PBS + 5% FCS and passed through a 
40pm filter. Cells were washed 3 times with PBS and then counted.
2.2.5d Cytokine detection
Cytokine Cytometric Bead Array (CBA) assay
Cytokines present in the supernatants from stimulated mouse splenocytes 
were detected quantitatively using a cytokine cytometric bead array (BD 
Biosciences Pharmingen). The mouse TH1/TH2 CBA was used to detect 
TNF-a, IFN-y, IL-5, IL-4 and IL-2 and the mouse inflammation CBA to detect 
TNF-a, IFN-y, IL-10, IL-6, IL-12p70 and MCP-1. The assay was carried out 
according to manufacturer’s instructions. Samples were examined by flow 
cytometry using a FACScalibur flow cytometer. Data was analysed using BD 
CBA software (BD Biosciences Pharmingen).
2.2.5e Immunofluorescence staining of cell surface markers
Prior to labelling, cells were incubated at 107cells/ml in blocking buffer (PBS
+ 1% BSA + 0.01% sodium azide) for 30 mins at 4°C to minimise non­
specific binding. Antibodies directed to cell surface markers (see Section 
2.1.1a) were diluted in the blocking buffer. Cells (106) were labelled with 50pl 
of diluted antibodies for 15 mins at 4°C in the dark, followed by two washes 
with blocking buffer. Labelled cells were examined by flow cytometry using a 
FACScalibur flow cytometer in conjunction with the CellQuest software 
package (Becton Dickinson, Oxford, UK).
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2.2.6 Statistics
Data were analysed using software packages Microsoft Excel 2002 and 
Minitab 13 for Windows. Statistical analysis was performed according to 
directions given by Dr. Sandro Leidi of the University of Reading Statistical 
services centre. Statistical significance between two independent groups was 
performed using Two Way ANOVA (Analysis of Variance) whereas multiple 
groups were analysed using a General Linear Model ANOVA.
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Chapter Three 
Purification and characterisation of capsular 
polysaccharides from Klebsiella pneumoniae
3.1 Introduction
In order to address the potential biological effects of K. pneumoniae CPS it is 
essential to have pure preparations because contaminating components may 
have an influence on the results generated from immunological studies. It is 
particularly problematic when the component needs to be purified from 
complex mixtures as found in bacterial extracts. Common contaminants of 
CPS preparations include LPS, DNA, and lipoproteins, and these “pathogen- 
associated molecular patterns” can have a major effect upon the immune 
system. Toll-like receptors function as pathogen recognition receptors in 
mammals and play an essential role in the recognition of these and other 
microbial components (Akira, 2001). Recognition often results in a host 
inflammatory response. It is therefore critical that these potential 
contaminants are removed from CPS preparations to be investigated.
LPS is a major component of the outer membrane of Gram negative 
bacteria. LPS exhibits a variety of biological activities, such as toxicity, 
adjuvanticity, complement activation, polyclonal B cell activation, and 
cytokine-inducing activities (Morrison and Ulevitch, 1978; Morrison and Ryan, 
1979). The removal of LPS from test samples prior to immunological assays 
in thus very important. For example it was shown that endotoxin 
contamination in recombinant human heat shock protein 70 preparation was
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responsible for the induction of TNFa release from murine macrophages 
(Gao and Tsan, 2003). This example highlights the effect LPS can have on 
experimental results. The potential presence of LPS has also complicated 
the interpretation of previous results on the biological effects of CPS from K. 
pneumoniae. The CPS and LPS share common localisation at the cell wall 
surface. Moreover, the spontaneous release of LPS by bacteria is well 
established (Cadieux et al., 1983) and contributes to contamination during 
CPS extraction. For this study a number of methods have been tried for CPS 
purification. Chemical treatments such as alkaline de-O-acylation, which 
selectively removes O-acyl fatty acids, can be effective in detoxifying LPS 
(Seid and Sadoff, 1981). However this method can cause degradation of the 
polysaccharide, depending on the polysaccharide structure. 
Ultracentrifugation, a method commonly used to recover LPS, does not 
significantly remove LPS from K. pneumoniae CPS (Cryz et al., 1985). A 
method that we have found more successful is gel filtration under 
dissociating conditions (elution buffers containing detergents). The original 
method as described by Adam et al. (1995) required elution at high pH and 
high temperature which we found could degrade CPS samples. Therefore the 
method was modified to use buffers at pH 7 which was then used for 
subsequent routine purifications (Zamze et al., 2002).
3.2 Objectives
The objective of the work described in this chapter was to produce a CPS 
preparation that was free from as many other known biologically active 
components as possible by improving methods of K. pneumoniae CPS 
purification.
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3.3 Purification of Klebsiella pneumoniae capsular 
polysaccharides
3.3.1 Klebsiella pneumoniae  CPS extraction
CPSs from a number of different serotypes of K. pneumoniae were obtained 
using the extraction and purification methods described in Section 2.2.1. The 
CPS extracts were subjected to nuclease, protease and ultracentrifugation 
treatment and then quantified for CPS, protein, nucleic acid and LPS content. 
Table 3.1 shows the typical content by weight of a CPS extract.
Table 3.1 Typical contents of a CPS extract
CPSs were extracted and then purified by ultracentrifugation, and digested 
with both protease and nuclease. Preparations were then analysed for LPS, 
protein and nucleic acid content.
Component CPS extract (typical % content)
Protein 10-15%
Nucleic acid 5%
LPS 1-2%
3.3.2 Size fractionation and purification
CPS extracts were then fractionated by gel filtration chromatography (TSK 
G5000). Figure 3.1 shows two examples of typical gel filtration profiles of K. 
pneumoniae CPS extracts. The carbohydrate eluted at two time points, as 
shown by refractive index (Figure 3.1, peaks 1 and 2). The first peak, labelled 
1, was a high molecular weight (MW) component with elution volume slightly 
less than the void volume of the column. CPS quantification by phenol
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Figure 3.1 Gel filtration profiles of Klebsiella pneumoniae CPS 
serotypes K26 and K27.
K. pneumoniae CPSs were extracted and purified as described in Section 
2.2.1. Chromatography was performed on a TSK  G 5000 column in PBS. 
Void and total volume (V0 and V t respectively) of this column are 
indicated. The flow rate was 0.25ml/minute. The refractive index and the 
absorbance of the eluant at 205nm  and 260nm  were monitored for K. 
pneumoniae CPSs (A) K26 and (B) K27. Peaks 1 and 2 were pooled 
separately. Pool 1 was shown to contain 90%  of the total carbohydrate 
loaded onto the column by the phenol sulphuric acid assay (Section 
2.2.3b).
109
Chapter Three
sulphuric acid assay showed that this peak contained almost 90% of the total 
carbohydrate recovered from the column. The second lower MW peak 
contained only a small amount of carbohydrate. All CPS extracts gave very 
similar results. The CPS extracts also contained protein and/or nucleic acid 
contamination, as shown by the 260nm absorbance profile. The MW of the 
CPS was also determined using the gel filtration column. Dextrans of known 
molecular weights (40,000, 70,000, 200,000, 500,000, 1,800,000) were used 
to calibrate the column as shown in Figure 3.2. The 1,800,000 MW dextran 
standard eluted at approximately 30 mins, similar to the elution time of CPS 
peak 1 (Figure 3.1). CPSs eluting in peak 1, were therefore estimated to 
have MW of approximately 2 x 106 Da.
Gel filtration profiles of CPS extracts following ultracentrifugation, nuclease 
and protease digestion are shown in Figure 3.3. The 260nm absorbance 
trace, which detects the presence of DNA and protein, varied for each of the 
samples. When the CPS extract was not subjected to ultracentrifugation or 
protease and nuclease digestion there were much more high MW protein and 
nucleic acid present as shown by the peaks at 20-30 mins. The samples 
subjected to ultracentrifugation, protease and nuclease digestion contained 
lower MW protein and nucleic acid, which eluted later than the carbohydrate 
(i.e. at 40-60mins). Separating CPS extracts by gel filtration chromatography 
allows the carbohydrate in the first peak to be pooled and most of the protein 
and nucleic acid to be removed from the sample.
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Figure 3.2 Gel Filtration profile of dextran standards.
Known molecular weights of dextran (40,000, 70,000 , 200 ,000 , 
500 ,000 ,1 ,800 ,000 ) from Leoconostoc ssp. were analysed by gel 
filtration chromatography on a TSK  G 5000 column in PBS containing 
0.25%  (w/v) sodium deoxycholate at 60°C . Void and total volume (Vc 
and V t respectively) of the column are indicated. The refractive index of 
the eluant was monitored.
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Figure 3.3 Gel filtration profiles of Klebsiella pneumoniae CPS 
serotype K11 subjected to different degrees of purification.
K. pneumoniae CPS K11 was subjected to different degrees of 
purification (A) no protease, nuclease or ultracentrifugation, (B) 
protease treatment, no nuclease or ultracentrifugation, (C ) protease, 
nuclease and ultracentrifugation treatment. Chromatography was  
carried out on a TSK G 5000 column in PBS. Void and total volume (V 0 
and V t respectively) of the column are indicated. The flow rate was  
0.25ml/min. The refractive index and the eluant absorbance at 205nm  
and 260nm  were monitored. Peaks 1 and 2 were pooled separately  
and analysed for carbohydrate content as described in Section 2.2 .3b. 
Pool contained 90%  of the total carbohydrate loaded onto the column.
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3.3.3 Removal of LPS from CPS extracts.
The following methods were attempted or used to remove LPS from the CPS 
extracts.
3.3.3a Triton X-114
Extraction of LPS by Triton X -114 was carried out as described in Section 
2.2.1f. There was a ten fold decrease in the amount of LPS present in the 
CPS extract as shown by the LAL assay, but there was a 50% loss of 
carbohydrate. Due to the loss of large amounts of CPS, this method was not 
used further.
3.3.3b Gel filtration chromatography under dissociating conditions.
When PBS was used as an elution buffer, LPS formed high MW  micelles and
co-eluted in pool 1 (high MW peak) with CPS. It was possible to disrupt 
micelle formation and therefore separate CPS and LPS using dissociating 
conditions. K55 LPS (Figure 3.4) was separated by gel filtration 
chromatography in PBS and also by published conditions using a 
dissociating buffer [10mM Tris-HCI (pH8.7) containing 0.2M NaCI, 1 mM 
EDTA and 0.25% (w/v) sodium deoxycholate] at 60°C (Adam et al., 1995). 
This allowed comparison of the refractive index traces, for each elution 
buffer, in order to determine at which time point LPS eluted from the column. 
When PBS was used as an elution buffer, LPS eluted at around 30 mins 
(indicated by A in Figure 3.4). When a dissociating buffer was used LPS 
eluted much later from the column at around 40-50 mins. This is indicated on 
the refractive index profile as B. In non-dissociating conditions CPS and LPS 
co-eluted, whereas under dissociating conditions LPS eluted much later.
113
R
ef
ra
ct
iv
e 
in
de
x 
A
bs
or
ba
nc
e 
26
0n
m
 
A
bs
or
ba
nc
e 
20
5n
m
Chapter Three
m
0.2CC-
0 .100-
m
m
80 00
M inutes
Figure 3.4 Gel filtration profiles of Klebsiella pneumoniae 
serotype K55 LPS (TSK G5000 column)
K. pneumoniae LPS was obtained by aqueous 45%  (w/v) phenol 
extraction as described in Section 2.2 .2a. LPS was then analysed  
by gel filtration chromatography on a TSK G 5000 column in either 
PBS (A) or a dissociating buffer [10mM Tris-HCI (pH 8.7) 
containing 0.2M  NaCI, 1mM ED TA  and 0 .25%  (w/v) sodium  
deoxycholate] at 60°C  (B). Void and total volume (V0 and V t 
respectively) of the column are indicated. The refractive index and 
the absorbance of the eluant at 205nm  and 260nm  were  
monitored.
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Since LPS and CPS eluted at different times from the column, so this was a 
good method for removing LPS from CPS extracts.
3.3.4 Gel filtration chromatography of Klebsiella pneumoniae CPS 
extracts and further analysis of pooled samples.
Using relatively high pH and temperature to elute CPS can lead to the loss of 
alkali labile substituents such as O-acetyl groups (many CPS contain these 
groups, e.g K. pneumoniae serotype K55) and partial de-O-acylation of lipids, 
which may be important if the CPS has a lipid-anchor. This could therefore 
modify the structure of the CPS and likely change its antigenicity or 
immunogenicity. Different conditions of temperature and pH were therefore 
investigated. CPS extracts were separated by gel filtration chromatography 
(TSK G5000) using the elution buffers shown in Table 3.2. Fractions were 
collected every 2 mins. The two carbohydrate peaks were pooled and 
subjected to further analysis.
3.3.4a Recovery and MW of polysaccharide
The refractive index profiles generated after gel filtration of CPS with different 
dissociating buffers were identical. Peak one eluted at 30 mins which 
confirmed that there was no gross change in the MW of the polysaccharide 
when dissociating buffers were used. To recover the samples, pools 1 and 2 
were dialysed extensively against water, at RT and freeze dried.
Table 3.2 Gel filtration elution buffers
Buffer CONDITIONS: Components / temperature / pH
A PBS 30°C
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B* (Sodium deoxycholate buffer)10mM Tris-HCI pH8.7 containing 
0.2M NaCI, 1mM EDTA and 0.25% (w/v) sodium deoxycholate 
at 60°C
C* (Sodium deoxycholate buffer)10mM Tris-HCI pH8.7 containing 
0.2M NaCI, 1mM EDTA and 0.25% (w/v) sodium deoxycholate 
at 30°C
D* (Sodium deoxycholate buffer) 10mM Tris-HCI pH7.5 containing 
0.2M NaCI, 1mM EDTA and 0.25% (w/v) sodium deoxycholate 
at 30°C
E* (Sodium deoxycholate buffer) 10mM PBS pH 7.0 containing 
0.25% (w/v) sodium deoxycholate at 60°C.
Residual detergent was removed by precipitation with 80% (v/v) ethanol. 
Total carbohydrate in pools 1 and 2 was quantified by the phenol sulphuric 
acid assay. The recovery of carbohydrate under all conditions was 80% or 
greater. For CPS extracts that were eluted with PBS, the recovery was 
slightly greater than that seen for dissociating buffers, probably due to losses 
at the precipitation step.
3.3.4b Effect of separating conditions on CPS antigenicity
The effect of using different elution buffers for gel filtration on CPS
antigenicity was investigated by ELISA using anti-CPS specific rabbit 
antisera. ELISA assays were carried out as described in Section 2.2.3a. 
Plates were coated with control CPS and CPS pool 1 recovered from each of 
the different elution conditions. These were then incubated with rabbit anti-
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capsular serum specific for K55 serotype. Figure 3.5 shows the change in 
anti-capsular antibody binding to K55 CPS extracts eluted with different 
buffers.
The absorbance at 490nm was plotted against reciprocal serum dilution for 
each elution condition. Absorbance values indicate the amount of binding of 
antibody to antigen. If the antigen was modified a reduction in antibody 
binding was expected and thus a loss in antigenicity. When K55 CPS 
extracts were eluted from the column with PBS containing 0.25% (w/v) 
sodium deoxycholate there was no change in absorbance levels when 
compared to the control CPS. This suggests no or very little modification of 
the CPS structure. For other buffers used there was some reduction in 
absorbance levels compared to control CPS, especially the Tris/ 
deoxycholate buffer at pH 8.7 and 60°C. The high temperature and pH may 
have modified the CPS and affected the binding of the specific anti-capsular 
antiserum. It was therefore decided that PBS containing 0.25% (w/v) sodium 
deoxycholate would be used to separate CPS extracts by gel filtration 
chromatography because no effect on the antigenicity of the CPS was 
detected.
3.3.4c Analysis of CPS purified by dissociating conditions
A representative profile of CPS fractionated using PBS, 0.25% sodium
deoxycholate at 60°C is shown in Figure 3.6. The carbohydrate, as with using 
PBS alone, eluted in two peaks and these two peaks were pooled. Pool 1 
which contained 90% of carbohydrate recovered from the column was further 
analysed for protein, LPS and nucleic acid content. Table 3.3 shows the
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—A— Tris/Deoxycholate / pH 8.7 / 60°C —x — Tris/Deoxycholate / pH 8.7 / 30°C  
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Figure 3.5 The binding of rabbit anti-capsular antiserum to 
Klebsiella pneumoniae serotype K55 (pool 1) following gel 
filtration.
K. pneumoniae C PS K55 was extracted and purified as described in 
the methods section. Chromatography was carried out on a TS K  
G 5000 column with different elution buffers (Table 3 .2). Peak one was  
pooled for each elution condition, dialysed against water, and freeze- 
dried, and detergent was removed by precipitation with ethanol. The  
binding of rabbit anti-capsular antiserum to K55 was determined by 
ELISA using K55 CPS extract not subjected to gel filtration as a control 
C PS. Anti-rabbit IgG (y-chain specific) HRP conjugate was used to 
detect capsular antiserum and O PD was used as a substrate. 
Absorbance was read at 490nm . These data are representative of 
other CPS extracts.
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Figure 3.6 Gel filtration profile of Klebsiella pneumoniae CPS 
serotype K31.
K. pneumoniae C PS was extracted and purified as described in the 
Section 2 .2.1 . Chromatography was carried out on a TSK  G 5000  column 
in PBS containing 0.25%  (w/v) sodium deoxycholate at 60°C . The flow  
rate was 0.25m l/m inute. The refractive index and the absorbance of the 
eluant at 205nm  and 280nm  were monitored. Peaks 1 and 2 w ere pooled 
and detergent was removed. Pool 1 was shown to contain 90%  of the total 
carbohydrate recovered fro the column by the phenol sulphuric acid assay  
(Section 2.2.3b).
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typical content by weight of pool 1 from a CPS extract separated by gel 
filtration chromatography under dissociating conditions. There was a large 
reduction in protein, nucleic acid and LPS content in CPS pool 1 compared to 
the CPS extract (Table 3.1 and 3.3). CPS pool 2 was analysed for protein 
and LPS. The LAL assay confirmed that almost all of the LPS were found in 
pool 2.
Table 3.3 Typical contents of CPS pool 1
CPS extract was separated on a TSK G5000 column in PBS containing 
0.25% (w/v) sodium deoxycholate. The two carbohydrate peaks were pooled 
and then subjected to LPS, protein and nucleic acid content analysis. Pool 2 
contained most of the protein and LPS from crude preparations.
Component Pool 1 typical % content
Protein 1%
Nucleic acid < 0.1% or non detectable
LPS 0.01%
3.4 Characterisation of Klebsiella pneumoniae 
capsular serotypes by SDS-PAGE
CPS extracts were analysed by SDS-PAGE using staining methods for 
detection of CPS, LPS and protein. K. pneumoniae CPS extracts were 
analysed by SDS-PAGE using 10% separating gels as described in Section 
2.2.3g. In some cases extracts were also analysed by western blotting using 
rabbit anti-CPS antisera. Figure 3.7 shows the SDS-PAGE and western blot 
profiles obtained for serotypes K31 and K3 crude extracts. Most of the 
capsular serotypes studied gave a variety of banding patterns, although all
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Figure 3.7 SDS-PAGE and western blot analysis of Klebsiella 
pneumoniae CPS serotypes K31 and K3.
K. pneumoniae CPSs were extracted as described in Section 
2.2.1b. C PS extracts (before gel filtration) were then analysed by 
SDS-page (A), followed by western blotting (B). Lanes 1-3 
contain K31 C PS extract (5/yg) and lanes 4 -6  contain K3 C PS  
extract (5/yg). Separation was on a 10% (w/v) gel and detection 
with Alcian blue followed by silver staining. For western blotting, 
C PS was transferred from a 10% gel onto a Nytran membrane  
and then detected with specific rabbit anti-capsular antisera  
followed by anti rabbit IgG HRP conjugate. Blots were then 
developed with DAB.
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have the characteristic smear at the top of the gel that indicates the presence 
of high MW CPS. The smear was probably due to the heterogeneity of the 
polysaccharides (different numbers of repeating units). K31 and K3 CPS 
extracts were used as examples. K31 CPS extract contained the typical high 
MW smear at the top of the gel and then many bands close together. K3 also 
had the high MW smearing but low molecular weight bands were fewer and 
less frequent. For western blotting, K31 and K3 CPS extracts were 
transferred from a 10% gel onto a Nytran membrane and were detected with 
specific rabbit anti-capsular antiserum to K31 and K3. The K31 blot shows a 
strong positive signal at the top of the gel where high MW  CPS were located, 
whereas K3 blot shows a weak signal across the whole length of the blot. 
This pattern was likely due to the degradation of the K3 CPS. The lower MW  
bands on the gel were not seen on the western blot. The evidence presented 
below suggests that these bands were not due to degraded CPS but were 
probably due to contaminating protein and LPS in the CPS extracts.
The K55 CPS extracts were fractionated by gel filtration chromatography with 
either dissociating buffer or PBS and then analysed by 10% (Figure 3.8) and 
15% (Figure 3.9) SDS-PAGE. LPS was visualised by silver staining, and 
CPS was visualised by staining with Alcian blue followed by silver staining. K. 
pneumoniae CPS was not detectable without the use of alcian blue. Lanes 8 
and 9 in Figure 3.8 (detection with alcian blue and silver staining) represent 
fractions that were eluted from the column with PBS. Both samples look very 
similar with a high MW smear and many low MW bands. The CPS extracts 
that were eluted with dissociating buffers (lanes 2-7), show very different
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Smear
1 CPS extract
2 Pool 1 dissociating* pH8.7 30°C
3 Pool 2 dissociating* pH3.7 30°C
4 Pool 1 dissociating* pH8.7 60°C
5 Pool 2 dissociating* pH8.7 60°C
6 Pool 1 dissociating* pH7.5 30°C
7 Pool 2 dissociating* pH7.5 30°C
8 Pool 1 PBS 30°C
9 Pool 2 PBS 30°C
‘dissociating buffer (10mM Tris/HCL 
containing 0.2M NaCI, 1mM EDTA 
and 0.25% (w/v) sodium 
deoxycholate).
Bands
Figure 3.8 10 % SDS-PAGE analysis of Klebsiella pneumoniae 
capsular polysaccharide serotype K55 after gel filtration 
chromatography.
Chromatography was carried out in a TSK  G 5000 column with 
either PBS at 30°C  or a dissociating buffer [10mM Tris-HCI (pH 8.7  
or 7 .5 ) containing 0.2M  NaCI, 1mM EDTA and 0.25%  (w/v) sodium  
deoxycholate] at 30°C  or 60°C. Peaks 1 and 2 containing 
carbohydrate were pooled and analysed by S D S -P A G E . 
Separation was carried out on a 10%  gel and detection with Alcian 
blue followed by silver staining.
123
Chapter Three
1 2 3 4 5 6
^  m
W m m m  *
Broad Band
Figure 3.9 15% SDS-PAGE analysis of Klebsiella pneumoniae 
CPS serotype K55 after gel filtration chromatography
K55 C PS was extracted and purified by gel filtration 
chromatography. Chromatography was carried out on a TSK  G 5000  
column with either PBS at 30°C  or a dissociating buffer [10m M Tris- 
HCI (pH 8.7 or 7 .5 ) containing 0.2M  NaCI, 1mM EDTA and 0 .25%  
(w /v) sodium deoxycholate] at 30°C  or 60°C . Peaks containing 
carbohydrate were pooled. C PS was then analysed along with LPS  
(extracted as shown in methods) by SD S-PA G E. Separation was  
carried out on a 15%  gel and detection with silver staining.
10
♦ f
1 K55 LPS (0.4ug)
2 K55 LPS (0.2ug)
3 Pool 1 PBS 30°C
4 Pool 2 PBS 30°C
5 Pool 1 dissociating* pH8.7 60°C
6 Pool 2 dissociating* pH8.7 60°C
7 Pool 1 dissociating* pH8.7 30°C
8 Pool 2 dissociating* pH8.7 30°C
9 Pool 1 dissociaitng* pH7.5 30°C
10 Pool 2 dissociating* pH7.5 30°C
‘ dissociating buffer (10mM 
Tris/HCL containing 0.2M NaCI, 
1mM EDTA and 0.25% (w/v) sodium 
deoxycholate
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profiles. Pool 1, which contained most of the CPS, had a characteristic smear 
at the top of the gel and no banding. The second pool had a smear and 
extensive banding which was due to LPS. Figure 3.9 (detection with silver 
staining only) shows a 15% SDS-PAGE of preparative run fractions. The gel 
was used to determine whether the bands seen in pool 2 on the 10% gel 
were due to CPS or LPS. The pools were compared to K55 LPS. Lanes 1 
and 2 contained K55 LPS, and showed distinct banding pattern with a broad 
band at the bottom of the gel. The CPS eluted with PBS (lanes 3 and 4) gave 
very similar profiles to each other and to K55 LPS. Lanes 5-10 showed pools 
that were eluted from the gel filtration column with dissociating buffers. These 
all produced similar profiles to each other. Pool 1 showed very little or no 
staining at all whereas pool 2 showed similar staining to that seen for K55 
LPS. This confirmed that pool 2 contained most if not all of the LPS, and 
pool 1 contained CPS. This was also consistent with the results of the LAL 
assay for pools 1 and 2.
In order to demonstrate that the banding patterns in pool 2 (high MW LPS 
components) seen on SDS-PAGE were not just specific for K. pneumoniae 
capsular serotype K55, K1 (Figure 3.10) and K52 (Figure 3.11 A) were also 
separated by gel filtration chromatography with PBS containing 0.25% (w/v) 
sodium deoxycholate. The carbohydrate-containing peaks were obtained and 
analysed by SDS-PAGE. In both cases, pool 2 contained material showing 
characteristic LPS profiles by SDS-PAGE. This includes the presence of one 
or more low MW bands. K55 and K1 have smooth-type LPSs whereas K52 is 
rough-type and therefore lacks the high molecular weight banding pattern.
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Figure 3.10 SDS-PAGE analysis of Klebsiella pneumoniae 
CPS serotype K3 pools 1 and 2.
Chromatography was carried out on a TSK  G 5000 column with 
PBS containing 0 .25%  (w/v) sodium deoxycholate at 60°C . Pools 
1 and 2 were then analysed by SD S -P A G E. Separation was on a 
10%  (w/v) gel and detection with Alcian blue followed by silver 
staining. Lanes 1 and 2 = pool 2, Lanes 3 and 4 = pool 1.
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Figure 3.11 SDS-PAGE 
analysis of Klebsiella 
pneumoniae CPS serotype 
K52.
K. pneumoniae C PS was 
extracted as described in Section 
2.2.1. Lane 1, K52 C P S  extract 
(with protease digestion); Lane 2, 
K52 C PS extract (no protease 
digestion). After extraction C PS  
was purified by gel filtration 
chromatography on a TSK  
G 5000 column in PBS containing 
0.25%  (w/v) sodium
deoxycholate at 60°C . Peaks 
containing carbohydrate were  
pooled. Lane 3, K52 C PS, pool 1; 
Lane 4, K52 C PS, pool 2. 
Separation was on a 15%  gel 
and detection with (A) silver 
staining or (B) Coom asie blue.
255KDa 
150KDa 
100KDa 
75KDa
50KDa
35KDa
25KDa
15KDa
10KDa
127
Chapter Three
We have demonstrated that gel filtration chromatography with dissociating 
buffers was a good reproducible method for the purification of CPS from 
many of the Klebsiella capsular serotypes.
The effect of protease digestion on CPS extracts could also be followed by 
SDS-PAGE analysis. Figure 3.11 shows a comparison of K52 CPS extract 
with or without protease treatment (lanes 1 and 2). Both the Coomassie blue 
and silver staining detection methods show the disappearance of a number 
of bands in lane 1 compared to lane 2 after protease digestion of the 
samples.
3.5 Characterisation and purification of Klebsiella 
pneumoniae LPS.
3.5.1 Purification of Klebsiella pneumoniae LPS.
LPS from a number of different serotypes of K. pneumoniae were extracted
by 45% (w/v) phenol extraction and purified by gel filtration chromatography 
as described in Section 2.2.2a. Chromatography was carried out on a HiPrep 
26/60 Sephacryl S-300HR column in Tris-HCI, pH8.5, 20mM, 2mM EDTA 
and 1% (w/v) sodium deoxycholate at RT. Figure 3.12 shows a gel filtration 
profile of K. pneumoniae serotype K55 LPS. The LPS, as shown by refractive 
index trace, was found in two peaks at 260 and 300 min (indicated as A and 
B, respectively). Peak A contains full length LPS (O-antigen, core antigen 
and lipid) whereas peak B contains LPS without O-antigen. This was 
confirmed by SDS-PAGE analysis (Figure 3.13). Peak A containing full length 
LPS was pooled and used in experiments described in following chapters. 
Absorbance readings at 260nm and 280nm show that there was very little
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Figure 3.12 Gel filtration profile of Klebsiella pneumoniae serotype 
K55 LPS (HiPrep 26/60 Sephacryl S-300HR column)
K. pneumoniae LPS was extracted by aqueous 45%  (w/v) phenol 
extraction and purified by gel filtration chromatography as described in 
Section 2.2 .2 . Chromatography was carried out on a HiPrep 26 /60  
Sephacryl S -300H R  column in 20m M  Tris-HCI, pH8.5, 2m M  EDTA and 
1% (w/v) sodium deoxycholate at room temperature. The flow rate was  
0.6ml/min. The refractive index and absorbance (280nm  and 260nm ) of 
the eluant were monitored.
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1 2 3
Bands
LPS  with varying num ber of 
repeating O -antigen units
Broad Band
LPS without O -antigen
Figure 3.13 SDS-PAGE analysis of K55 LPS before and after 
gel filtration.
K. pneumoniae LPS was extracted by aqueous 45%  (w/v) 
phenol extraction and purified by gel filtration chromatography 
as described in Section 2.2.2. The two LPS peaks as shown in 
Figure 3.12, A and B (Lane 2 and 3 respectively), w ere pooled 
separately and then analysed by SD S-PA G E on a 15%  gel. 
Lane 1 represents LPS that was not subjected to gel filtration 
chromatography.
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protein or DNA eluting at the same time as LPS. This was therefore a good 
method for removing DNA and protein contamination from LPS preparations. 
The possibility of CPS contamination in LPS preparations was also unlikely 
because during purification the sample was subjected to a 100,000 x g spin 
(Section 2.2.2a) that would have pelleted LPS but not CPS.
3.5.2 SDS-PAGE analysis of LPS from different O antigenic types of 
Klebsiella pneumoniae.
LPS was extracted from different O-antigenic Klebsiella strains, R:K17, 
04:K3, 02:K3 and 01 :K1, which represent each of the LPS types 
[polymannose O-antigen (03), polygalactose (01 and 02), ribose/galactose 
O-antigen (04 ) and rough type LPS (R)]. LPS was then characterised by 
SDS-PAGE as shown in Figure 3.14. The banding patterns were different for 
each LPS studied, although they all have the broad intense band at the 
bottom of the gel that represents LPS with no O-antigen. The high MW bands 
in lanes containing K36, K3 and K1 are due to LPS with different numbers of 
repeating units of O-antigen. K17 which has a rough LPS (i.e. no O-antigen) 
shows no high MW banding (Lane 1) when a low concentration was loaded 
onto gel. When high concentration of K17 LPS was loaded onto the gel 
(Lane 2) high MW bands were observed. This was probably due to LPS 
micelle formation.
3.6 Discussion
The aim of the work described in this chapter was to improve methods of 
CPS purification in order to obtain highly purified K. pneumoniae CPS 
preparations that could be used to investigate their immunogenicity and 
immunomodulating properties. It was very important that sample preparations
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Figure 3.14 SDS-PAGE analysis of LPS from various 
Klebsiella pneumoniae capsular serotypes.
K. pneumoniae LPS was extracted by aqueous 45%  (w/v) 
phenol extraction. The LPS was then analysed by S D S -P A G E  
on a 15%  gel. LPS was visualised by silver staining. Lanes 1 
and 2, LPS extracted from capsular serotype strain K17, 0 .2 //g  
and 0.4//g; Lanes 3 and 4 LPS from serotype K36, 0.2/yg and 
0.4/yg; Lanes 5 and 6 LPS from serotype K3, 0.2/vg and 0.4/vg; 
Lanes 7 and 8 LPS from serotype K 1, 0.2/yg and 0.4/yg.
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used were free from contaminants, in particular those that have a major 
influence on the immune system. When extracting CPS from K. pneumoniae 
many other components are co-extracted, including LPS, proteins, nucleic 
acids and lipoproteins. All of these microbial products are recognised by toll­
like receptors and have been reported to result in an inflammatory response. 
The presence of even small amounts of endotoxin in samples could cause 
adverse reactions such as shock when these preparations were used as 
antigens for immunising experimental animals (Fraker et al., 1988). It is 
therefore critical that LPS is removed from preparations.
Classical purification and chemical detoxification methods have been used 
and evaluated by others for their effectiveness in removing residual LPS, 
whilst still preserving the structural and functional integrity of the CPS. 
Previous studies indicated that LPS could not be removed from CPS by 
ultracentrifugation, anion-exchange chromatography or gel filtration 
chromatography with acetic acid (Adam et al., 1995). The use of chemical 
treatments like de-O-acylation can be an effective way to detoxify the LPS 
(Seid and Sadoff, 1981), but similar treatments can lead to loss of structure 
or immunogenicity of the CPS depending on polysaccharide structure. Using 
a relatively high pH can lead to the loss of alkali labile substituents such as 
O-acetyl groups and probably partial de-O-acylation of lipids (CPS-lipid 
anchors). For examples, the serogroup A of N. meningitidis CPS contains O- 
acetyl groups which can be easily removed at an alkaline pH and results in 
its reduced immunogenicity (Berry et al., 2002). Some of the Klebsiella 
CPSs contain O-acetyl groups: these include K55 (Kenne and Lindberg,
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1983) and K22 (Parolis et al., 1988) so their structure may be affected by 
alkaline detoxification. A method described by Adam and colleagues using 
gel filtration chromatography with a sodium deoxycholate containing buffer 
(Adam et al., 1995) showed promise of being a good method for CPS 
purification as very little LPS remained in the preparation. The only problem 
anticipated with this method was the high pH and temperature of the buffer 
and its possible effect on the CPS immunogenicity and structure. It was 
therefore investigated further and modification of conditions was considered.
CPS extracts were first fractionated on a TSK G5000 gel filtration column 
without detergent. The carbohydrate eluted in two peaks as shown by 
refractive index profiles. The first high MW peak contained 90% of the 
carbohydrate recovered from the column. Following ultracentrifugation and 
protease and nuclease digestion of CPS extracts, the protein and nucleic 
acids contaminants eluted later from the column than the high MW CPS 
(Figure 3.3). This allowed CPS to be pooled that contained less than 1% 
protein and no nucleic acid detectable by UV absorbance.
Removal of LPS was much more difficult. A method described using Triton- 
X114 failed to remove a significant amount of LPS. More successful was the 
use of gel filtration chromatography with dissociating buffers. CPS extracts 
were fractionated on a TSK G5000 column with a range of dissociating 
buffers. Two carbohydrate peaks were obtained. When dissociating buffers 
were used, LPS micelle formation was disrupted and therefore resulted in 
LPS eluting later from the column than CPS (Figure 3.4). Therefore CPS
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could be pooled and separated from LPS. Subsequent SDS-PAGE analysis 
confirmed the presence of LPS in the CPS extracts. Pool 2 (lower MW  
carbohydrate) from the gel filtration of K55 separated under dissociating 
conditions gave similar profiles to those of K55 LPS (Figure 3.9). In contrast, 
pool 1 (high MW carbohydrate) appeared to be LPS free. CPS could not be 
detected in pool 1 with silver staining only (Figure 3.9, lanes 5, 7, and 9), but 
with a combination of Alcian Blue and silver staining CPS was detected 
(Figure 3.8, lanes 3, 4 and 6). Pool 1 therefore contained highly purified CPS.
Several dissociating buffers were investigated and all gave similar refractive 
index profiles which indicated no gross change in CPS MW. Recovery was 
also very similar for all conditions at 80% or greater. The only variation was 
the effect on the antigenicity of the polysaccharide. Some of the buffers were 
of high pH or used at high temperatures, and these could affect CPS 
structure and its antigenicity. Antigenicity was determined by the binding of 
rabbit anti-capsular antiserum to pool 1 compared to control CPS (not 
subjected to gel filtration chromatography). When the CPS extract was 
eluted with PBS containing 0.25% (w/v) sodium deoxycholate at 60°C there 
was no change in antibody binding to the CPS. It was for this reason that this 
elution buffer was used for CPS purification, although it must be noted that 
these antigencity experiments were only carried out for K55 CPS.
In conclusion, previous methods of CPS purification have been modified. 
These modifications have been shown to have no effect on CPS 
immunogenicity and molecular weight. Gel filtration profiles, SDS-PAGE
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analysis and quantification methods have shown that pool 1 (high MW  CPS) 
is free from nucleic acid and contains no more than 1% protein and 0.01%  
LPS by weight. Although 0.01% LPS may still have biological effects, LPS 
hyporesponsive mice will be used in experiments in Chapters 4 and 5 to 
determine the properties of CPS independent of LPS. The CPS preparation 
therefore could confidently be used for our immunological studies.
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Chapter Four
The immunogenicity and adjuvanticity of 
capsular polysaccharides from Klebsiella
pneumoniae.
4.1 Introduction
K. pneumoniae is a Gram negative bacterium in the genus Klebsiella of the 
family Enterobacteriaceae. It is an opportunistic pathogen that frequently 
causes nosocomial infections, mainly in immunocompromised patients. 
Infections range from mild urinary infections to severe bacteremia and 
pneumonia with a high mortality and morbidity rate. K. pneumoniae is 
encapsulated and antibodies toward the CPS are protective (Donta et al., 
1996). Antigenic capsule material is termed the K antigen, and there are at 
least 90 K antigens reported. The structures of most of the K antigens have 
been determined. They typically contain one charged monosaccharide 
constituent, normally glucuronic acid, together with hexoses and 6- 
deoxyhexoses. In addition, non-carbohydrate constituents, such as formyl or 
acetyl groups and ketal-linked pyruvates are also found (Orskov, 1984).
K. pneumoniae LPS itself is of interest. Chemically, LPS consists of an O- 
specific polysaccharide sidechain, a core oligosaccharide, and a lipid 
component, termed lipid A. Structural differences in O-polysaccharide have 
been exploited for serological typing based on O-antigens (Kelly et al., 1993). 
In contrast to the large number of capsular serotypes (K antigens), only 9 O- 
antigens have been recognised in K. pneumoniae based on structure and
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reactivity of the O-polysaccharides with specific antibodies and structure 
(Hansen et al., 1999). Serotype 01 is the most common among clinical 
isolates. The remaining eight groups are made up of 02, 02ac, 03, 04, 05, 07, 
08, and 012. The O antigens consist of repeating units containing different 
monosaccharides, such as D-Man, D-Gal and L-Rha and in some cases 
substituted with O-acetyl groups.
Several reports in the literature describe strong immunostimulatory, anti- 
tumour and adjuvant effect for capsular polysaccharide extracts from K. 
pneumoniae. The CPS extracts have been shown to exhibit strong adjuvant 
effects on antibody responses to various antigens in mice (Nakashima et al., 
1971; Nakashima, 1972; Nakashima and Kato, 1975). After mice were 
immunised subcutaneously with CPS the number of cells in lymphoid organs 
increased (Yokochi et al., 1980a). K. pneumoniae CPS K1 and K3 in 
particular were shown to induce the release of TNFa, and they could also 
suppress tumours in mice (Ho et al., 2000; Choy et al., 1996). The exact 
composition of the extracts and the nature of the immunostimulatory 
components are not known. In some cases these activities have claimed to 
be attributed directly to CPS, and not, for example, to contaminating LPS in 
the preparations.
Commercially, a K. pneumoniae polysaccharide extract, Biostim, is used to 
boost the immune system. Biostim, also known as RU-41740 or C1740, is a 
cell wall extract consisting of at least two large glycoproteins. When 
administered orally, Biostim has been shown to boost the immune system
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against chronic bronchial bacterial infections (Fietta et al., 1992) and to 
enhance antibody responses to intramuscularly administered inactivated 
influenza virus vaccine (Profeta et al., 1987). In vitro studies with LPS- 
hyporesponsive mouse B cells (Wood and Moller, 1984) and human B cells 
(Martinez-Maza et al., 1985) have shown Biostim to be a polyclonal B cell 
activator. Biostim is a very heterogeneous mixture, and the actual component 
(s), with polyclonal B cell activation ability has not yet been reported.
Certain O-polysaccharide structures of K. pneumoniae LPS appear to have 
greater adjuvant properties than others. The mannose homopolymers 
present in K. pneumoniae 0 3  and 0 5  have been shown to induce greater 
antibody responses in mice to soluble protein antigens than LPS with other 
O-polysaccharide structures (Ohta et al., 1985; Kido et al., 1985). An 
adjuvant effect was also observed in mice which are hyporesponsive to LPS 
(Ohta et al., 1985). Mutants that lack O-specific polysaccharide derived from 
K. pneumoniae 03 had weaker adjuvant activity than the parental LPS (Ohta 
et al., 1987) suggesting that the mannose-rich O-polysaccharide is essential 
for adjuvant activity. Yokochi and colleagues showed that K. pneumoniae 03 
LPS could activate the complement pathway to a greater extent than non 
mannose containing O-polysaccharide LPSs, although the mannose-rich O- 
polysaccharide in the absence of lipid A did not stimulate complement 
(Yokochi et al., 1990). Paeng and colleagues (1996) have produced an E. 
coli LPS that possesses a mannose homopolymer by transforming E. coli K- 
12 with rfb genes that are required for synthesising the mannose
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homopolymer on LPS. Similar to K. pneumoniae 03 LPS, it has the ability to 
activate complement, and also to cause enlargement of regional lymph node.
In summary, both LPS and CPS from K. pneumoniae have been shown to 
have immunostimulatory properties. LPS expressing a mannose-rich O- 
polysaccharide has enhanced adjuvant activity compared to other LPS and 
activates complement to a greater extent. CPS extracts have the ability to 
enhance antibody production and have anti-tumour effects. Investigating the 
immunomodulating properties of K. pneumoniae LPS and CPS would provide 
important insights into the mechanisms of activation of innate immunity by 
microbial carbohydrates.
4.2 Objectives
The aim of the work described in this chapter was to carry out further 
investigations on the adjuvanticity of K. pneumoniae CPS extracts, and to 
establish, in particular, whether any biological activity could be attributed to 
the CPS itself.
4.3 The adjuvant effect of Klebsiella pneumoniae CPS 
and LPS extracts on the humoral response to CGG in 
mice
To assess the adjuvant activity of CPS and LPS extracts from K. pneumoniae 
the IgG response to chicken gamma globulin (CGG) in the presence of these 
components was determined. Only IgG response to CGG was measured 
because previous studies have shown that the antibody response generated 
to CGG is predominantly IgG, and the presence of an adjuvant is an absolute
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requirement for antibody production (Le Bon et al., 2001). The CPS extracts 
used in this study have been subjected to ultracentrifugation and protease 
and nuclease digestion unless otherwise stated. The typical content by 
weight of a CPS extract was 10-15%  protein, 5% nucleic acid, and 1-2% 
LPS. For all experiments, unless stated otherwise, groups of 3 mice were 
immunised by the intra peritoneal route with 5pg of CPS extract or LPS 
together with 100pg of CGG. Mice were bled 7 and 21 days post 
immunisation and serum was collected. The serum was pooled for each 
group of mice due to the large number of CPS preparations to be tested. The 
antibody response to CGG was assessed by ELISA as described in Section 
2.2.4g.
4.3.1 Adjuvant properties of K. pneumoniae CPS and LPS in C57BL/6 
mice
In order to confirm the adjuvant potential of K. pneumoniae CPS and LPS 
studies were performed in comparison with a known adjuvant, Titermax. 
Preliminary studies were carried out in C57BL/6 mice. Figure 4.1 shows the 
antibody response to CGG using K. pneumoniae K1 and K3 CPS and LPSs 
from capsular serotypes K1/K3 (combined) and K55 as adjuvants. These 
LPS types were used because K1 and K3 O-polysaccharides are 
homopolymers of D-Gal and K55 O-polysaccharide of its LPS is a mannose 
homopolymer. At days 7 and 21 an increase in IgG to CGG was observed for 
all adjuvants compared to mice immunised with only CGG. K1/K3 CPS 
extract and K55 LPS enhanced the IgG response to CGG to a greater extent 
than other adjuvants at day 7. At day 21 K55 LPS induced the greatest
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Figure 4.1 The effect of different adjuvants on the serum IgG 
antibody response to chicken gamma globulin (CGG) in 
C57BL/6 mice
Groups of three C57BL/6 mice were immunised by the intra 
peritoneal route with 100//g of C G G  in PBS with or without 
adjuvant. W hen injected with Titermax, an equal volume of C G G  
was emulsified with the adjuvant before injection. W hen injected 
with LPS and CPS, 5/yg of adjuvant was mixed with the C G G . 
The mice were bled at day 7 (A) and 21 (B), serum was pooled 
for each group and then analysed for IgG by ELISA. IgG was  
detected using goat anti-mouse IgG (y chain specific) H R P  
conjugate and the reaction developed using O P D  substrate. 
Absorbance was read at 490nm . These data are m eans of 
duplicate wells and are from one representative study out of two.
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adjuvant effect. At day 7 and 21 Titermax induced the lowest levels of IgG to 
CGG compared to other adjuvants.
4.3.2 Adjuvant properties of K. pneumoniae CPS and LPS in C3H/HeJ 
and C3H/HeN mice.
Although preliminary studies showed that K. pneumoniae K1 and K3 CPS 
extracts could induce an antibody response to CGG, the possibility that the 
adjuvant effect was due to contaminating LPS could not be ruled out. To 
control for LPS contribution to adjuvanticity C3H/HeJ mice were used. These 
mice are hyporesponsive to LPS.
The presence of small amounts of contaminating LPS in commercial stocks 
of CGG was confirmed by the LAL assay. To determine whether this 
contributed to the immunogenicity of CGG, the responses to CGG before and 
after LPS removal were compared in C3H/HeJ and C3H/HeN (wild type) 
mice (Figure 4.2). Clearly without LPS removal there was a response to 
CGG in C3H/HeN but not C3H/HeJ mice, confirming that the CGG contained 
LPS which acts as an adjuvant in C3H/HeN mice. When LPS is removed no 
IgG could be detected in either C3H/HeN or C3H/HeJ mice. This enforces 
the idea that an adjuvant was required to induce an antibody response to 
CGG.
The adjuvant activity of K. pneumoniae K1/K3 and K55 CPS extracts and 
K55 and K1/K3 LPS were studied in C3H/HeJ mice (Figure 4.3). The 
reported immunostimulatory properties of K. pneumoniae CPS extracts have 
been limited to mainly those from K1 and K3 (Ho et al., 2000; Choy et al., 
1996), so another CPS was included to determine whether the activity
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Figure 4.2 A comparison of serum IgG antibody responses 
in C3H/HeN and C3H/HeJ mice after LPS removal from  
chicken gamma globulin (CGG).
LPS was removed from CG G  using a Vivapure Mini Q spin 
column. Groups of 3 C 3H /H eN  and C 3H /H eJ mice w ere  
immunised by the intra peritoneal route with 100/yg of C G G  with
(A) or without (B) LPS removal. Mice were bled at day 7 and 
serum was pooled and assessed by ELISA as described in 
Section 2.2.4g. These data are means of duplicate wells and are  
from one representative study out of two.
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Figure 4.3 A comparison of the adjuvanticity of CPS and 
LPS from K. pneumoniae K1, K3 and K55 in C3H/HeJ mice
Groups of three C 3H /H eJ mice were immunised by the intra 
peritoneal route with 100/yg of chicken gam m a globulin (C G G ) 
mixed with 5//g of LPS or C PS extract from K1/K3 (A) or K55
(B). Mice were bled at 21 days and serum was pooled and 
assessed for IgG to C G G  by ELISA. IgG was detected by goat 
anti-mouse IgG (y chain specific) HRP conjugate and developed  
with O P D  substrate. Absorbance readings w ere taken at 490nm  
wavelength. These data are means of duplicate wells and from  
are one representative study out of two (A) or four (B).
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reported was unique to those strains. In this study K1, K3 and K55 CPS 
extracts and K55 LPS were shown to act as adjuvants in C3H/HeJ mice. The 
IgG levels with the inclusion of CPS or LPS were much greater than with 
CGG alone. There was no IgG response to CGG using K1 and K3 LPS as 
adjuvants in C3H/HeJ mice. Interestingly, K55 LPS still functioned as an 
adjuvant in C3H/HeJ mice.
The effect of dose of CPS extract on the IgG response to CGG was also 
investigated (Figure 4.4). K. pneumoniae K55 CPS extract is shown as an 
example. In C3H/HeJ and C3H/HeN mice 50pg and 25pg doses elicited 
greater IgG levels to CGG than 5ug. It important to note that experiments 
were nevertheless carried out using 5ug of CPS extract as an adjuvant 
because the response was still easily detectable. It was also more practical 
to use as little CPS extract as possible due to the length of time required for 
extraction and purification.
Figure 4.5 shows the relative decrease in adjuvanticity of K. pneumoniae 
CPS and LPS extracts in C3H/HeJ compared to C3H/HeN. For K1 and K3 
LPS extracts the adjuvant activity was completely abrogated in the C3H/HeJ 
mice, but remained in C3H/HeN mice. For K55, K1 and K3 CPS extracts the 
response was reduced in C3H/HeJ mice compared to C3H/HeN, which 
suggested that LPS contributes to the CPS extracts’ adjuvanticity in 
C3H/HeN mice. Surprisingly there was a reduction in the response of mice to 
Titermax in C3H/HeJ mice, even though the Titermax was shown to be free 
from LPS by the LAL assay. These results illustrate the adjuvant properties
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Figure 4.4 The effect of dose of K. pneumoniae K55 CPS 
extract on the IgG antibody response to chicken gamma 
globulin (CGG).
Groups of three C 3H /H eN  and C 3H/HeJ mice were immunised 
by the intra peritoneal route with 100//g of CG G  mixed with K55  
C PS extract (5, 25 or 50*/g). C3H /H eJ (A) and C 3H /H eN  (B) 
mice were bled at day 21 and serum antibody was pooled and 
then assessed by ELISA for IgG. These data shown are m eans  
of duplicate wells and were from one representative study out 
of two.
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Figure 4.5 Relative decrease in adjuvanticity of K. 
pneumoniae CPS and LPS extracts in C3H/HeJ compared 
with C3H/HeN mice.
C 3H /H eN  and C3H /H eJ mice were immunised by the intra 
peritoneal route with 100/yg chicken gamma globulin (C G G ) 
mixed with 5/vg of either K1/K3 LPS, K1/K3 C P S  extract, K55  
LPS, K55 C PS extract, K55 C PS pool 1 or Titermax. Mice were  
bled at day 21 and serum IgG antibody levels were assessed  
by ELISA. IgG responses were compared in the C 3H /H eN  and 
C3H /H eJ mice by calculating the antibody level (titre) in the 
C3H /H eJ mice as a percentage of the titre in C 3H /H eN  mice. 
Results are ± 10% taken as the average of three experiments.
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of LPS but also the adjuvant activity of CPS extracts independent of LPS. 
Although adjuvant activity was still maintained in C3H/HeJ mice for CPS 
extracts, the magnitude of the response was reduced compared to IgG levels 
observed in C3H/HeN mice.
4.4 The contribution of the polysaccharide 
component of Klebsiella pneumoniae CPS extracts to 
adjuvanticity.
As described earlier, several studies have suggested that the adjuvanticity of 
K. pneumoniae CPS extracts is due to CPS and not other components in the 
preparations (Ho et al., 2000; Choy et al., 1996; Yokochi et al., 1980a; 
Nakashima, 1972; Nakashima and Kato, 1975; Nakashima et al., 1971). 
Methods for preparing CPS in these studies were not adequately described 
making it difficult to assess the purity of the CPS used. The purification 
methods used for this project are described in Chapter 3. Briefly, K. 
pneumoniae CPS were extracted and subjected to ultracentrifugation and 
protease and nuclease digestion. This sample was referred to as K. 
pneumoniae CPS extract, and was used for the studies described in this 
chapter. Further purification of CPS extracts was carried out. CPS extracts 
were separated by gel filtration on a TSK G5000 column with PBS containing 
(w/v) 0.25% sodium deoxycholate at 60°C and two carbohydrate peaks were 
obtained. Pool 1 contained most of the carbohydrate material so a CPS 
concentration could be determined. Mice were immunised with CGG 
containing 5pg of CPS pool 1. For pool 2 a volume equal to that which 
contained 5pg of CPS in pool 1 was used. The typical content by dry weight
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of CPS pool 1 was 1% protein, 0-0.01% nucleic acid, 0.01% LPS. Pool 2 
contained most of the LPS and protein from the CPS extract.
The adjuvant effect of CPS pools 1 and 2 from serotypes K17, K55, and K52 
was investigated (Figures 4.6-4.8). Figure 4.6 shows the IgG response to 
CGG when K17 CPS pool 1 was used as an adjuvant in both C3H/HeJ and 
C3H/HeN mice. There was no IgG response to CGG in C3H/HeJ mice 
indicating that the high MW purified CPS pool 1 did not have adjuvant effects 
on antibody responses. An IgG response to CGG in C3H/HeN mice, 
however, was observed, which indicated that the adjuvant activity of the K17 
CPS pool 1 was solely due to LPS. Figure 4.7 shows the adjuvant effects of 
K55 CPS pools 1 and 2, and the CPS extract on the IgG response to CGG in 
C3H/HeJ mice. Similar to K17 CPS pool 1, there was no adjuvant activity in 
K55 CPS pool 1. Most of the adjuvant activity was present in K55 CPS pool 
2 and at a level equivalent to that of unfractionated K55 CPS extract. The 
same conclusions could be drawn from Figure 4.8. In C3H/HeJ mice there 
was no adjuvant effect of K52 CPS pool 1, and the response seen in 
C3H/HeN mice was therefore due to LPS. The adjuvant activity was 
contained within K52 CPS pool 2. These results suggest that the K. 
pneumoniae CPS pool 1, a very pure CPS preparation, from a number of 
different serotypes did not enhance the IgG response to CGG independent of 
LPS. Most of the adjuvant activity is attributed to K. pneumoniae CPS pool 2 
as shown for K55 and K52.
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Figure 4.6 Serum IgG responses to chicken gamma 
globulin (CGG) using K. pneumoniae K17 CPS pool 1 
as an adjuvant in C3H/HeJ and C3H/HeN mice
K17 C PS extract was separated by gel filtration 
chromatography on a TSK  G 5000 column with PBS  
containing 0 .25%  (w/v) sodium deoxycholate and refractive 
index-positive peaks 1 and 2 were pooled. Groups of three 
C 3H/HeJ (A) and C 3H /H eN  (B) mice were immunised by 
the intra peritoneal route with 100/yg C G G  mixed with K17 
pool 1 C PS (5/yg). Mice were bled 21 days post 
immunisation. Blood serum was pooled and analysed by 
ELISA as described in Section 2.2.4g. The data shown are 
means of duplicate wells and are from one representative 
study out of three.
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Figure 4.7 Serum IgG responses to CGG using K. 
pneumoniae K55 CPS pools 1 and 2 as adjuvants.
The CPS pools were collected after gel filtration 
chromatography of K55 C PS extract on a TSK  G 5000  column 
with PBS containing 0 .25%  (w/v). Groups of three C 3H /H eJ  
and C 3H /H eN  (data not shown) mice were immunised by the 
intra peritoneal route with 100/yg of CG G  mixed with 5/yg of 
either K55 C PS pool 1 or pool 2. Mice were bled 21 days post 
immunisation, serum was pooled and then analysed for IgG by 
ELISA, as described in Section 2.2.4g. These data shown are  
means of duplicate wells and are from one representative study 
out five.
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Figure 4.8 A comparison of serum IgG responses to chicken 
gamma globulin (CGG) using K52 CPS pool 1 and 2 as 
adjuvants in C3H/HeJ and C3H/HeN mice.
The CPS pools were collected after gel filtration chromatography  
of K52 C PS extract on a TSK  G 5000 column with PBS containing 
0 .25%  (w/v) sodium deoxycholate. Groups of three C 3H /H eJ (A) 
and C 3H /H eN  (B) mice were immunised by the intra peritoneal 
route with 100/vg C G G  mixed with either K52 C PS pool 1 (5/jg  
C P S ) or pool 2. Mice were bled 21 days post immunisation, 
serum was pooled and analysed by ELISA as described in 
Section 2.2.4g. The data shown are means of duplicate wells and 
are from one representative study out of two.
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To further analyse the adjuvant properties of K55 CPS extract, the effect of 
protease treatment was investigated. Mice were immunised with CGG 
together with K55 CPS extract either before or after protease treatment to 
identify any difference in adjuvant properties of the samples. Results are 
shown in Figure 4.9. There was a reduction in the levels of IgG to CGG when 
the CPS extract was protease treated, but the adjuvant activity was still 
present.
The effect of varying degrees of alkali treatment upon the adjuvant properties 
of K55 CPS extract was investigated. K55 CPS extract was suspended in 
0.1M NaOH and incubated for either 1h at room temperature, 1h at 37°C, or 
18h at 37°C. Samples together with CGG were then used to immunise 
C3H/HeN and C3H/HeJ mice. The results are shown in Figure 4.10. The 
serum IgG levels to CGG are greatest in both C3H/HeN and C3H/HeJ when 
K55 CPS extract was used as an adjuvant. Following alkali treatment of the 
K55 CPS extract, the IgG levels to CGG decreased when temperature and 
incubation time for alkali treatment were increased. After alkali treatment for 
18h at 37°C adjuvant properties were lost in both C3H/HeJ and C3H/HeN 
mice as shown by IgG levels to CGG equal to those of mice immunised with 
CGG alone. This harsh alkali treatment would probably detoxify LPS (Seid et 
al., 1981), which is consistent with the lack of adjuvant effect in the C3H/HeN 
mice, depolymerise nucleic acid, de-O-acyelate other lipid components and 
denature protein. The CPS itself is relatively stable, although it may be 
slightly modified, and any O-acetyl substituents or lipid-linked anchors are 
lost.
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Figure 4.9 The effect of protease treatment on the 
adjuvanticity of K55 CPS extract in the C3H/HeJ mice
CPS was digested with Subtilisin for 18h at 37°C  as 
described in section 2.2.1c. Groups of three mice were  
injected by the intra peritoneal route with either 100/yg of 
CG G  with no adjuvant, or together with untreated or 
protease treated K55 CPS. Mice were bled after 21 days. 
The serum was pooled and IgG to C G G  was measured by 
ELISA as described in Section 2.2.4g. The data shown are  
means of duplicate wells and are from one representative 
study out of two.
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Figure 4.10 Effect of different alkali treatments on the 
adjuvanticity of the CPS extract from K. pneumoniae K55.
K55 C PS extract (150/yg) was suspended in 750/yl 0.1 M 
NaO H and then incubated for either 1h at room temperature, 
1h at 37°C, or 18h at 37°C . Groups of three C 3H /H eJ (A) and 
C 3H /H en (B) mice were immunised by the intra peritoneal 
route with 100//g of C G G  mixed with 5/yg K55 C PS extract 
either untreated or alkali treated. The mice were bled 21 days 
post immunisation. Serum was pooled and then analysed for 
IgG to C G G  by ELISA, as described in Section 2.2.4g. These  
data shown are means of duplicate wells and are from one 
representative study out of two.
157
Chapter Four
4.5 The humoral response to capsular 
polysaccharides from Klebsiella pneumoniae
In addition to assessing the adjuvanticity of K. pneumoniae CPS extracts, the 
serum antibody response to K. pneumoniae CPSs K17, K52 and K55 was 
also studied. This was to determine the nature of the response to the 
adjuvant. Mice were immunised with K. pneumoniae CPS pool 1 (very pure 
CPS). C3H/HeJ mice were used to control for LPS contamination because 
LPS has adjuvant properties and could have an effect on the antibody 
response to CPS. Investigating the antibody responses in both C3H/HeJ and 
wild type (C3H/HeN) mice provides insights into the effect of LPS on the 
antibody response to Kiebsieila polysaccharides.
Figure 4.11 shows the serum IgM levels in C3H/HeN and C3H/HeJ mice 
immunised with K. pneumoniae K17 and K52 CPS pool 1. Both C3H/HeN  
and C3H/HeJ mice produced IgM in response to K17 and K52 CPS pool 1, 
although the response in the C3H/HeJ mice was lower. It was possible that 
this was due to the presence of LPS in the CPS pool 1 and the LPS had an 
adjuvant effect upon the anti-polysaccharide response. K55 gave a very 
poor IgM response in both C3H/HeN and C3H/HeJ mice (data not shown), 
but an IgG response was detected as shown in Figure 4.12A. Similar to the 
IgM response, IgG levels were greater in C3H/HeN mice compared to 
C3H/HeJ mice. This was the case for pool 1 of K55 and K52 CPS (Figure 
4.12B), although no IgG was detected for K17 CPS pool 1.
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Figure 4.11 Serum IgM levels to Klebsiella pneumoniae 
capsular serotypes K17 and K52 in C3H/HeN and C3H/HeJ 
mice.
K. pneumoniae CPSs K17 and K52 were extracted and purified 
by gel filtration chromatography on a TSK  G 5000 column as 
described in the methods section. Groups of three C 3H /H eN  
and C3H/HeJ mice were immunised with 5/yg of K17 (A) and 
K52 (B), mice were bled 21 days post immunisation. Serum  
was pooled and assessed for IgM by ELISA as described in 
Section 2.2.4f. These data shown are means of duplicate wells 
and are from one representative study out of two.
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Figure 4.12 Serum IgG levels to Klebsiella pneumoniae 
capsular serotypes K55 and K52 in C3H/HeN and C3H/HeJ 
mice.
K. pneumoniae CPSs K55 and K52 were extracted and then 
purified by gel filtration chromatography as described in the 
methods section. Groups of three mice were immunised with 
5//g of K55 (A) and K52 (B). Mice were bled 21 days after 
immunisation, serum was pooled and analysed for IgM by ELISA  
as described in Section 2.2.4f. These data shown are m eans of 
duplicate wells and are from one representative study out of two.
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4.6 Discussion
From reports in the literature it is not clear whether K. pneumoniae CPSs 
alone have any immunostimulatory activity, or contribute in any way to the 
adjuvanticity of CPS extracts. It is possible that co-extracted components are 
contributing to adjuvant activity. Microbial products have major 
immunomodulatory effects on the immune system; such components include 
bacterial DNA containing unmethylated CpG motifs, LPS, outer membrane 
proteins (Omp), porins and lipoproteins. OmpA from K. pneumoniae has 
been shown to bind to and activate human macrophages (Soulas et al., 
2000) as well as dendritic cells and then signal through TLR2 to induce 
maturation (Jeannin et al., 2000). Porin OmpK36 from Klebsiella can activate 
the classical complement pathway (Alberti et al., 1996). For LPS, bacterial 
lipoproteins and CpG motifs it is well recognised that these constituents have 
a major effect on the immune system via toll like receptors, TLR4, TLR2 and 
TLR9 respectively. Bacterial DNA (Klinman et al., 1999), lipopeptides (Sieling 
et al., 2003) and LPS (Skidmore et al., 1975; Schenck et al., 1969) possess 
adjuvant properties. However the possibility that K. pneumoniae CPSs have 
unique biological properties cannot be ruled out. This may be mediated, for 
example, through the presence of a lipid-linked anchor or through an unusual 
structural feature of the polysaccharide. The latter appears to be the case for 
p-glucan, which is immunostimulatory and recognised through Dectin-1 
expressed on macrophages and dendritic cells (Brown and Gordon, 2001). 
Polysaccharides, when used as human vaccine antigens for example, are 
normally inert and do not induce an overt inflammatory reaction. If 
immunomodulatory effects can be demonstrated for certain polysaccharides,
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these would potentially be safe when used as an adjuvant. For example, 
Biostim is well tolerated in humans but has desirable adjuvant properties 
(Profeta et al., 1987).
To confirm the adjuvanticity of K. pneumoniae CPS extracts, mice 
hyporesponsive to LPS (C3H/HeJ) were immunised with K55, K1 and K3 
CPS extracts. All CPS extracts enhanced the IgG response to CGG 
independent of LPS, and were therefore deemed to have additional adjuvant 
properties (Figure 4.3). Although a response was seen independent of LPS, 
the IgG levels were greater in wild type mice. This suggests that LPS did 
contribute to adjuvanticity of CPS extracts. An increase in dose of CPS 
extract from 5 to 50pg did have an effect on the magnitude of the IgG 
response to CGG in C3H/HeJ mice, but 5ug of CPS still gave a good 
detectable response which suggests that adjuvant activity is present at low 
doses. Other studies in the literature have shown that K. pneumoniae CPS 
extracts enhance the antibody response to bovine serum albumin (BSA) 
(Nakashima, 1972; Nakashima and Kato; 1975, Nakashima et al., 1971), but 
none of these studies have shown this to be independent of LPS.
To determine the contribution of the CPS component in the K. pneumoniae 
CPS extracts, methods of purification of CPS were established as shown in 
Chapter 3. After purification the resulting K. pneumoniae CPS pool 1 was a 
very pure high MW CPS preparation. CPS pool 2 contained protein, LPS and 
lower MW carbohydrate from the CPS extract. The adjuvanticity of these 
preparations was established in C3H/HeJ mice. No IgG response to CGG
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was observed in C3H/HeJ mice when K. pneumoniae CPS pool 1 from 
strains K55, K52 and K17 were used as adjuvants. An antibody response 
was observed when these same CPS pool 1 were used in C3H/HeN mice, 
which implies that the only component in the pure CPS preparation to have 
adjuvant activity was LPS. These results almost certainly confirm that high 
MW  K. pneumoniae CPSs K55, K52 and K17 do not have the ability to 
enhance antibody responses to model protein antigens. The adjuvant activity 
appears to be due to K. pneumoniae CPS pool 2 which contained mostly 
LPS and protein. When either K55 or K52 CPS pool 2 was used as an 
adjuvant in C3H/HeJ mice, an increase in the IgG response to CGG was 
observed. Therefore, there is an undefined component (s) within pool 2 which 
can augment antibody responses. These observations are quite significant as 
certain studies in the literature almost certainly attributed these activities 
directly to the CPS.
To further establish the nature of the adjuvant, the effect of protease and 
alkali treatments were studied. Protease treatment of the K. pneumoniae K55 
CPS extract resulted in a slight reduction in the antibody response to CGG, 
suggesting that a protein, lipoprotein or glycoprotein contributed to 
adjuvanticity. Increasing time and temperature of incubation of the CPS 
extract with NaOH also resulted in a reduction of adjuvant properties. Harsh 
alkali treatment would denature protein and DNA and detoxify LPS as shown 
by the lack of response in C3H/HeN mice. K55 CPS is fairly stable but could 
be modified by loss of its O-acetyl group and, if present, lipid anchors. These 
results similarly suggest that the CPS itself does not function as an adjuvant,
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although it is possible that modifications to the CPS have altered its 
properties. Milder alkali treatment reduced the enhancement of the IgG 
response to CGG but did not completely abrogate it.
LPS from K. pneumoniae capsular serotypes K1 (01), K3 (02) and K55 (03) 
were studied. The LPS O antigens of this species display very limited 
structural variation with only 9 recognised O serotypes. Three main serotypes 
consist of linear polymers of D-galacto-pyranose residues (galactan II) or 
both D-galacto -pyranose and D-galacto-furanose (galactan I) (serotypes 01 
and 02) and linear polymers of a-linked D-Man residues (serotype 03). 
Serotype 03 appears to be the most interesting. When K55 LPS was tested 
as an adjuvant in C3H/HeJ mice the IgG response to CGG was enhanced, 
but when K1 or K3 LPS was used the antibody response to CGG was 
absent. LPS with a mannose-rich O-polysaccharide is 100 times more potent 
at activating the complement system than LPS containing other O-antigen 
structures (Kido et al., 1985). It has also been shown to possess greater 
adjuvant activity by enhancing antibody responses to protein antigens such 
as bovine gamma globulin (Kido et al., 1985) and ovalbumin (Ohta et al., 
1985). The latter study was carried out with LPS hyporesponsive mice. This 
observation creates a possible problem for assessing the adjuvant properties 
of K. pneumoniae CPS extracts from K55:03 in C3H/HeJ. An IgG response 
to CGG could be observed in C3H/HeJ mice when K55:03 LPS was used an 
adjuvant, so it was difficult to determine whether the adjuvant properties of 
K55 CPS extract in C3H/HeJ mice are due to LPS or not. However it is 
important to note that mice were immunised with 5pg of LPS and 5pg of CPS
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containing only 600ng of LPS, and both gave similar IgG responses to CGG 
(see Figure 4.3). In retrospect it would have been valuable to look at the dose 
response of K55 LPS, to see the magnitude of antibody response to CGG.
The humoral response to K. pneumoniae CPS pool 1, pure CPS preparation, 
showed variation among capsular serotypes. An IgM response was observed 
for K17 and K52, but none for K55 in C3H/HeJ mice. K55 and K52 both 
produced IgG responses in C3H/HeJ mice. A study by Cryz and colleagues 
showed that the immunogenicity in mice varied amongst capsular serotypes, 
but all evoked IgG responses, but K17 CPS was not included in this study 
(Cryz et al., 1985). Although responses were observed in C3H/HeJ mice they 
were reduced compared to C3H/HeN mice. It is possible that LPS in the K. 
pneumoniae CPS pool 1 is having an adjuvant effect on the humoral 
response to the CPS.
In conclusion, it is unlikely that highly purified capsular polysaccharides from 
K. pneumoniae have adjuvant properties which result in augmentation of the 
humoral response to a soluble protein antigen. Components within CPS 
extracts other than LPS appear to have the ability to enhance antibody 
responses at very low doses, so are therefore very potent. The next stage is 
therefore to identify the component which has these immunostimulating 
properties and to determine whether this is a known or novel adjuvant.
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Chapter Five 
Possible mechanisms of adjuvant action of 
capsular polysaccharide extracts from 
Klebsiella pneumoniae.
5.1 Introduction
An adjuvant can be defined as any product (or combinations of 
components) which modulates the humoral or cellular immune responses 
against an antigen or pathogen. Vaccines come in several forms: live 
attenuated, replicating pathogens and non-replicating inactivated pathogens 
and their subunits. Subunit vaccines are considered to be the safest, but 
because of their poor or absent immunogenicity, they often require the 
addition of an adjuvant to induce an effective immune response. Currently 
only Alum is licensed for use in humans. Many microbial components are 
strong adjuvants, but are also associated with toxicity. Complete Freunds 
adjuvant, based on paraffin oil containing heat killed whole mycobacterial 
cells is a highly effective adjuvant, but is too toxic for human use (Billiau and 
Matthys, 2001). LPS is also an adjuvant but again associated toxicity 
prohibits its delibrate use in human vaccine formulations.
Although vaccine adjuvants are recognised as a group of immunomodulating 
agents, the mechanisms underlying their activities are generally poorly 
defined. There are several concepts that attempt to explain their mode of 
action. For example, certain adjuvants are able to convey long term 
presentation of the antigen (depot effect); others help to target immune cells
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(e.g. by delivering antigens of a particulate nature to antigen presenting 
cells). Some adjuvants exhibit a capacity to elicit the production of different 
patterns of cytokines (i.e. Th1 or Th2) and/or enhance the levels of 
costimulatory molecules on APCs (Moingeon et al., 2001). Emulsion-based 
Alum and insoluble adjuvants are thought to work by helping to form a depot 
of antigen, although it has been suggested that Alum may be contaminated 
with LPS. Antigens and adjuvants are sequestered at the injection site and 
are released over a period of time to stimulate APCs such as macrophages 
and DCs. Particulate adjuvants, such as liposomes and immunostimulating 
complexes (ISCOMs), bind to antigens and form aggregates, which can then 
target APCs. More effective targeting of antigen can be achieved by using 
adjuvants with ligands that are recognised by receptors on APCs. For 
example the mannose receptor binds compounds that contain D-Man, 
GlcNAc or D-Fuc residues, such as those found on some saponin adjuvants 
(Cox et al., 1998). Therefore adjuvant-antigen complexes can be targeted to 
APCs via specific pattern recognition receptors.
Bacterial components such as LPS, lipoprotein, bacterial DNA, peptidoglycan 
and flagellin are recognised by TLRs. Pathogen recognition by TLRs results 
in rapid activation of innate immunity by inducing the production of 
proinflammatory cytokines and upregulation of costimulatory molecules. 
Activation of innate immunity subsequently leads to effective adaptive 
immunity. TLRs provide a critical link between innate and adaptive immunity 
and therefore have been considered as adjuvant receptors. Bacterial DNA 
contains immunostimulatory motifs that trigger an innate immune response
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characterised by a predominantly Th1-type cytokines. These motifs consist of 
an unmethylated CpG dinucleotide flanked by two 5’ purines and two 3’ 
pyrimidines and are recognised by TLR 9. CpG DNA has been shown to 
augment the immune response to ovalbumin (Klinman et al., 1999) and 
hepatitis B surface antigen (McCluskie and Davis, 1999) in mice and rats 
respectively. It is for this reason that development of adjuvants has focussed 
on molecules that stimulate innate immunity through TLRs.
K. pneumoniae CPS extracts have been shown to have immunostimulatory 
properties, including the enhancement of antibody responses to normally 
non-immunogenic proteins (Nakashima et al., 1971; Nakashima and Kato, 
1975; Nakashima, 1972). The mechanism of the immunostimulatory action of 
the CPS extracts is poorly understood. However, one such extract referred to 
as Biostim is used orally in humans to treat persistent bacterial bronchial 
infections. In vitro studies using mouse (Wood and Moller, 1984) and human 
(Martinez-Maza et al., 1985) cells have shown Biostim to be a strong 
polyclonal B cell activator. It also has the ability to activate human monocyte- 
derived macrophages directly and inhibit the intracellular multiplication of 
Legionella pneumophilia (Rajagopalan et al., 1987). The component(s) 
present in the polysaccharide extracts that possesses these activities have 
not been identified.
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5.2 Objectives
The aim of the work described in this chapter was to investigate possible 
mechanisms by which K. pneumoniae CPS extracts enhance the antibody 
response to CGG.
5.3 Results
The results described in the following sections include different K. 
pneumoniae samples. A summary of preparations is shown in Table 5.1. In 
the case of CPS pool 2 which contained components co-extracted with CPS, 
a CPS concentration cannot be accurately determined; therefore an 
equivalent volume to that used for CPS pool 1 was used.
Table 5.1 K. pneumoniae preparations
K. pneumoniae Methods Components
CPS extract CPS extracted as described in 
Section 2.2.1, subjected to 
ultracentrifugation and protease 
and nuclease digestion
CPS (typical % content) 
10-15% protein 
5% nucleic acid 
1-2% LPS
CPS pool 1 CPS extracts separated on a 
TSK G5000 column, high MW  
pool.
Mostly CPS (very pure) 
1 % protein 
<0.10% nucleic acid 
0.01% LPS
CPS pool 2 CPS extracts separated on a 
TSK G5000 column, lower MW  
pool.
Contains mostly protein 
and LPS from CPS 
extract.
LPS Extracted and purified as 
described in the Section 2.2.2.
Very Pure
5.3.1 Proliferation of C3H/HeJ and C3H/HeN splenocytes in response to 
K. pneumoniae capsular polysaccharide extracts.
Studies were carried out to investigate the induction of proliferation of
splenocytes by K. pneumoniae CPS extracts. These experiments were 
carried out using the spleens from C3H/HeN and C3H/HeJ mice. The use of
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C3H/HeJ mice enabled us to study the effects of CPS extracts that are not 
due to LPS. Figure 5.1 shows the proliferation of C3H/HeJ and C3H/HeN 
splenocytes after stimulation for 72h with different concentrations of K. 
pneumoniae K55:03 LPS. Incorporation of tritiated thymidine into DNA of 
dividing cells was used to indicate proliferation of splenocytes. C3H/HeN  
splenocytes proliferated in response to LPS in a dose dependent manner. In 
contrast, the C3H/HeJ splenocytes did not proliferate in response to K55 
LPS. No significant difference was seen between the media only control 
(Opg/ml LPS) and stimulation with 0.1 - 10pg/ml LPS. These results confirm 
that the C3H/HeJ splenocytes do not proliferate in response to Klebsiella 
LPS.
Two K. pneumoniae capsular serotypes, K55 and K52 were investigated. In 
Chapter 4 it was shown that purified high MW CPSs from K55 and K52 (i.e. 
pool 1) did not have the ability to enhance an antibody response to CGG, but 
other components within the CPS extracts (i.e. pool 2) were responsible for 
this adjuvant effect. Two possible components contributing to adjuvanticity 
are LPS and DNA. Table 5.2 shows the concentration of these components 
present in K55 and K52 CPS extracts. Purified DNA and LPS from these two 
capsular serotypes were used separately to stimulate splenocytes in order to 
determine the level of proliferation induced by each component at 
concentrations similar to or greater than those found in CPS extracts.
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Figure 5.1 Proliferation of splenocytes from C3H/HeN and 
C3H/HeJ mice stimulated with LPS from Klebsiella 
pneumoniae serotype K55.
Spleens were taken from naive C 3H /H eN  and C 3H /H eJ mice and 
cell suspensions were prepared. Cells (2 x 105/well) were cultured 
with medium alone or K55 LPS (0.1-10/yg/ml). K. pneumoniae LPS  
was extracted by aqueous 45%  (w/v) phenol and purified as 
described in the methods section. Cells were pulsed with tritiated 
thymidine after 72h of culture and were then frozen 18h later. 
Upon thawing proliferation was determined using a scintillation 
counter. Data represents the mean of three experiments ± s.e.m .
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Table 5.2 Concentration of CPS, DNA and LPS in K. pneumoniae K55 
and K52 CPS extracts.
Component K55 CPS extract K52 CPS extract
CPS 25pg/ml 25pg/ml
LPS 600ng/ml 50ng/ml
DNA < 50ng/ml <50ng/ml
The incorporation of tritiated thymidine into C3H/HeJ splenocytes after 
stimulation with K55 (A) and K52 (B) CPS extracts is shown in Figure 5.2. 
Both K. pneumoniae K55 and K52 CPS extracts induced the proliferation of 
C3H/HeJ splenocytes which was significantly different (p<0.005) from 
splenocytes stimulated with media only. Purified Klebsiella DNA and LPS 
failed to stimulate splenocyte proliferation, even at concentrations greater 
than those present in the extracts. This indicates that the LPS and DNA in 
the CPS extracts were not inducing the proliferation of C3H/HeJ splenocytes.
In order to investigate further the nature of the stimulatory components, K. 
pneumoniae K55 and K52 CPS extracts were subjected to a variety of 
procedures including further purification, protease and alkali treatments 
(Figure 5.3 and 5.4).
PMA and ionomycin were used as a positive control to show splenocytes 
from both C3H/HeJ and C3H/HeN had the ability to proliferate. This is 
illustrated in Figure 5.3A where both C3H/HeJ and C3H/HeN splenocytes 
proliferated to similar extents in response to PMA and ionomycin treatment.
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Figure 5.2 Proliferation of C3H/HeJ splenocytes stimulated with 
K52 and K55 CPS extracts.
Spleens were taken from naive C3H/HeJ mice and a cell suspension 
was prepared. Cells were cultured with either media only, 25//g/m l 
K52 (A) or K55 (B) C PS extract, K55 LPS (100ng/m l -  V g /m l)  or K52 
DNA (50ng/ml). DNA was prepared using a Qiagen DNA purification 
columns (Qiagen, W est Sussex, U.K.) that bind DNA to an anion- 
exchanger resin under appropriate low-salt and pH conditions and 
elute DNA in high-salt conditions. Cells were pulsed with tritiated 
thymidine after 72h of culture and were frozen 18h later. Upon 
thawing proliferation was determined using a scintillation counter. 
Data represents the mean of 3 experiments ± s.e.m . (M edia only ^  
sample;**, p<0.005).
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Figure 5.3 Proliferation of C3H/HeN and C3H/HeJ splenocytes 
stimulated with K55 CPS.
Spleens were removed from naive C 3H /H eN  and C 3H /H eJ mice and 
single cell suspensions were prepared. Cells (2 x 105 /well) were cultured 
with either medium alone, 1/yg/ml K55 LPS, K55 C P S  extract with or 
without protease treatment, C PS extract separated by gel filtration 
chromatography (C PS pooh and CPS pool 2), or C P S  extract subjected 
to alkali treatment. Alkali treatment of K55 C PS extract (150^/g) was  
carried out in 0.1 M NaO H (750/vl) and incubated for either 1h at room 
temperature (alk* 1h RT), 1h at 37°C  (alk* 1h 37°C ) or 18h at 37°C  (alk* 
18h 37°C). All C PS samples were at 25/vg/ml. Cells were pulsed with 
tritiated thymidine after 72h of culture and were frozen 18h later. Upon 
thawing proliferation was determined using a scintillation counter. Data
represents the mean of 3 experiments ± s.e.m . For (A) C 3H /H eN  ^
C3H /H eJ and (B) media only ^sam ple; *, p<0.05, **, p<0.005.
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Figure 5.4 Proliferation of C3H/HeN and C3H/HeJ splenocytes 
stimulated with K52 CPS.
Spleens were removed from naive C 3H /H eN  and C3H /H eJ mice and 
cell suspensions were prepared. 2 x 105 cells per well were cultured 
with K52 C PS extract, C PS extract subject to protease digestion, CPS  
extract separated on a TSK  G 5000 column (pool 1 and 2), and CPS  
extracts subject to alkali treatment. Alkali treatm ent of K52 C PS extract 
(150/yg) was carried out in 0.1 M NaOH (750/vl) and incubated for either 
1h at room temperature (alk* 1h RT) or 1h at 37°C  (alk* 1h 37°C ). Cells 
were also cultured with K55 LPS (100ng/m l) and with media alone. All 
CPS were at 25/yg/ml. Assays were pulsed with tritiated thymidine after 
72 hours of culture and were frozen 18h later. Upon thawing 
proliferation was determined using a scintillation counter. Data  
represents the mean of three experiments ± s.e.m . For (A) C 3H /H eN  ^  
C 3H/HeJ and (B) media only ^sam ple; *, p<0.05, **, p<0.005.
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In response to treated or untreated K55 CPS, the proliferation of C3H/HeJ 
splenocytes was significantly (p<0.05) less than C3H/HeN splenocytes for all 
except the CPS extract treated with 0.1M NaOH for 18h at 37°C, where 
activity was similar to those stimulated with media only. These results 
suggest that all the K55 samples, except the one treated extensively with 
alkali, contained biologically active LPS that contributed to the proliferation of 
C3H/HeN splenocytes. The proliferation of splenocytes from C3H/HeJ mice, 
which is independent of LPS, is shown in Figure 5.3B. There was no 
significant difference in the level of proliferation between C3H/HeJ 
splenocytes stimulated with media only and those stimulated with either 
purified K55 LPS, K. pneumoniae K55 CPS pool 1 (very pure CPS) or K55 
CPS extract subjected to extensive alkali treatment. Both K55 LPS and K55 
CPS pool 1 induced proliferation in C3H/HeN splenocytes due to the 
presence of LPS. In contrast, K. pneumoniae K55 CPS pool 2 induced 
proliferation in C3H/HeJ mice (p<0.005). The active components present in 
CPS extracts can therefore be separated from and are independent of high 
MW  CPS. After mild alkali treatment (0.1M NaOH for 1h at either RT or 37°C) 
the K55 CPS extract induced less proliferation than untreated K55 CPS 
extract. Interestingly, the proliferation of C3H/HeJ splenocytes is significantly 
greater (p=0.01) when K55 CPS extract was protease treated. This suggests 
that intact proteins are not responsible for the activity. It is possible that the 
increased proliferation is due to the production of active peptides, 
lipopeptides or glycopeptides following protease treatment.
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Similar experiments were carried out with K. pneumoniae CPS K52 extract 
(Figure 5.4). Similar to results with K55 CPS extract, proliferation did not 
occur when CPS pool 1 and LPS were used to stimulate C3H/HeJ 
splenocytes but proliferation was observed in C3H/HeN splenocytes 
suggesting the level of LPS contained in the pool 1 was still sufficient for 
activity. Consistent with results for K55, protease digestion of the K52 CPS 
extract had little effect on the proliferation of C3H/HeN splenocytes. 
However, unlike K55 CPS extract, protease treatment of K52 CPS extract did 
not increase proliferation in C3H/HeJ splenocytes. Surprisingly, mild alkali 
treatment of K52 CPS extract resulted in an enhanced proliferation of 
C3H/HeN splenocytes compared to untreated K52 CPS extract. The reason 
for this is not clear. It was observed that alkali treatment resulted in reduced 
viscosity of the CPS extracts which may allow active components greater 
accessibility to the responsive immune cells.
In summary, both K52 and K55 CPS extracts can induce proliferation of 
mouse splenocytes independent of LPS, but this activity is not due to very 
high MW  CPS in pool 1.
5.3.2 Proliferation of C3H/HeJ and C3H/HeN B and T cells in response to 
K. pneumoniae capsular polysaccharide extracts.
It has been shown that C3H/HeJ splenocytes proliferate in response to both 
K. pneumoniae K52 and K55 CPS extracts. To determine which cell type 
proliferates, splenocytes were labelled with CFSE. After labelling, 
splenocytes were cultured with various stimuli for 72h and then labelled with 
either anti-B220 or anti-CD3 antibodies, markers of B and T cells
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respectively. When cells proliferate, the overall intensity of CFSE labelling is 
reduced with each round of cell division. This is shown as an individual peak 
of reduced intensity. Figure 5.5 shows the lack of proliferation of T cells in 
response to K52 and K55 CPS extracts. C3H/HeN and C3H/HeJ T cells did 
not proliferate in response to either K55 or K52 CPS extracts with their 
profiles being identical to that of splenocytes stimulated with media only. 
Similar results were observed when splenocytes were stimulated with DNA 
and LPS from K. pneumoniae. As with the splenocyte proliferation assays 
using thymidine incorporation, the concentrations of LPS and DNA used were 
greater than those present in CPS extracts. PMA and ionomycin were used 
together as a positive control due to its ability to induce the proliferation of T 
cells. The results show that K. pneumoniae CPS extracts have no effect on T 
cell proliferation.
Figure 5.6 shows the proliferation of B cells in response to CPS extracts. 
The B cells in the C3H/HeN splenocyte population proliferated in response to 
K55 and K52 CPS extracts, and LPS and DNA from K. pneumoniae. B cells 
from C3H/HeJ mice also proliferated in response to both K52 and K55 CPS 
extracts, although proliferation was greater for K52 CPS extract. No 
proliferation of B cells was observed when stimulated with Klebsiella DNA at 
50ng/ml but some limited proliferation could be observed with 1 pg/ml DNA. 
The DNA preparation was found to contain LPS which could account for the 
good proliferation of B cells seen with C3H/HeN splenocytes. As both K55 
and K52 CPS extracts used in this experiment contained less than 1 pg/ml 
LPS and 50ng/ml DNA (Table 5.2), these results suggest that the
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Figure 5.5 CFSE analysis of T cell proliferation in response to K52 and K55 CPS 
extracts.
Spleens from naive C 3 H /H e N  and C 3 H /H e J  m ice w ere taken  and cell suspensions  
w ere  prepared. Cells (1 x 107 cells /m l) w ere  labelled with 5/vM C F S E  at 3 7 °C  for 10 
min. Cells w ere  then cultured with either K52 D N A , K 55 L P S , K 55 or K 52 C P S  
extracts (25/vg/m l), P M A  (5n g /m l) + lonomycin (200ng/m l), or m ed ia  alone. A fter 72h, 
cells w ere  labelled with an ti-C D 3  antibody and exam ined by flow  cytom etry. G ates  
w ere  placed around the C D 3  positive population to determ ine proliferation of these  
cells. Cell divisions result in reduction o f the C F S E  fluorescence intensity. T h e  
experim ent w as repeated  4  tim es, and one representative data set is shown.
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Figure 5.6 CFSE analysis of B cell proliferation in response to K52 and K55 
CPS extract.
S pleens w ere  taken  from naive C 3 H /H e J  and C 3 H /H e N  m ice and single cell 
suspension w ere  prepared. Cells (1 x 107cells /m l) w ere labelled with 5 //M  C F S E  at 
3 7 °C  for 10 min. Cells w ere  w ashed and then cultured for 72h with m edia  alone, K52  
D N A , K 55 LPS, K 55 or K 52 C P S  extracts (25/yg/m l). Cells w ere  then labelled with 
an ti-B 220 antibody and exam ined by flow cytom etry. G ates w ere  placed around the  
B 220 positive population to determ ine proliferation of these cells. Cell divisions result 
in reduction of the C F S E  fluorescence intensity. T h e se  data  are  from one  
representative study out of four.
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proliferation of B cells was likely due to a component (s) in the CPS extracts 
which was not LPS or bacterial DNA.
5.3.3 Cytokine production from C3H/HeJ splenocytes after stimulation 
with K. pneumoniae capsular polysaccharide extracts.
The cytokine profiles induced by various stimuli were determined. 
Splenocytes from C3H/HeJ mice were cultured with a range of samples. After 
48h supernatants were removed and analysed using a cytokine Cytometric 
Bead Array (CBA) assay. Figure 5.7 shows the release of cytokines from 
C3H/HeJ splenocytes when stimulated with K55 and K52 CPS extracts 
(panels A and B, respectively). K55 CPS extract induced the release of TNF- 
a, IFN-y, MCP-1, IL-10 and IL-6. Very little cytokine release was observed 
from splenocytes stimulated with K55 LPS or with media alone. K52 DNA 
induced the release of various cytokines but these were of a significantly 
lower concentration than those induced with K55 CPS extract. Similar results 
were observed for the K52 CPS extract, with the release of TNF-a, IFN-y, 
MCP-1, IL-10 and IL-6 by splenocytes. Minimal cytokine production was 
shown for splenocytes stimulated with K55 LPS, media only and K52 CPS 
pool 1. Most cytokine production was induced by K52 CPS pool 2. This 
suggests and consistent with other studies in this thesis that most of the 
immunostimulatory activity of CPS extracts is found in the CPS pool 2, rather 
than the highly purified CPS in pool 1. The immunomodulatory effects are 
unlikely due to LPS contamination as the studies were carried out in 
C3H/HeJ mice. The release of IL-2, IL-4, IL-5 and IL-12p70 was also 
analysed, but none of these cytokines were detected in any of the 
supernatants. The release of IL-12p70 in particular was studied at various
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Figure 5.7 Cytokine release from C3H/HeJ mouse splenocytes 
after culture with K52 and K55 CPS extracts.
Spleens were removed from naive C3H /H eJ mice and cell 
suspensions were prepared. Cells (2 x 105 /well) w ere cultured with 
25/yg/ml K55 (A) or K52 (B) CPS extracts or pooled samples 
generated after gel filtration chromatography. Cells were also 
cultured with LPS, DNA, or media alone. Supernatants were  
removed after 48h and then analysed for cytokines using a cytokine 
Cytometric Bead Array (CBA) assay (BD Biosciences, Pharmingen). 
Data represents the mean of three experiments ± s.e.m .
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time points (18h, 2 days and 3 days). Both ELISA and CBA assays failed to 
detect the presence of IL-12p70 in any of the supernatants.
Preliminary studies were also carried out to determine cytokine release 
stimulated by known TLR2 agonists, MDP (N-acetylmuramyl-L-alanyl-D- 
isoglutamine) and Pam3Cys (Pam3Cys-Ser(lys)4 HCI). Figure 5.8 shows the 
release of cytokines from C3H/HeJ splenocytes after stimulation with MDP 
and Pam3Cys. K. pneumoniae K52 and K55 CPS extracts were included for 
comparison. All stimuli were used at 25pg/ml. Very little cytokine production 
was observed for splenocytes cultured with either MDP or media alone. 
Pam3Cys induced the release of TNF-a, IFN-y MCP-1, IL-6 and IL-10, but 
less IFN-y was produced compared to both K52 and K55 CPS extracts.
5.4 Discussion
Chapter 4 in this thesis confirmed that Klebsiella CPS extracts augmented 
the antibody response to CGG, and provided strong evidence that the highly 
purified CPS in pool 1 is not the active component. This chapter examined 
the effect of these polysaccharide extracts on splenocyte populations. Both 
K52 and K55 CPS extracts induced the proliferation of splenocytes as shown 
by thymidine incorporation. Further studies using CFSE-labelled splenocytes 
confirmed that B cells, but not T cells proliferated in response to the 
Klebsiella CPS extracts. The component responsible for its effect on B cells 
has yet to be identified, but Klebsiella CPS extracts are known to contain 
both LPS and bacterial DNA, which have been reported to be polyclonal 
activators of B cells. Unmethylated CpG dinucleotides found in bacterial
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Figure 5.8 Cytokine release from C3H/HeJ mouse splenocytes 
after culture with K55 and K52 CPS extracts, Pam3Cys and MDP.
Spleens from naive C 3H /H eJ mice were removed and single cell 
suspensions were prepared. Cells (2 x 105/well) were cultured with 
25/vg/ml of K52 or K55 C PS extract, Pam 3Cys (Pam 3C ys- 
Ser(lys)4HCL), or M D P (N-acetylmuramyl-L-alanyl-D-isoglutamine). 
Supernatant was removed from each well 48h later. Cytokines were  
analysed by a cytokine Cytometric Bead Array (CBA) assay (BD  
Biosciences Pharmingen). Data represents the mean of three  
experiments ± s.e.m.
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DNA induce murine B cell proliferation and secretion of immunoglobulin in 
vitro and in vivo (Krieg, 2003, Messina et al., 1991). LPS can also induce the 
proliferation of B cells (Jaworski et al., 1982). In order to determine whether 
LPS in the CPS extracts was contributing to the proliferation of B cells, 
experiments were performed in LPS-hyporesponsive (C3H/HeJ) mice. 
Klebsieiia LPS failed to induce proliferation of C3H/HeJ splenocytes. 
C3H/HeJ splenocytes cultured with Klebsiella DNA at an equal or greater 
concentration to that present in the CPS extracts, showed very limited 
proliferation compared with CPS extracts. This confirmed that DNA and LPS 
present in the CPS extracts were not responsible for the proliferation of B 
cells.
Klebsiella LPS used in these studies was type 03. This LPS contains a 
mannose rich O-polysaccharide. LPSs possessing this type of O-antigen 
have been shown to have greater adjuvant activity than other LPS types 
(Ohta et al., 1985; Kido et al., 1985; Ohta et al., 1987; Yokochi et al., 1990; 
Yokochi et al., 1992). Chapter 4 showed how LPS containing mannose 
homopolymers could augment an antibody response to CGG in mice 
hyporesponsive to LPS. The failure of this LPS to induce the proliferation of B 
cells in splenocytes from C3H/HeJ mice suggests that a direct effect on B 
cells is not involved in its adjuvanticity. These observations are consistent 
with those of Ohta and colleagues (Ohta et al., 1985), who also suggested 
that LPS containing a mannose O-polysaccharide does not enhance B cell 
responses by inducing TLR4-independent B cell proliferation. Instead, it has 
been shown that an increase in adjuvant activity correlates with increased
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complement fixation by linear mannan-possessing LPS (Yokochi et al., 
1990). This may be an alternative mechanism for enhanced adjuvanticity in 
the absence of TLR4 signalling.
No T cell proliferation was observed for any of the samples except when 
stimulated with PMA and ionomycin. PMA is a phorbol ester that activates 
protein kinase C (PKC) which is important in many processes including 
controlling cell division. Phorbol esters activate PKC because they resemble 
diacylglycerol. lonomycin is a calcium ionophore. It is used in conjunction 
with PMA because PKC can only induce cell proliferation in the presence of 
calcium ions.
T cells in C3H/HeJ and C3H/HeN splenocytes populations failed to proliferate 
when cultured with LPS. This result contrasts with findings from previous 
studies showing that in vitro stimulation of purified splenic T cells with LPS 
can induce their proliferation. This activity was shown to be polymyxin B 
sensitive, and T cells from C3H/HeJ mice failed to proliferate (McGhee et al., 
1979, Vogel et al., 1983). These studies used isolated T cells, and it might 
be possible in these studies that contaminating cells such as B cells were 
proliferating in response to LPS. Although LPS has also been shown to 
stimulate T cells in vivo this was dependent on the presence of APCs and 
type 1 interferons (Tough et al., 1997). In this study, Kiebsielia DNA failed to 
stimulate C3H/HeN and C3H/HeJ T cells from splenocyte populations in vitro. 
Although T cell stimulation by CpG DNA has been shown in in vivo studies, 
the effect was indirect and mediated by type 1 interferons (Sun et al., 1998).
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In vitro studies presented in this thesis indicate that Klebsiella DNA has no 
effect on T cell proliferation.
Interestingly, both Klebsiella K52 and K55 CPS pool 1 failed to induce the 
proliferation of C3H/HeJ splenocytes, although stimulation of C3H/HeN 
splenocytes was observed. This suggests strongly that a TLR4 agonist, most 
likely LPS, in the Klebsiella CPS pool 1 induced B cell proliferation in the 
C3H/HeN mice. These results are entirely consistent with the data described 
in Chapter 4. Klebsiella CPS pool 1 has no adjuvant properties in LPS- 
hypresponsive mice. In contrast, Klebsiella CPS pool 2 could induce 
proliferation of B cells in a LPS- or TLR4-independent manner. This again 
was consistent with the presence of LPS-independent adjuvant activity within 
this pool as shown in Chapter 4 of this thesis.
Klebsiella CPS extracts that were protease digested and subjected to mild 
alkali treatment still induced significant proliferation of C3H/HeJ splenocytes 
suggesting that intact protein and alkali-sensitive lipids were not contributing 
to the activity. Samples subjected to harsher alkali treatment failed to induce 
proliferation of both C3H/HeN and C3H/HeJ splenocytes. The latter treatment 
would detoxify LPS (confirmed by the lack of B cell proliferation in C3H/HeN 
splenocytes), denature DNA and proteins, and de-O-acylate lipid 
components. The CPS is stable under these conditions but any lipid-linked 
anchors would be lost. The active component(s) is therefore relatively stable, 
resistant to protease and nuclease digestion and alkali conditions. It also 
appears to be heat and alcohol resistant as the sample was subjected to
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ethanol precipitation and heating at a temperature of up to 100°C during the 
extract procedure. Although highly purified CPS of very high MW  has no 
immunomodulatory effects the possibility of the presence of biologically 
active, smaller lipidated CPS in pool 2 has not been ruled out.
Profiles of cytokine release from C3H/HeJ splenocytes were also determined 
to be in accordance with the results of the proliferation assays. Very little 
cytokine production above the media only control was observed when 
C3H/HeJ splenocytes were cultured with LPS. Both K55 and K52 CPS 
extracts induced TNF-a, IFN-y, MCP-1, IL-6 and IL-10. The production of 
cytokines was induced by components present in Klebsiella CPS pool 2 but 
not in pool 1. Klebsiella DNA at the concentration present in the CPS extracts 
induced TNF-a, IFN-y, IL-6, and MCP-1, albeit at lower concentrations 
compared to the CPS extracts. This confirms that cytokine release induced 
by CPS extracts was not solely due to Klebsiella DNA stimulation. CpG DNA 
is a ligand for TLR9 and was expected to produce the above set of 
proinflammatory cytokines.
Interestingly no IL-12p70 was detected in supernatants from cells stimulated 
with either DNA or CPS extracts in this study. IL-12 is a proinflammatory 
cytokine which induces the production of IFN-y. A large amount of IFN-y was 
detected in the supernatants and therefore the absence of IL-12p70 was 
surprising. Biologically active IL-12 is a heterodimeric protein composed of 
p35 and p40 subunits (Stern et al., 1990). If more IL-12p40 is produced, 
homodimers form, which can bind to IL-12R, but fail to mediate a signal
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thereby serving as a functional antagonist to IL-12p70 heterodimers (Mattner 
et al., 1993, Ling et al., 1995). Only the presence of IL-12p70 was assayed, 
so it was possible that there was an over production of IL-12p40 and 
homodimers were being formed. Cells stimulated with CPS extracts also 
produced high levels of IL-10, a negative regulator of IL-12 production, which 
could also explain the absence of IL-12. The production of IFN-y was still 
observed, even when no IL-12p70 was detected. IL-18 is also a known IFN-y 
inducing cytokine. It is generally thought that both IL-12 and IL-18 are 
required for IFN-y production but a number of studies in the literature have 
suggested that IFN-y can be induced by IL-18 in an IL-12 independent 
manner (Muller et al., 2001b, Xing et al., 2000, Wakatsuki et al., 2003). This 
possibility should be further investigated in the future.
Known TLR 2 ligands, Pam3Cys and MDP, were also included in the study. 
Bacterial lipoproteins are a family of proinflammatory cell wall components 
found in both Gram negative and Gram positive bacteria. The stimulatory 
activity of bacterial lipoprotein resides in its acylated amino terminus, and is 
mimicked by the synthetic Pam3Cys lipopeptide. Pam3Cys is known to 
induce the production of IL-1, IL-6 and TNF-a from macrophages (Muller et 
al., 2001a). In these studies, both TNF-a and IL-6 were produced by 
C3H/HeJ splenocytes. The presence of IL-1 was not determined. Very little 
IFN-y was produced compared to the amounts induced by CPS extracts. 
MDP failed to have a dramatic effect on cytokine release. MDP is chemically 
synthesised and is the minimal essential structure of peptidoglycan, a 
constituent of bioactive cell walls from Gram negative and Gram positive
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bacteria. Nagao and colleagues reported similar observations in that MDP 
failed to activate murine macrophages in vitro (Nagao et al., 1992, Nagao et 
al., 1990).
Klebsiella CPS extracts were shown to induce B cell proliferation in a mixed 
splenocyte population. Whether or not B cells are activated directly without 
the involvement of APCs is not known. It is possible that B cell proliferation is 
via cytokine production such as IL-6, which was shown to be present in the 
supernatant, from APCs. No T cell proliferation was observed, consistent 
with the absence of IL-2 in the supernatants of the cell cultures. No IL-12 
was induced with CPS extracts but IFN-y was produced. IFN-y is 
predominantly produced by T cells, natural killer cells (NK), and NKT cells in 
response to infection, cytokines or mitogens. Evidence has shown the 
importance of IFN-y in both acquired and innate immunity (Magram et al., 
1996, Andersson et al., 1998). IFN-y is a major proinflammatory cytokine 
because of its ability to activate macrophages and endothelial cells 
(Goodbourn et al., 2000, Dalton et al., 1993). It is important that adjuvants 
have the capacity to induce cytokines that can activate APCs. Adjuvants that 
stimulate APCs can enhance antigen presentation, increase cytokine 
production and costimulatory molecule expression such as CD80, CD86, and 
CD40 on APCs. TNF-a, a proinflammatory cytokine capable of inducing the 
maturation of DCs, was produced by cells stimulated with Klebsiella CPS 
extracts. Mature DCs migrate from the peripheral tissues to the draining 
lymph nodes, where they instruct the adaptive immune response by 
stimulating T lymphocytes. Both IL-6 and IFN-y can induce immunoglobulin
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class switching. The in vitro effects of Klebsiella CPS extracts on splenocytes 
have similarity to a known TLR2 agonist, Pam3Cys, but were not identical 
with respect to IFN-y production.
Our results suggest that Klebsiella CPS extracts from K52 and K55 contain 
components that can activate immune cells via at least TLR2 and TLR4, but 
not TLR9. Stimulation with CPS extracts resulted in the production of major 
proinflammatory cytokines by splenocytes, and the proliferation of splenic B 
cells. Lack of availability of TLR or TLR-associated adapter protein knockout 
mice including TLR2 and MyD88 during the course of this thesis investigation 
has prevented further dissection of the underlying mechanism of their 
adjuvant activity. However these studies will be pursued when these mice 
become available. Since the compositions of Klebsiella CPS extracts have 
not been clearly defined, further investigations are needed in order to 
determine the identities of the immunostimulatory components in the 
extracts. However, our results have disproved the assumption that pure CPS 
is one of these components. In addition, this is the first study to indicate an 
immunomodulatory component or components from Klebsiella CPS extracts 
that appear to be extremely resistant to heat, protease, nuclease and alkali 
treatments. Further biochemical purification and immunological analysis will 
be required in order to determine whether or not the component(s) is a novel 
adjuvant candidate, and their mode of action.
192
Chapter Six
Chapter Six 
Results
193
Chapter Six
Chapter Six
The role of complement in the humoral 
response to Streptococcus pneumoniae 
capsular polysaccharides
6.1 Introduction
The discovery of complement receptors on the surface of B cells was the first 
indication that complement has an important role in the induction of antibody 
responses (Lay and Nussenzweig, 1968; Bianco et al., 1970; Nussenzweig, 
1974). Pepys and colleagues showed that the antibody response to T- 
dependent antigens was abrogated by transient depletion of C3 in mice with 
cobra factor venom (CVF) (Pepys, 1974). Other studies in guinea pigs 
(Ellman et al., 1971, Bottger et al., 1986), dogs (O'Neil et al., 1988), humans 
(Hazlewood et al., 1992) and mice (Fischer et al., 1996) established that 
genetic deficiencies in complement components C2, C3 or C4 resulted in 
reduced humoral responses. The conjugation of the C3d fragment of C3 to 
T-dependent and T-independent type II antigens has also been studied. 
Dempsey showed that fusing mouse C3d to hen egg lysozyme (HEN) 
resulted in HEN becoming 1,000 to 10,000 fold more immunogenic in mice 
compared to unmodified HEN (Dempsey et al., 1996). Test and colleagues 
showed that the same effect could be seen when C3d was coupled to a 
pneumococcal serotype 14 CPS, a T-independent type II antigen (Test et al., 
2001). Thus, C3d acts as an adjuvant for antibody responses.
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The effect of complement on B cell responses is mediated by complement 
receptor 1 (CD35) and 2 (CD21) which are found on the surface of both B 
cells and follicular dendritic cells (FDCs). Studies have been carried out using 
antibodies specific to CD21 and CD35 in mice. The administration of CD21- 
specific antibodies resulted in a diminished primary antibody response to T- 
dependent and T-independent antigens, whereas CD35-specific antibodies 
had less effect on the humoral response (Thyphronitis et al., 1991, 
Gustavsson et al., 1995, Heyman et al., 1990). Another study which 
involved the use of soluble CD21 resulting in reduced T-dependent 
responses in mice (Hebell et al., 1991), further highlighted the more 
significant role of CD21 in enhancing antibody responses compared to CD35.
A variety of methods have been used to dissect the role of complement in 
humoral responses, some which have already been described. A number of 
groups have generated mice that are deficient in CD21 and CD35 by gene 
disruption. CD21 and CD35 are encoded at a single locus (Cr2) in mice. 
Disruption of the CR2 locus abolishes expression of both CD21 and CD35. 
Several groups have independently generated Cr2 -/- mice (Ahearn et al., 
1996, Molina et al., 1996, Croix et al., 1996), and all groups showed the 
humoral response to be diminished in their mutant mice, although the degree 
of impairment was not consistent. Ahearn and colleagues showed there was 
no antibody response in Cr2 -/- mice to bacteriophage 0X174, not even 
when an adjuvant was administered (Ahearn et al., 1996). Although high 
antigen doses did induce a low antibody response, this was significantly 
reduced compared to wild type (WT) mice. Similar results were observed by
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Croix and colleagues, in that mice that did not express CD21/CD35 on B 
cells failed to make an antibody response to (4 hydroxy-3-nitrophenyl)acetyl 
(NP)-keyhole limpet hemocyanin with alum adjuvant (Croix et al., 1996). 
Other independent studies showed the antibody response to sheep red blood 
cells (SRBC) was reduced compared to wild type mice to both low and high 
dose antigen (Molina et al., 1996), whereas the antibody response to NP 
conjugated to CGG was reduced in Cr2 -/- with low dose antigen, but 
increasing dose partially corrected this deficit (Chen et al., 2000).
There are two mechanisms that can account for the role of CD21 and CD35 
in enhancing antibody responses. Firstly, co-ligation of the B cell receptor 
(BCR) with the complement complex (CD21/CD19/CD81) by C3 fragments 
(C3d) attached to antigen results in lowering of the threshold for B cell 
activation. Secondly, retention of the antigen-complement complex by FDCs 
in germinal centres via binding to CD21/CD35 enables B cells to access 
antigen (Carroll, 1998, Fang et al., 1998, Qin et al., 1998). Studies have been 
carried out to determine whether FDCs or B cells are important in the 
abrogated response to T-dependent antigens in Cr2 -/- mice. Fang and 
colleagues showed that a defective antibody response was still observed 
even when Cr2 -/- mice were reconstituted with Cr2 +/+ bone marrow 
suggesting an important role for FDCs (Fang et al., 1998). Other studies 
showed that mice lacking CD21/CD35 expression on B cells also failed to 
produce an antibody response (Croix et al., 1996). It is clear from these 
studies that expression of CD21 and CD35 on both B cells and FDCs is 
important in producing a good antibody response. Cr2 -/- mice have been
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shown to be able to form germinal centres, although they are fewer in 
number and reduced in size. They also display accelerated loss of serum 
antibody and fewer long-lived antibody-forming cells (Chen et al., 2000).
Most studies have examined the role of complement in the humoral response 
to T-dependent antigens. Fewer studies have focussed on T-independent 
type II antigens and the role of complement in the response to these antigens 
still remains controversial. Early studies from Pepys showed no change in 
the antibody response to polyvinylpyrrolidone 360 in mice depleted of C3 
(Pepys, 1974). In contrast Markham and colleagues showed that depletion of 
C3 abrogated the antibody response to pneumococcal serotype 14 
polysaccharide but had no effect on the response to the sialic acid containing 
group B Streptococcus type III capsular polysaccharide (Markham et al., 
1982). Other studies have shown a reduced IgM and IgG response to group 
B Streptococcus type III capsular polysaccharide in Cr2 -/- mice. This 
impairment was characterised by negligible uptake of Ag by FDCs and MZ B 
cells (Pozdnyakova et al., 2003). One explanation for the differences 
observed in the humoral response to group B Streptococcus type III capsular 
polysaccharide is that CVF depletes circulating C3 but is unlikely to affect the 
local production of C3 by myeloid cells in lymphoid compartments. Studies 
have shown that local synthesis of C3 is important and can enhance antibody 
responses to protein antigens independent of C3 in the circulation (Verschoor 
et al., 2001, Fischer et al., 1998).
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6.2 Objectives
The role of complement in the antibody responses to physiological TI-2 
antigens remains unclear. Most studies have focussed on model TI-2 
antigens, such as DNP-Ficoll. CPSs from Gram positive S. pneumoniae are 
commercially available as a 23-valent polysaccharide vaccine and usually 
devoid of LPS contamination that is commonly found in CPS preparations 
from Klebsiella pneumoniae and other Gram negative bacteria. This allowed 
us to study a large set of structurally diverse and clinically relevant TI-2 
antigens and to establish the role of mouse complement receptors 1 and 2 in 
anti-CPS responses by comparing the responses of C57BL/6 and Cr2-/- 
mice.
6.3 Results
6.3.1 Expression of CD21/CD35 in Cr2 -/- and C57BL/6 mice.
The level of expression of complement receptors CD21/CD35 in wild type
(C57BL/6) and Cr2-/- mice was compared by FACs. As shown in Figure 6.1 
Cr2-/- mice used in this study have a much reduced level of expression but 
not a complete absence of CD21/CD35. This is consistent with other studies 
which have shown that this particular line of Cr2-/- mice express a truncated 
form of CD21/CD35 due only exons 9 and 10 being spliced out (Hasegawa et 
al., 2001). Although there appear no major differences in antibody responses 
between this and other lines of Cr2-/- mice, it was nevertheless important that 
studies in Cr2-/- mice were compared to those in C3-/- mice (complement 
component 3-deficient mice).
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  Isotype control
  C r2 m ice
  C 57B L /6  m ice
Empty
C D 21/C D 35
Figure 6.1 Expression of CD21/CD35 on naive 
splenocytes from C57BL/6 and Cr2-/- mice.
Splenocytes were harvested and labelled with an antibody 
to C D 21/C D 35 and appropriate isotype controls were used. 
These data are representative of 3 separate experiments.
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6.3.2 The presence of natural IgM antibodies in naive mice to 
Streptococcus pneumoniae CPSs.
Natural IgM antibodies are an important part of innate immunity. Some of 
these antibodies recognise microbial carbohydrates. Serum from mice has 
been shown to contain these natural antibodies. It is therefore important to 
assess the presence of natural IgM in naive C57BL/6 and Cr2-/- mice to S. 
pneumoniae capsular serotypes. Blood was taken from naive mice and 
analysed by ELISA. Figure 6.2 shows a comparison of IgM levels in naive 
C57BL/6 and Cr2-/- mice to different capsular serotypes. IgM levels to 2, 9V, 
9N, 14, 18C, 19A, 19F, and 23F in C57BL/6 were significantly higher than in 
Cr2-/- mice. For CPSs 1, 3, 4, and 6B there was no significant difference in 
IgM levels in naive C57BL/6 and Cr2-/- mice. The background IgM levels for 
the pneumococcal cell wall polysaccharide (CW-PS), a common contaminant 
of pneumococcal preparations, were also determined in Cr2-/- and C57BL/6 
mice. The IgM levels were found to be significantly reduced in Cr2-/- mice 
compared to C57BL/6 mice.
6.3.3 The humoral response to Streptococcus pneumoniae CPS in wild 
type mice
6.3.3a Dose response
Very few studies have investigated the humoral response to S. pneumoniae 
CPSs in mice. Before investigating the immune response in Cr2 -/- the 
responses in wild type mice needed to be established. Studies that have 
been carried out have shown that there are several parameters that can 
influence the immune response to polysaccharide antigens; these include
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Figure 6.2 A comparison of serum IgM levels in naTve C57BL/6 
and Cr2-/- mice to Streptococcus pneumoniae capsular 
polysaccharides.
Sera from naive C 57BL/6 and Cr2-/- mice were analysed for IgM to 
a range of pneumococcal serotypes by ELISA at 1 in 200 dilution 
and preabsorbed with 100ug/ml C W -PS. IgM levels to C W -P S  were  
determined at a 1 in 200 dilution without preabsorption. Goat anti­
mouse IgM (jj chain specific) HRP conjugate was used to detect 
IgM. O PD  was used as a substrate. Data represents the mean of 
six to ten mice ± s.e.m .(Cr2 ^C 57/B I6; *, p<0.05; **, p<0.01).
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genetic background, age of mice, antigen dose and route of administration. 
C57BL/6 mice aged 8 - 1 2  weeks were immunised by the intra peritoneal 
route with a mixture of S. pneumoniae CPSs 19A, 19F, 6B, and 14 at a range 
of doses (0.1 - 5pg of each CPS). Mice were bled 7 days post immunisation 
and then serum was analysed for IgM by ELISA. The dose response is 
shown in Figure 6.3. For each dose the absorbance is compared. Any 
increase in absorbance reflects an increase in IgM levels in the serum. For all 
CPSs tested there was clearly an increase in IgM levels when dose was 
increased. Serum taken 21 days post immunisation gave similar results (data 
not shown).
6.3.3b Cell Wall polysaccharide preabsorption
The purified pneumococcal CPSs obtained from either NIBSC or Statens 
Serum Institute may contain a certain amount of CW-PS which is a major 
constituent of the pneumococcal cell wall (Musher et al., 1990). When mice 
are immunised with purified pneumococcal CPSs they are also immunised 
with CW-PS. It is therefore important that CW-PS is used to absorb mouse 
serum to remove antibodies to this polysaccharide when assessing 
antibodies to pneumococcal capsular polysaccharide antigens by ELISA. 
The presence of natural IgM to CW-PS as shown in Figure 6.2 means that 
naive mouse serum should also be pre-absorbed with CW-PS. Absorption 
was carried out with 100pg/ml of CW-PS for one hour at RT at a 1 in 50 
dilution of serum in PBS with 0.05% (w/v) Tween. CW-PS coated ELISA 
plates were used to verify that all CW-PS specific antibodies were prevented 
from binding to CW-PS by the absorption technique. This method has been
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Figure 6.3 Comparison of serum IgM response (7 days post 
immunisation) to Streptococcus pneumoniae capsular 
polysaccharides types 19A, 19F, 14 and 6B at different doses in 
C57BL/6 mice.
Groups of three C57BL/6 mice were immunised i.p with a mixture of 
pneumococcal CPS serotypes (19A, 19F, 14 and 6B) at a range of 
doses (0.1 -  5/vg of each C PS in sterile PBS) or with PBS alone. 
Blood was taken 7 days post immunisation and pooled and then 
analysed for IgM levels to serotypes 19A (A), 6B (B), 19F (C ) and 14 
(D ) by ELISA. Mouse IgM was detected by goat anti-mouse IgM (jj 
chain specific) HRP conjugate. ABTS was used as a substrate. IgM 
levels were assessed by absorbance readings at 405nm  wavelength. 
These data are means of duplicate wells and are representative of 
two separate experiments.
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used by others but at a reduced concentration of CW-PS for absorption 
(Musher et al., 1990; Aaberge et al., 1993; Sankilampi et al., 1996), but our 
studies have shown that CW-PS concentrations less than 100pg/ml are not 
consistent at neutralising the serum of CW-PS specific antibodies.
6.3.3c Effect of Booster
The effect of a booster immunisation was also investigated. Mice were 
immunised as before with a 5pg mix of CPSs 19A, 19F, 6B and 14 and then 
again at day 14. Mice were bled 7 days before and after booster 
immunisation. Figure 6.4 shows the effect of a booster on the IgM response 
to CPSs 19A and 19F. There was little difference in absorbance levels before 
and after administration of a booster immunisation. This was also the case 
for the other pneumococcal CPSs and at all doses employed (data not 
shown). These results are entirely consistent with what is generally known 
about polysaccharide antigens. Polysaccharide antigens do not induce 
immunological memory, which is a prerequisite for enhancement of an 
immune response by a booster immunisation. It is therefore for this reason 
there was no effect on the IgM levels present in the serum of mice before and 
after booster immunisation. This has been shown to be the case for 
pneumococcal CPSs (Baker et al., 1971; Aaberge et al., 1993).
6.3.3d Longevity of IgM response
The longevity of the IgM response to pneumococcal CPSs 19A and 19F are 
shown in Figure 6.5. Mice were bled 6 months post immunisation and serum 
was analysed for IgM and compared to day 7 and 21 levels. All time points
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Figure 6.4 Comparison of serum IgM responses to 
Streptococcus pneumoniae capsular polysaccharides 19A and 
19F before and after booster immunisation in C57BL/6 mice.
Groups of three C57BL/6 mice were immunised with a mixture of 
pneumococcal C PS serotypes 19A, 19F, 6B and 14 (5//g of each) or 
PBS only. A booster was given at day 14 (sam e as the first 
immunisation). Mice were bled at day 7 and day 21, serum was 
pooled and then analysed by ELISA using a goat anti-mouse IgM (jj 
chain specific) HRP conjugate and ABTS substrate. IgM levels were  
assessed by absorbance at 405nm  wavelength. Only 19A (A) and 
19F (B) are shown. These data are means of duplicate wells and are  
representative of two separate experiments.
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Figure 6.5 Long term serum IgM response to 
Streptococcus pneumoniae capsular polysaccharides 
types 19A and 19F in C57BL/6 mice.
Groups of three C57BL/6 mice were immunised i.p with a 
mixture of 5//g of pneumococcal serotypes 19A, 19F, 14 
and 6B or PBS only. Mice were bled 7days, 21 days and 6 
months after immunisation with the four polysaccharides. A  
booster was given at day 14 (sam e as the first 
immunisation). Serum was pooled and analysed by ELISA, 
only 19A (A) and 19F (B) are shown. IgM levels were  
assessed by absorbance at 405nm  wavelength. These data  
are means of duplicate wells and are representative of 2 
separate experiments.
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have very similar absorbance values, which indicate that antibody levels are 
maintained for at least 6 months post immunisation. This was also the case 
for pneumococcal CPSs 6B and 14 (data not shown). Other studies in 
BALB/c and CBA/J mice have also shown that the antibody levels to 
pneumococcal CPSs are maintained for up to five months (Aaberge et al., 
1993).
The antibody response to pneumococcal CPSs 19A, 19F, 6B and 14 was 
investigated in BALB/c mice to determine whether the kinetics of the 
response were different for this mouse strain. A dose response 7 days post 
immunisation is shown in Figure 6.6. There is an absorbance increase for all 
CPSs compared to PBS control, but doses between 0.1 and 5pg have no 
effect on the magnitude of the antibody response. The dose dependent 
response that was observed in C57BL/6 mice (Figure 6.3) is not applicable to 
BALB/c mice. A booster immunisation was also given and resulted in no 
effect on the magnitude of the antibody response (data not shown).
6.3.4 A comparison of serum IgM responses to Streptococcus 
pneumoniae CPSs in C57BL/6 and Cr2-/- mice.
To compare the serum IgM response to CPSs in C57BL/6 (H-2b) and Cr2-/- 
(H-2b) mice, mice were immunised i.p with 5pg of each CPS. From the dose 
response data generated (Figure 6.3) 5pg of CPS gave a good detectable 
response for all of the CPS tested. For these experiments mice were 
immunised with individual CPS rather than a mixture of CPSs. Many 
previous studies have immunised mice with many different capsular 
serotypes at the same time to study the antibody responses to different CPSs
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Figure 6.6 Comparison of serum IgM responses (7 days post 
immunisation) to Streptococcus pneumoniae capsular 
polysaccharides types 19A, 19F, 14 and 6B at different doses in 
BALB/c mice.
Groups of three BALB/c mice were immunised i.p with a mixture of 
pneumococcal C PS serotypes (19A, 19F, 14 and 6B) at a range of 
doses (0.1 -  5/yg of each C PS in sterile PBS) or PBS alone. Blood 
was taken 7 days post immunisation and pooled and then analysed for 
the IgM to serotypes 19A (A), 6B (B). 19F (C) and 14 (D ) by ELISA. 
IgM was detected with goat anti-mouse (jj chain) HRP conjugate using 
ABTS as a substrate. Absorbance was measured at 405nm . These  
data are means of duplicate wells and are representative of 2 separate  
experiments.
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(Aaberge and Lovik, 1996, Aaberge et al., 1993), which is the method applied 
to Section 6.3.3 in this chapter. An extension to this work was to determine 
the specificity of the IgM response to each CPS. Results (from Dr. S. Zamze, 
Edward Jenner Institute for Vaccine Research, U.K.) have shown that the 
IgM produced after immunisation is not always specific to the immunising 
CPS. For example, mice immunised with 23F not only produced an antibody 
response to 23F but also to a range of pneumococcal CPSs (Figure 6.7). 
This was also the case when other CPSs were used to immunise mice (data 
not shown). For this reason it was decided that further experiments would be 
carried out using only single CPS immunisations.
Twenty one days after immunisation mice were bled and serum was 
assessed for IgM levels for each mouse. Figure 6.8 shows a comparison of 
IgM levels in C57BL/6 and Cr2-/- mice to pneumococcal CPSs after 
immunisation with either CPS or PBS only. These data are representative of 
three independent experiments. It is important that when comparing the 
response of both groups of mice that PBS-immunised mice are included. As 
shown in Figure 6.2 there was a significant difference between levels of IgM 
in naive Cr2-/- and C57BL/6 mice. It was for this reason that the difference 
between PBS-immunised and CPS-immunised mice for both Cr2-/- and 
C57BL/6 was compared rather than just the CPS-immunised mice.
The data shown in Figure 6.8 represents the absorbance values for sera at a 
1 in 200 dilution. Initial experiments as described in this chapter were carried 
out using pooled sera from 3 mice and end point titre dilutions. However, on
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1.2
1
0 .8  
0 .6
0 .4
0 .2
0
23F □ PBS only
Coating polysaccharide
A
Figure 6.7 The binding of serum IgM to pneumococcal 
CPSs after immunisation of C57BL/6 mice with CPS 
serotype 23F.
Groups of three C57BL/6 mice were immunised with either 
5/yg of 23F (■) or PBS only (□). Mice were bled 21 days post 
immunisation and serum was collected and pooled. Serum  
was analysed at a 1 in 200  dilution (preabsorbed with C W -P S  
100jt/g/ml) for IgM to a range of pneumococcal C PSs by 
ELISA (Section 2 .2 .4e). These data are means of duplicate 
wells and are representative of 3 separate experiments.
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211
Ab
so
rb
an
ce
 
49
0n
m
Chapter Six
1.8
16
14
1.2
1-
0.8
0.6
0.4
0.2
0
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
19A
C57/BI6PBS Cr2PBS C57/BI6 Cr2 immunised
control control immunised
19F
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1.2
1
0.8
0.6
0.4
0.2
C57/BI6PBS Cr2PBS C57/BI6 Cr2immunised
controls controls immunised
***
C57PBS Cr2 PBS
control control
057/ BI6 Cr 2 immunised
immunised C57/BI6FBS Cr2 FBS control C57/B6 Cr2 irmunised
control immunised
Figure 6.8 A comparison of serum IgM responses to Streptococcus 
pneumoniae capsular polysaccharides 9N, 2, 23F, 18C, 3, 6B, 9V, 
14,19A, 1 ,19F, and 4 in C57BL/6 and Cr2-/- mice.
Groups of three C57BL/6 and Cr2-/- mice were immunised by the intra 
peritoneal route individually with 5/vg of pneumococcal C PS serotypes 9N, 
2, 23F , 18C, 3, 6B, 9V, 14, 19A, 1, 19F and 4 or with PBS only. Mice were  
bled 21 days post immunisation and serum from each mouse was  
analysed for IgM to the C PS by ELISA at a 1 in 200  dilution of mouse 
serum. Goat anti-mouse IgM H R P conjugate was used to detect IgM. 
O P D  was used as a substrate. Levels of IgM were assessed by 
absorbance at 490nm  wavelength. Each mouse is shown by ( • )  and the 
mean of each group of mice is shown by (— ). These data are m eans of 
duplicate wells from one representative study out of three. Significant 
differences are indicated as *** p=0.003.
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examining the response from individual mice we noted considerable 
variation. Variation among mice in response to polysaccharide appears to be 
normal (Pozdnyakova et al., 2003). In order to interpret the results and allow 
statistical analysis it was decided the best approach would be to assay the 
sera from individual mice using two dilutions with absorbance values falling in 
the middle part of the titration curve. This approach for the analysis of anti- 
CPS antibody responses by ELISAs has been used as commonly as end 
point titres. In all cases where comparisons of titration curves from pooled 
sera and single readings from individual mice were carried out, the result, 
with respect to the difference in C57BL/6 and Cr2-/- mice, was the same. It 
was therefore decided that absorbance for a single dilution of serum provided 
the correct conclusions.
For all of the pneumococcal CPSs explored only capsular serotype 4 gave a 
significantly reduced response in the Cr2-/- mice compared to C57BL/6 mice. 
This indicates a complement dependent antibody response to serotype 4 
CPS. The other CPSs vary in the magnitude of the response. Capsular 
serotype 14, when immunised alone, resulted in no IgM response above 
naive levels. This was also the case when the dose was increased to 10pg 
(data not shown). The other CPSs gave IgM responses in C57BL/6 and Cr2- 
/- mice with the responses to both 9V and 9N being very low. Independent 
studies have also been carried out in C3-deficient mice (C3-/-) in our group. 
The results of these studies are consistent with those obtained with Cr2-/- 
mice.
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The humoral response to pneumococcal CW-PS in C57BL/6 and Cr2-/- mice 
was also determined. Mice were immunised with 5pg of CW-PS and serum 
IgM and IgG levels were determined 7 and 21 days post immunisation. At 
day 7 there was consistently a very poor antibody response to CW-PS, but at 
day 21 the response was varied in C57BL/6 and Cr2-/- mice (data not 
shown). Three experiments were carried out in total, two with Cr2-/- mice and 
one with C3-deficient mice. Two experiments showed there was a good 
response in C57BL/6 mice but none in Cr2-/- mice. One experiment showed 
there was no difference in the IgM response in C57BL/6 and Cr2-/- mice. No 
serum IgG was found in any of the mice studied.
The model T-independent type II antigen DNP- ficoll was also included in the 
studies for comparison. Haas and colleagues showed that the IgM response 
in Cr2-/- to DNP-ficoll was normal compared to wild type mice, but the IgG 
response was significantly reduced (Haas et al., 2002). Figure 6.9 shows the 
IgM and IgG responses to DNP-ficoll. The IgM response was normal, but IgG 
response was significantly reduced in Cr2-/- mice. Our results expressed in 
absorbance values for DNP-Ficoll antibody responses are consistent with the 
literature.
Effect of dose on the complement dependent IgM response to type 4
Preliminary studies have been carried out to look at the effect of dose on the 
complement dependent response to capsular serotype 4. It was shown by 
Chen and colleagues that increasing dose of a protein antigen can overcome 
complement dependency (Chen et al., 2000). Figure 6.10 shows a
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Figure 6.9 A comparison of serum IgM and IgG responses to 
DNP-ficoll in C57BL/6 and Cr2-/- mice.
Groups of three C57BL/6 and Cr2-/- mice were immunised with 5/yg 
of DNP-ficoll. Mice were bled at 21 days post immunisation, then 
serum was analysed for (A) IgM and (B) IgG by ELISA. IgM was 
detected in individual mice at 1 in 200 dilution of serum for IgM and 
1 in 100 dilution for IgG with goat anti-mouse IgM H R P conjugate. 
Individual mice are indicated by ( • )  and the m ean of a group of 3 
mice is shown as (— ). These data are the m eans of duplicate wells 
from one representative study out of two (second study in C3  
deficient). Significant differences are indicated as ** p = 0 .001.
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Figure 6.10 A comparison of serum IgM responses to different 
doses of Streptococcus pneumoniae capsular serotype 4 in 
C57BL/6 and Cr2-/- mice.
Groups of three C57BL/6 and Cr2-/- mice were immunised by the 
intra peritoneal route individually with either 5/yg (A), 15//g (B), and 
25jjq (C ) of pneumococcal serotype 4 or PBS only. Mice were bled 21 
days post immunisation and serum was analysed by ELISA for the 
presence of IgM to serotype 4. Goat anti-mouse IgM (jj  chain specific) 
H R P conjugate was used to detect IgM. O P D  was used as a 
substrate. Levels of IgM were assessed by absorbance at 490nm  
wavelength. Each mouse is shown by ( • )  and the mean of each 
group of mice is shown by (— ). These data are means of duplicate 
wells. (A) is one representative study out of five conducted. (B) and 
(C ) are data from one preliminary study. Significant differences are  
indicated as * p < 0 .05  and ** p<0.005.
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comparison of IgM responses in C57BL/6 and Cr2-/- mice after immunisation 
with 5|ig, 15^ig, and 25jj.g of serotype 4. For all three doses there was a 
significant reduction in the response of Cr2-/- mice compared to C57BL/6  
mice. Increasing dose did not overcome the complement dependent IgM 
response of capsular serotype 4, although it must be noted that these data 
were from a single experiment and the maximum dose was 25jig. it is 
therefore important that before any conclusions are made, that this work is 
repeated and possibly dose range is extended to include greater doses.
The effect of co-immunisation of CPSs on the IgM response in Cr2-/- 
mice
The IgM response to co-immunised CPSs was also investigated. Mice were  
co-immunised with 19A, 19F, 6B, and 14. Figure 6.11 shows a comparison of 
IgM levels in Cr2-/- and C57BL/6 mice to 19A, 19F, 6B, and 14. The  
absorbance levels in the Cr2-/- mice are significantly reduced compared to 
C 57BL/6 mice. Interestingly when these CPS were immunised individually 
the IgM response was not complement dependent. Preliminary studies have 
been carried out to determine if the same response was observed with a 
different combination of fours CPSs. CPSs 9V, 9N, 18C and 23F were used 
to immunise mice and both Cr2-/- and C57BL/6 mice responded the same to 
the CPSs (data not shown).
6.3.5 A comparison of serum IgG responses to Streptococcus 
pneumoniae CPSs in C57BL/6 and Cr2-/- mice.
The IgG response in C57BL/6 and Cr2-/- mice to pneumococcal CPSs and 
DNP-ficoll was investigated. No IgG was detected in mice that were
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Figure 6.11 A comparison of serum IgM levels in C57BL/6 and 
Cr2-/- mice immunised with a mixture of Streptococcus 
pneumoniae capsular polysaccharides 1 4 ,19A, 19F and 6B
Groups of three C57BL/6 and C r2-/- mice were co-immunised (i.p) 
with 5/yg each of pneumococcal serotypes 14, 19A, 19F and 6B or 
PBS alone. Blood was taken 21 days post immunisation and then 
analysed for IgM levels to serotypes 14 (A), 19F (B), 19A (C ) and 
6B (D) by ELISA at 1 in 200 dilution of mouse serum. IgM was  
detected by goat anti-mouse IgM (// chain specific) HRP  
conjugate. O P D  was used as a substrate. Absorbance at 490nm  
wavelength was used to assess IgM levels. Each mouse is shown 
by ( • )  and the mean of each group is shown by (— ). These data 
are means of duplicate wells from one representative study out of 
two. (* p< 0.05; ** p<0.02)
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immunised with CPSs 1, 2, 3, 6B, 9V, 9N, 18C, 19F, or 23F (data not 
shown). Previous studies have shown an absence of an IgG response to 
pneumococcal CPSs in mice when immunised with polysaccharide alone 
(Aaberge et al., 1993, Aaberge and Lovik, 1996, Test et al., 2001). However, 
IgG was found in some of the mice immunised with CPSs 4, 19A and 14. 
Figure 6.12 shows a comparison of IgG responses in Cr2-/- mice and 
C57BL/6 to serotypes 19A and 14. For both CPSs the IgG response is 
completely complement receptor dependent as shown by the absence of a 
response in the Cr2-/- mice. Even though there is an IgG response in 
C57BL/6 mice this is very variable, only two out of the three mice have an 
IgG to 19A response (Figure 6.12A).
The specificity of the IgG response to these polysaccharides was also 
determined. It has been shown that some batches of the 23-valent 
polysaccharide vaccine contain protein contaminants including 
pneumococcal surface protein A (PspA) and pneumococcal surface adhesion 
A (PsaA) (Yu et al., 2003). The IgG response could therefore be to a protein 
in the pneumococcal preparations. To investigate the presence of protein in 
our preparations, the pneumococcal CPSs were analysed by gel filtration 
chromatography on a TSK G5000 column with PBS at 40°C. Figure 6.13 
shows a gel filtration profile for serotype 9V. This was representative of the 
other serotypes. The CPS eluted as a single peak around 30 mins as shown 
by refractive index indicating a molecular weight of approximately 2000 kDa. 
The 280nm trace, which indicates the presence of protein within the 
preparation, is very low. The pneumococcal CPSs were quantified for protein
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Figure 6.12 A comparison of serum IgG responses to 
Streptococcus pneumoniae capsular polysaccharides types 
19A and 14 at day 21.
Groups of three C 57BL/6 and Cr2-/- mice were immunised (i.p) 
with either 5//g of pneumococcal serotype 19A and 14 or PBS  
control. Mice were bled 21 days post immunisation and then 
serum was analysed for IgG responses to 19A (A) and 14 (B) by 
ELISA. IgG was detected by goat anti mouse IgG H R P  
conjugate for individual mice at a 1 in 200 dilution (A) and 1 in 
50 dilution (B) of mouse serum. Absorbance at 490nm  
wavelength was used to assess IgG levels. Individual mice are  
indicated by ( • )  and the mean of a group of mice is shown by 
(— ). These data are means of duplicate wells from one 
representative study out of two (A) and three (B)
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Figure 6.13 Gel Filtration profiles of Streptococcus pneumoniae 
capsular polysaccharide serotype 9V
Pneumococcal C PS serotype 9V  (100/yg) was eluted on a TSK  G 5000  
column in PBS at 40°C  as described in methods section 2.2.1 d. The  
refractive index (C ) of eluant was monitored together with absorbance  
at 205nm  (A) and 280nm  (B).
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content by the method described in Section 2.2.3c. The assay showed there 
to be less than 200ng/ml of protein in 100pg/ml of CPS. Mice were only 
immunised with 5ug of CPS which contained approximately 10ng of protein.
In order to show that the IgG response is specifically to the CPSs and not to 
contaminants, a number of methods were adopted. The IgG response to 
19A was shown to cross react with 19F but not to any other CPSs by ELISA. 
CPSs 19A and 19F are structurally similar (Lee and Fraser, 1980) so it was 
expected that antibodies that bind to 19A would also bind to 19F. The 
structures of the pneumococcal CPSs are illustrated in Figure 1.4 in the 
Introduction. IgG to serotypes 4 and 14, did not cross react with any of the 
other CPSs and were therefore serotype specific. Further, periodate 
oxidation of CPS 14 resulted in loss of IgG binding indicating recognition of a 
polysaccharide component. Oxidation of CPS 14 is known to destroy B cell 
epitopes. Proteins, in contrast, are periodate resistant so they would not be 
altered by this process. All the evidence suggests that the IgG response is 
pneumococcal serotype specific and not to a protein contaminant, and where 
there was an IgG response it was complement dependent.
As shown in section 6.3.4, the IgM response to DNP-ficoll is not complement 
dependent. Figure 6.9B shows the IgG response to DNP-ficoll in both Cr2-/- 
and C57BL/6 mice. The response in Cr2-/- is significantly reduced compared 
to C57BL/6 mice. The IgG response is therefore complement dependent.
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6.4 Discussion
Much of our knowledge about the humoral immunity to TI-2 antigens comes 
from the studies of non physiological antigens. Only one recent study by 
Pozdnyakova and colleagues (Pozdnyakova et al., 2003), investigated the 
role of complement in the humoral response to a clinically relevant 
polysaccharide. S. pneumoniae is a major cause of morbidity and mortality in 
the paediatric population worldwide. The polysaccharide capsule protects the 
bacteria from innate immune defences. The host antibody response to the 
capsule is therefore crucial. Purified S. pneumoniae CPS can induce direct 
activation of C3 via the alterative pathway (Griffioen et al., 1991). C3d signals 
through CD21, which is highly expressed on MZ B cells. MZ B cells have 
been shown to have an important role in the response to T-independent type 
II antigens, by the abrogated antibody response to polysaccharides in mice 
that lack MZ B cells (Pyk -/- mice) (Guinamard et al., 2000). CD21 is 
expressed on B cells as a complement complex (CD21/CD19/CD81). Co­
ligation of the B cell receptor with the complement complex by C3d attached 
to antigen lowers the threshold for B cell activation (Carroll, 1998). FDCs 
also express CD21 along with CD35. These proteins are expressed from the 
same locus in mice. These receptors are important for retention of 
complement coated antigen within the spleen (Fang et al., 1998, Qin et al., 
1998). Evidence in the literature shows complement to have an important 
role in the host response to pneumococcal CPS. To further investigate the 
role of complement, the humoral response in mice deficient in complement 
receptors CD21 and CD35 (Cr2-/-) from M Carroll (Ahearn et al., 1996) was 
studied.
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Prior to investigating the differences in the immune response to S. 
pneumoniae CPSs in C57BL/6 (wild type) and Cr2-/-, the nature of the IgM 
response in wild type mice was established. Firstly the levels of natural 
serum IgM antibodies against CPS in naTve wild type mice were determined. 
Natural serum antibodies, mostly of the IgM isotype, are produced by B1 
cells. These natural antibodies appear in the absence of apparent antigenic 
stimulation. Natural IgM antibodies were detected to all CPSs, but levels did 
differ among serotypes. The presence of natural IgM to some CPSs has very 
low (e.g. serotypes 1 and 4). The level of natural IgM to the common teichoic 
acid of S. pneumoniae (CW-PS) was also assessed. The presence of natural 
IgM which bind the phosphocholine moiety of CW-PS has been shown to be 
protective in pneumococcal infection (Briles et al., 1981), although we 
detected relatively low levels of natural IgM to CW-PS compared to some 
CPSs. The importance of natural IgM in innate immunity to S. pneumoniae 
has been demonstrated in mice that lack secretory IgM. The presence of 
natural IgM to S. pneumoniae activates complement via the classical 
pathway which is one major route of clearance of S. pneumoniae (Brown et 
al., 2002).
The presence of natural IgM was also detected in Cr2-/- mice, although 
levels of IgM to most of the CPSs were lower in Cr2 -/- mice compared to 
wild type. It has been previously shown (Ahearn et al., 1996) that the Cr2-/- 
mice used in this work have no difference in either their total cell numbers or 
the ratios of peripheral mononuclear cells to granulocytes compared to wild 
type mice. There are no significant differences in the number of splenic
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lymphocytes, or ratios of CD4 to CD8 T cells. In contrast there is a significant 
reduction in the B1-a (lgM+ CD5+) population of peritoneal B1 cells. Other 
studies have shown that there is a loss of certain B1 cell specificities and not 
a proportional decline in the repertoire. It was shown that the Cr2-/- mice had 
a similar frequency of phosphorylcholine specific CD5+ B1 cells, but a 
reduction in the number of intestinal ischemia-reperfusion injury specific 
antibodies compared to wild type mice (Fleming et al., 2002, Reid et al., 
2002). CD21 and CD35 are therefore important in the maintenance of the B1 
cell repertoire to some, but not all, specificities. This may explain why there is 
a reduction of natural antibodies to certain pneumococcal serotypes in Cr2-/- 
mice. Pneumococcal polysaccharides that are structurally similar like 9V  
and 9N, 19A and 19F all have similar levels of natural antibodies. Natural 
antibodies to structurally similar CPS are probably produced from the same 
B1 cell specificities.
After determining the levels of natural IgM, the kinetics of the primary 
antibody response to co-immunised CPSs in wild type mice was determined. 
Mice responded in a dose dependent manner to pneumococcal serotypes 
6B, 14, 19A and 19F and gave an IgM response at both 7 and 21 days post 
immunisation. A booster immunisation given 7 days after the initial 
immunisation had no effect on the antibody levels to the polysaccharides, 
although this is not surprising considering polysaccharide antigens do not 
induce immunological memory. This observation is consistent with other 
studies which show the administration of a booster has no effect on the 
magnitude of the anti-pneumococcal CPS response (Aaberge et al., 1993;
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Baker et al., 1971). Interestingly, the IgM response could still be detected 6 
months post immunisation for serotypes 6B, 14, 19A, and 19F. This has been 
shown previously in BALB/c mice for pneumococcal CPSs (Aaberge et al., 
1993). CPSs are high molecular weight molecules that have a long half life. 
This, together with their poor internalisation by B cells, results in potent 
persistent signalling (Mond et al., 1995a). This could explain the longevity of 
the antibody response.
The antibody response to pneumococcal CPSs was compared in Cr2-/- and 
wild type mice. For these studies, immunisations with a single rather than a 
mixture of CPSs were used following the discovery that the IgM antibodies 
generated against one CPS serotype may cross react with structurally 
unrelated CPSs (Figure 6.7). This could explain the difference in the IgM 
response to serotype 14 (Figure 6.8) when immunised alone or when co­
immunised with CPSs 6B, 19A, 19F (Figure 6.3 and 6.11). When immunised 
alone there is no response to serotype 14 in C57BL/6 but when co­
immunised there is an obvious increase in IgM levels compared to PBS- 
immunised mice. It is possible that when mice are co-immunised with 6B, 
14, 19A and 19F that the IgM produced to 6B, 19A, 19F cross reacts with 
serotype 14.
The lack of response to pneumococcal CPS 14 could also be explained by a 
number of studies in the literature looking at conformational epitopes of 
pneumococcal serotype 14 (Wessels and Kasper, 1989, Laferriere et al., 
1998, Zou et al., 1999). It was shown that antibodies directed against
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pneumococcal serotype 14 recognise a conformational epitope fully 
expressed only on high molecular forms of the antigen (Wessels and Kasper, 
1989). This has also been shown for group B Streptococcus type III (Zou et 
al., 1999) and group B N. meningitidis (Jennings et al., 1985) CPS. 
Pneumococcal CPS 14 is structurally related to that of group B 
Streptococcus type III, differing only in that the pneumococcal CPS 14 
polysaccharide lacks sialic acid residues. The conformational epitope for 
group B Streptococcus type III has been shown to exist mainly in a random 
coil form, which structurally mimics self antigens, but it can infrequently and 
spontaneously form extended helices. The immune system may preferentially 
select these helical epitopes because they are unique to the polysaccharide 
(Zou et al., 1999). It is possible that this can also be applied to pneumococcal 
CPS 14 and the absence of an antibody response is due to the conformation 
of the polysaccharide. If an extended helical structure is not formed then 
antibodies will not recognise the conformational epitope.
The CPSs when immunised individually varied in their immunogenicity in wild 
type mice. Some CPSs induced a good IgM (e.g 19F, 3, and 4) response 
whereas others only induced low or no IgM antibodies (e.g. 9N, 9V and 14) to 
the CPSs. Interestingly, there was no correlation between the levels of 
natural IgM to CPSs and the subsequent increase in serum IgM post 
immunisation. Natural IgM to CPS type 4 was low but a good IgM response 
was observed after immunisation, whereas type 19A which also gave a good 
IgM response after immunisation had much higher levels of natural IgM than 
type 4.
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In this study, only the IgM response to capsular serotype 4 was CD21/CD35 
dependent. Other studies showed that complement depletion with CVF in 
BALB/c mice resulted in abrogation of the primary antibody response and 
diminished plaque forming cell (PFC) response to pneumococcal serotypes 
14 (Markham et al., 1982) and 3 (Pepys, 1974). Our studies show deficiency 
of CD21 and CD35 to have little effect on the IgM antibody response to CPSs 
14 and 3. This was consistent with studies in C3-/- mice (unpublished data 
from Dr. S. Zamze, Edward Jenner Institute for Vaccine Research, UK.). 
Possible reasons for the difference in the results could be the different mouse 
strains, route of immunisation or the effect of CVF on components of the 
immune system other than complement.
It is not known why the IgM anti-serotype 4 CPS response is dependent on 
complement. The only structural feature of serotype 4 that is different to the 
other pneumococcal CPSs is the presence a cyclic pyruvate modification, 
which is the immunodominant epitope (see structure Table 1.4 in the 
Introduction). Differential complement dependency in the humoral response 
to CPS may also be explained by the involvement of different B cell subsets. 
When human B cells were co-stimulated in vitro with capsular serotype 4 and 
anti-CD21 antibodies, the anti-CPS response was enhanced (Griffioen et al., 
1992). It could be hypothesised that the IgM response to capsular serotype 4 
is produced from a different subset of B cells than other pneumococcal 
serotypes. MZ B cells could be the major producer of antibodies to capsular 
serotype 4. These cells have high levels of CD21 expression. The antibody 
response to other pneumococcal serotypes could be from peritoneal B1 cells
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which do not express CD21. Therefore in Cr2-/- mice, the antibody response 
to only capsular serotype 4 would be abrogated.
Pneumococcal CPS 4 has been shown in other studies to act differently to 
most other pneumococcal CPSs. It was found not to be recognised by the 
mannose receptor (Zamze et al., 2002) and other mammalian lectins such as 
SIGN-R1 (unpublished data from Dr. E. McGreal, Oxford University, U.K.). It 
could therefore be speculated that serotype 4, has different properties than 
other pneumococcal CPSs. A preliminary study to look at the effect of dose 
on the CD21/CD35 dependent response to serotype 4 (Figure 6.10) showed 
there to be no effect, in contrast to T-dependent antigens where complement 
dependency can be overcome by increasing dose (Chen et al., 2000).
Interestingly, it was shown that when mice were co-immunised with 
pneumococcal CPSs 6B, 14, 19A and 19F the IgM response is complement 
receptor dependent, but when these CPSs were immunised independently 
the IgM response was the same in Cr2 -/- and wild type mice. Why this is so 
is not known. A preliminary study using a combination of 4 other serotypes 
showed no difference in response in Cr2-/- or wild type mice. It is possible 
that the combination of 6B, 14, 19A, and 19F activate complement to a 
greater extent than each serotype alone or that different B cell populations 
respond to the different antigens as mentioned previously for serotype 4. 
There is no obvious reason why 6B, 14, 19A and 19F should be different to 
other combinations of CPSs. It is important that these studies are continued 
and other combinations of serotypes are considered especially because of
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the possible implications this may have on multivalent polysaccharide 
vaccines. It is possible that a combination of CPSs may induce anti-CPS 
antibodies by a different mechanism from that of individual CPSs.
Also included in the study was DNP-ficoll a model T-independent type II 
antigen. The IgM response was found to be normal in Cr2 -/- compared to 
wild type but the IgG was significantly reduced in the Cr2-/- mice. These 
results are consistent with other studies with DNP-ficoll (Haas et al., 2002). It 
was for this reason that the IgG response of mice to pneumococcal CPSs 
was included in the study. Most of the studies in the literature showed little or 
no IgG response in wild type mice to pneumococcal CPSs, when 
administered alone without adjuvants (Aaberge et al., 1993, Aaberge and 
Lovik, 1996, Test et al., 2001). In the present study no IgG was detected for 
the following CPSs 1, 2, 3, 6B, 9V, 9N, 18C, 19F, and 23F. IgG was found 
in some, but not all, mice immunised with CPSs 4, 19A, and 14. The IgG 
response was shown probably to be specific to the polysaccharide and not to 
a protein contaminant within the CPS preparations (Figure 6.13). No IgG 
response was seen in the Cr2-/- mice which suggest that when there is an 
IgG response it is CD21/CD35 dependent. This study should be continued 
with greater number of mice to look at the frequency of an IgG response in 
normal mice.
In conclusion, the role of CD21/CD35 in the primary serum antibody 
response to S. pneumoniae CPS was studied. The IgM response to 
pneumococcal CPS 4 was shown to be dependent on CD21/CD35, whereas
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there was no difference in the response of Cr2-/- mice to any of the other 
CPSs investigated compared to wild type mice. Similar studies in C3-/- mice 
illustrate the consistency of the results (unpublished data from Dr. S. Zamze, 
Edward Jenner Institute for Vaccine Research, UK.). There was no IgG 
response to most of the CPSs, only CPSs 4, 14, and 19A produced an IgG 
response and this was shown to be specific. It was also shown that where 
there was IgG response it was CD21/CD35 dependent.
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7.1 The adjuvant properties of Klebsiella pneumoniae 
capsular polysaccharides
Many efforts are underway to find new vaccines for various pathogens. 
Together with these studies it is important that appropriate adjuvants are 
studied. Live vaccines stimulate immunity via transient infection caused by 
the replicating organism. Although these vaccines can be cost effective and 
easy to produce, there are serious intrinsic health risks associated with the 
use of live pathogens as vaccines. The more favoured type of vaccines are 
composed of inactivated organisms or their constituents. These non­
replicating vaccines are the safest, but often lack sufficient immunogenicity 
and require adjuvants to elicit an adequate immune response. Currently Alum 
is the only licensed adjuvant in humans. Consequently the development of 
new adjuvants is a major goal in the vaccine field. It is important that vaccine 
adjuvants are defined products with low toxicity and elicit an appropriate 
response to protective antigens from each type of infection. One of the major 
aims of this thesis was therefore to further investigate potential adjuvant 
properties of microbial polysaccharides and the mechanisms for their 
biological activities.
Initial reports suggested that K. pneumoniae CPS extracts have 
immunostimulatory, anti-tumour and adjuvant properties (Nakashima, 1972;
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Nakashima and Kato, 1975; Yokochi et al., 1980a; Choy et al., 1996; Ho et 
al., 2000). They also concluded that the CPS in these extracts was 
responsible for these effects, although the contents of the CPS extracts in 
these studies were not well defined. It is more than likely that these CPS 
extracts contained microbial components, such as LPS and bacterial DNA, 
which are reported to have strong immunostimulatory properties via TLR 
engagement. Native LPS or bacterial DNA has not been considered as 
adjuvant candidates due to their toxicity to cells. In order to reduce toxicity 
chemically altered LPS or synthetic CpG oligonucleotides are required. In 
contrast, CPSs are commonly used as antigens in human vaccines and are 
generally considered to be stable and not overtly toxic. If the reported 
adjuvant properties of Klebsiella CPS were due to CPS alone and these CPS 
are non-toxic to cells, then they would be desirable adjuvant candidates for 
use in humans. It was therefore important for our studies that the CPS was 
very pure and well characterised.
A successful method of K. pneumoniae CPS purification was established. 
Gel filtration chromatography was performed using a TSK G5000 column in 
PBS containing 0.25% (w/v) sodium deoxycholate. This method gave a 
highly pure CPS preparation termed CPS pool 1 which contained only trace 
amounts of nucleic acid, protein and LPS. Prior to purification our studies 
showed that CPS extracts from K. pneumoniae serotypes K1, K3, K55, and 
K52 enhanced the antibody response to CGG and therefore contained active 
components. Adjuvanticity was still observed independent of the TLR4 
siganlling pathway and therefore of LPS. This result has confirmed that there 
are components in the CPS extracts other than LPS that can augment the
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antibody response to CGG. Following further CPS purification the CPS pool 1 
(pure high MW CPS) failed to induce an antibody response to CGG in LPS- 
hyporesponsive mice. This was the case for a number of different serotypes. 
It was therefore concluded that high MW CPS did not contribute to the 
adjuvant properties of CPS extracts on the enhancement of the antibody 
response to CGG.
Possible mechanisms to account for the observed adjuvanticity were 
explored. These included the induction of cytokines and stimulation of B cell 
proliferation. K52 and K55 CPS extracts induced the proliferation of B cells 
but not T cells. Both LPS and bacterial DNA were ruled out as the main 
contributing factors of B cell proliferation. K52 and K55 CPS extracts induced 
the release of TNFa, IFNy, IL-10, and IL-6. Both proliferation and cytokine 
production from splenocytes was induced by CPS pool 2 but none, or very 
little, from CPS pool 1.
Our studies confirm that CPS extracts do have immunostimulatory properties, 
and establish for the first time that these properties are not only due to LPS 
and bacterial DNA. Studies also showed that a contribution from the high MW  
CPS in the extracts was unlikely. It is not clear what the active component (s) 
are, possibly lipopeptide or glycopeptide, which are biologically active in 
small quantities.
CPS extracts are able to induce antibody responses to a non-immunogenic 
protein in vivo, and in vitro studies have highlighted the ability of these
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extracts to induce proliferation and release of various cytokines from 
splenocytes. Of particular interest is the release of IFNy. IFNy is produced 
predominantly by T, NK and NK T cells. IFNy exhibits a wide array of 
proinflammatory activities and plays a key role in amplifying both innate and 
adaptive immune responses. IFNy is a major product of Th1 cells and further 
skews the immune response toward a Th1 phenotype (cell-mediated 
immunity). IFNy achieves this by promoting Th1 effector mechanisms such 
as innate cell-mediated immunity (via activation of NK cell function), specific 
cytotoxic activity (via T cell and APC interactions) and macrophage activation 
(Schroder et al., 2004). IFNy also influences naive CD4+ cell differentiation 
toward a Th1 phenotype. The induction of IFNy from splenocytes by CPS 
extracts is therefore of major importance in terms of its use as an adjuvant 
due to the various effects IFNy has on the immune system. It has not been 
shown in our studies whether the CPS extracts induce Th1 or Th2 immune 
responses. A Th1-skewed antibody response results in the production of 
lgG2a and lgG3 whereas Th2 response induces both IgE and lgG1. The 
antibody isotypes generated against CGG in the presence of K. pneumoniae 
CPS extracts should be determined in further investigations. Similarly, it 
would also be important to determine the effect of CPS extracts on the 
induction of cytotoxic T lymphocytes.
7.2 The role of complement in the humoral response 
to Streptococcus pneumoniae CPS
S. pneumoniae is a major cause of morbidity and mortality in the paediatric 
population worldwide. There is strong evidence that resistance to 
pneumococcal infection is mediated by the presence of antibodies against
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the CPS of the bacteria. A polysaccharide vaccine consisting of the CPSs 
from 23 different serotypes has been used. This vaccine is successful in 
immunocompetent adults but is not efficacious in young children due to the 
T-independent nature of the CPS antigen. A protein-polysaccharide 
conjugate vaccine is currently licensed for use in the US. This converts the 
response from T-independent to T-dependent and therefore induces a 
primary as well as a memory response in children. It is important to continue 
studies that dissect the immune response to polysaccharide antigens 
because conjugate vaccines are not readily available in developing countries 
where disease incidence is highest. For example, it may be possible to 
induce a better response to polysaccharides with the aid of adjuvants. The 
main aim of this part of the thesis was to further understand factors that effect 
the immunogencity of polysaccharides and in particular the possible role of 
complement receptors in the induction of a primary anti-CPS antibody 
response.
Our studies focussed on a panel of capsular polysaccharides from S. 
pneumoniae. This provided a set of structurally different polysaccharides 
that could be compared to each other and to a model TI-2 antigen. Antibody 
responses to CPSs generated mostly IgM and increased in a dose- 
dependent manner. The use of a booster immunisation failed to have any 
effect on anti-CPS antibody levels. This was consistent with the lack of 
memory induction by these types of antigens in general. Interestingly, CPSs 
induced long-lived antibody responses as indicated by the presence of anti- 
CPS IgM antibodies in the mouse serum 6 months post immunisation.
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Natural IgM could also be detected in naive wild type mice to most of the S. 
pneumoniae CPSs, although levels of natural IgM did not determine the 
magnitude of antibody responses following immunisation with different CPSs.
To dissect the role of CD35 and CD21 (complement receptors 1 and 2 
respectively) in the humoral response to CPSs from S. pneumoniae, mice 
deficient in these receptors (Cr2-/-) were utilised. Complement and 
complement receptors have been shown to be important in the antibody 
response to protein antigens but fewer studies have focussed on T- 
independent antigens. The mechanism by which complement can augment 
antibody responses is thought to be via the engagement of CD21 on B cells 
with complement bound antigen. CD21 is found in a complex with CD81 and 
CD19 and co-ligation of the BCR with this complex result in lowering of the 
threshold for B cell activation. Our studies focussed on a panel of clinically 
relevant T-independent antigens. Our first observation was that the levels of 
IgM in naive mice to most of the pneumococcal CPSs tested were 
significantly reduced in Cr2-/- mice compared to wild type mice. Cr2-/- have 
been shown to have a reduced number of peritoneal B1 cells and to have lost 
certain specificities in the B cell repertoire (Fleming et al., 2002, Ahearn et 
al., 1996, Reid et al., 2002). Following immunisation with individual CPSs in 
both Cr2-/- and wild type mice the IgM response was similar in both groups 
for all CPSs except for serotype 4. The presence of IgG in the mouse sera 
was also investigated. IgG was detected to some CPS in wild type mice, but 
this was very rare. Although no IgG to the CPSs was detected in Cr2-/- mice
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suggesting that the IgG response, when present, is possibly complement 
dependent.
It is unclear as to why pneumococcal CPS type 4 was the only CPS tested to 
have a complement-dependent IgM response. Subsequently, similar results 
were obtained using C3-/- (unpublished data from Dr. S. Zamze, Edward 
Jenner Institute for Vaccine Research, U.K.). In parallel with the CPSs, a 
model antigen, DNP-Ficoll, was used for comparison. The IgM response was 
normal in Cr2-/- mice but the IgG response was reduced which is consistent 
with what has been described in the literature (Haas et al., 2002). This 
highlights the differences in responses to different T-independent type II 
antigens, and the difference between CPS and a model antigen. MZ B cells 
and B1 cells are thought to be important in the response against 
polysaccharides. MZ B cells express CD21 but B1 cells express very little or 
none at all. It is possible that the B cells which are responding to type 4 are 
MZ B cells. This could explain why the response is complement dependent, 
whereas, mostly B1 cells are producing antibodies in response to the other 
pneumococcal CPSs. Further work to determine which B cells are producing 
antibodies in response to the pneumococcal CPSs could possibly provide an 
answer to why the IgM response to type 4 is complement dependent, these 
experiments are currently being carried out in the group. Interestingly, other 
studies have highlighted differences between type 4 CPS and other 
pneumococcal CPSs with regard to its lack of binding to the mannose 
receptor (Zamze et al., 2002) and a number of other mammalian lectins 
(unpublished data from Dr. E. McGreal, Oxford University, U.K.). Whether
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differences in the interaction of type 4 CPS with APCs via lectin recognition 
affects the immune response remains to be determined.
7.3 Final Summary
The work presented in this thesis has provided further significant insights into 
the immunogenicity and potential adjuvant properties of CPS. Compared to 
other studies of K. pneumoniae CPS as adjuvants, this is the only study in 
which well defined products have been used and possible microbial 
contaminants have been ruled out. Although high MW CPS did not appear to 
be responsible for adjuvant or immunostimulatory properties of the CPS 
extracts, a component which is heat and protease resistant and potent in 
very small amounts may be responsible for the effects. The possible role of 
lower MW CPS (possibly lipidated) has not been ruled out. Further studies 
are continuing in the lab to define the adjuvant component(s).
Although complement receptors 1 and 2 have been shown to be important in 
the humoral response to TD antigens this is not the case for all TI-2 antigens. 
This is the first study that focussed on the use of an array of structurally 
different and clinically relevant TI-2 antigens. Our results have shown that 
only one of these have an IgM complement receptor dependent response. An 
IgG response to the CPS was very rare in mice used in our studies but when 
present it was totally dependent on the presence of complement receptors 1 
and 2. The use of complement to enhance the IgG response to CPS may be 
an important issue in the improvement of CPS-based vaccines. The 
conjugation of C3 fragments to CPS, or increasing the activation of 
complement by CPS may represent two ways of inducing anti-CPS IgG
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responses. Our studies have also highlighted the differences in humoral 
response to CPSs and model TI-2 antigens and that overall conclusions on 
CPS immunogenicity cannot always be made from studies of single antigens.
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